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ABSTRACT 
 
INFLUENCE OF FINANCIAL AND POLICY ENVIRONMENTS 
 
 ON THE BUSINESS STRATEGY OF BIOTECHNOLOGY  
 
COMPANIES IN INDIA 
by Sumesh Mohan Arora 
August 2010 
The biotechnology industry thrives on innovation and new knowledge creation, 
but is also capital intensive with a complex regulatory environment (Hine and Kapeleris 
2007).  It is seen as a sunrise industry by the Indian government (Natesh and Bhan 2009).  
Current literature on the business strategy of Indian biotechnology companies and the 
influence from external factors is very limited.  The objective of this research was to 
qualitatively test the applicability of the Miles and Snow (1978) theory of organizational 
behavior which describes four strategy choices: prospector, analyzer, defender and 
reactor, in the context of the Indian biotechnology sector.  Research on Western 
biotechnology companies (Wiesenfeld-Schenk 1994) indicates these companies are likely 
to follow prospector strategies since they operate in a rapidly changing business 
environment (Hynes and Mollenkopf 2006).  India has also undergone many policy 
changes starting with trade liberalization in the early 1990’s (Kumar 2006), the 
formalization of a venture capital industry in 1988 (Mitra 2000), and a patent regime 
change in 2005 (Mueller 2008).  This research looked at the impact of the financial and 
policy environments in India on the business strategy of small-to-medium sized, privately 
held, indigenous biotechnology companies.  These companies were classified within the 
M-S framework based on the following parameters: innovativeness of their product 
  iii
offering, value proposition, marketing strategy, extent of professional networking, 
financing strategy, and intellectual property creation.  Based on a series of semi-
structured interviews conducted in India and the United States, this research found firms 
pursuing the analyzer strategy comprised the largest group (45%) in the survey sample of 
20 firms. There were only six prospectors (30%) and four defenders (20%).  Although 
this was contrary to general expectations that most biotechnology companies should be 
prospectors, research showed the Miles and Snow theoretical framework was applicable 
in the case of the Indian biotechnology sector.  The implications of this research are to 
provide a structural framework for managers in biotechnology or other emerging 
industries to analyze product development and marketing decisions.  The researcher has 
attempted to formulate policy recommendations, including a qualitative model for inter-
organizational collaboration, for the promotion of this sector in India or other developing 
countries.
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CHAPTER I 
INTRODUCTION 
Globally, the biotechnology industry is on track to reach the $100 billion revenue 
mark by the end of this decade (Giovannetti and Jaggi 2008) and encompasses over 4,000 
public and private companies most of which are located in the United States and Europe.  
With annual revenues of $2 billion, the biotechnology sector in India is still very small 
compared to the global biotechnology marketplace; however it has seen growth in excess 
of thirty percent per annum between 2004 and 2008 (BioSpectrum 2009).  This 
dissertation is focused on understanding the business strategies of privately held, 
indigenous biotechnology companies based in India and the policy and financial 
environments in which they operate.  It is important to understand the role of small-to-
medium sized enterprises (SME’s) in biotechnology in India, as it is a very young 
industry with only a handful of recognizable names on the global stage.  The largest 
biotechnology company in India was only 16th on the list of top twenty pharmaceutical 
companies (BioSpectrum 2008), and the company placing 20th among the top 20 
biotechnology companies had revenues of less than ten million dollars (BioSpectrum 
2004).  Even in the western countries, where biotechnology companies have come of age, 
they have had to learn to adapt quickly to rapidly changing market conditions in order to 
survive (Szaro 2006).  The national government of India and governments of some states 
including Karnataka, Andhra Pradesh, and Maharashtra have been promoting this sector 
as a means for economic development and export growth with broad implications for 
Indian agriculture and healthcare.  These states hope to replicate their pattern of success 
from the information technology (IT) sector into the biotechnology sector. 
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Current academic research on the business strategy in the Indian biotechnology 
sector, however, is restricted to only a few well-established companies.  Research on their 
ability to adapt to external environment in policy and finance arena is practically non-
existent.  Indian policy makers have to consider the differences between the IT and 
biotechnology sectors in order to successfully implement programs, which will spur the 
growth of the latter.  Entrepreneurship and innovation are key ingredients for the 
development of biotechnology companies from the very early stages (Hine and Kapeleris 
2007, 1), yet the global biotechnology industry is deficient in managers and researchers 
with appropriate commercialization skills.  Hine and Kapeleris (2007) further identified 
the need to assess the external environment of biotechnology organizations from 
scientific, regional, policy, and resource perspectives along with the ability to define 
networks and alliances in this industry, but have done so mostly in well developed 
countries in Europe, North America and Australia. 
Company strategy and management styles may be studied using a variety of 
academically tested frameworks such as Porter’s strategies seeking competitive 
advantage (Porter 1985) or Miles and Snow (1978) strategy based on a business’s 
intended rate of product-market development.  The research question for this dissertation 
was to seek if the business organizational strategy framework developed by Miles and 
Snow (1978) provided an effective theoretical basis to study the behavior of selected 
Indian biotechnology companies.  This dissertation tested the Miles and Snow (M-S) 
theory in the context of an emerging industry in a developing nation, thereby contributing 
to existing research, which has largely applied the M-S framework to mature businesses 
in developed nations.  The M-S framework (Miles and Snow 2003) looks at how 
companies adapt to their external environment and their resulting strategy choice, which 
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helps them become a successful business. Interviews with senior managers of these 
companies and other individuals related to policy, finance, and technical aspects of this 
industry were conducted to develop the M-S typology matrix.  The classification of these 
companies within the M-S framework was based on the following parameters: type and 
innovativeness of their product or service offering, value proposition, marketing strategy, 
extent of professional networking, decision making process, market competition, 
financing strategy, research and development activity and intellectual property creation.  
Extensive secondary data were used to understand the external environments in which 
these companies are operating.  The implications of this research are to provide a 
structural framework for managers in biotechnology or other emerging industries to 
analyze product development and marketing decisions.  The researcher also attempted to 
formulate policy recommendations for the promotion of this sector in India or other 
developing countries. 
The field of biotechnology is new and broad.  Stem cell research, cellulosic 
biofuels, bioinformatics, genetically modified crops, human genome, recombinant DNA, 
fermentation, biosensors, and personalized medicine are some of the terms in the jargon 
of the biotechnology industry.  These terms represent “a generic set of biochemical and 
bioengineering techniques,” which collectively makeup the biotechnology industries and 
are hailed as the “next strategic technology” after microelectronics (Ruttan 2001, 368).  
They represent an extremely broad spectrum of products and services, which impact 
human and animal healthcare, agriculture and energy production, or in other words the 
very basis of human existence.  The Oxford English Dictionary (2nd  ed.) defines 
biotechnology as “the branch of technology concerned with modern forms of industrial 
production utilizing living organisms, esp. micro-organisms, and their biological 
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processes.”  While the science behind this industry is believed to replace the information 
technology industries as the “dynamic growth” engine during the first half of the twenty-
first century (Ruttan 2001, 368), it is equally important to understand the development of 
the business side of biotechnology and how this sector has been influenced by external 
environmental factors such as socio-cultural factors with regards to ethics, policy factors 
dictating regulation, and perceived economic potential of this industry, which has yet to 
fully materialize (Hine and Kapeleris 2007, 174).  
Biotechnology is a young industry, with some of the first biotechnology 
companies being formed in the United States as late as 1970, prior to which almost all 
activity in this field was research conducted by universities and the federal government .  
Michael Fumento (2006) notes in his book that “biotech is where the automobile was a 
century ago,” (5) but while it is a paradigm-jump forward, it is also an extension of 
medicinal, industrial and agricultural practices already in use.  The accounting firm of 
Ernst and Young (E&Y) has been issuing an annual report on the status of global 
biotechnology for twenty-three years and consider the culture of innovation to be an 
integral part of this industry (Giovannetti and Jaggi 2008).  This lends biotechnology as 
an ideal platform for an academic study of how innovations occur and the business 
models adopted by companies to bring products and services into the marketplace.  
According to E&Y, Australia, China and India are now seen as the emerging hotbeds for 
biotechnology companies, besides the more established areas in the USA, Europe and 
Japan.  It is important to understand the development path being followed by the 
emerging biotechnology industry in these nations. 
Comparisons are often made between the growth of the biotechnology industry 
and the personal computer industry.  Two companies, Genentech and Apple Computer, 
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which are considered to be leaders among the respective industries, were formed within 
seven days of each other in April 1976 in the San Francisco Bay Area.  However, it is 
important to understand that the foundations of the personal computer industry were laid 
in 1959 when the integrated circuit (IC) was invented.  On the other hand, the discovery 
of the recombinant DNA, which is considered to be a founding technology for 
biotechnology, did not occur till 1972;  although some consider the elucidation of the 
structure of DNA by Watson and Crick in the 1950’s as the starting point for modern 
biotechnology.  In contrast to the information technology (IT) industry, the biotechnology 
industry is one of the most regulated and capital-intensive industries.  For example, it can 
take over $100 million and almost 15 years to take a given drug candidate to market 
(Woicheshyn and Hartel 1996).  The product cycles in the computer industry tend to be 
shorter in duration and the trajectory for the development of this industry was predicted 
by the “Moore’s Law” which states that the number of transistors on a chip would double 
every year (need reference).  The biotechnology industry also faces a host of 
controversial ethical issues such as the use of genetically modified crops and patenting of 
human gene clones (Ruttan 2001, 387), which are absent from the IT industry.  Creation 
and protection of intellectual property in the biotechnology industry is capital intensive, 
but essential to the success of most companies (Hine and Kapeleris 2007, 27) whereas the 
computer software industry promotes “open source” development.  This comparison 
shows that while IT and biotechnology are both considered high growth industries, the 
environment in which the respective companies operate face very different issues. The 
biotechnology industry, however, has benefitted from the advances in computing power 
in areas such as bioinformatics and gene sequencing and this comparison is valuable to 
this dissertation given the rapid development of the computer and software industry in 
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India over the last ten years.  According to the National Association of Software and 
Services Companies, revenues for information technology industry in India exceeded $60 
billion in 2009 (NASSCOM 2010). Software exports from India grew at an annual 
compounded rate of 46 percent from 1990 to 2000 and the Indian government expressed 
support for this sector as early as 1972 (Parthasarathi and Joseph 2002).  
Biotechnology started gaining national attention as early as 1980 as part of India’s 
Sixth Five Year Plan spanning 1980-85.  The role of biotechnology in advancing the 
nation’s agricultural and health sectors was formalized when the Indian Central 
Government created the Department of Biotechnology (DBT) under the Ministry of 
Science and Technology.  The DBT states its vision as “attaining new heights in 
biotechnology research, shaping biotechnology into a premier precision tool of the future 
for creation of wealth and ensuring social justice - specially for the welfare of the poor” 
(Department of Biotechnology, n.p.).  While the Indian biotechnology sector still 
represents less than two percent of the global biotechnology revenues (BioSpectrum 
2009), the DBT’s website claims a role in producing about 5,000 research publications 
and 4,000 post-doctoral students since its inception in 1986.  The DBT defines 
biotechnology as a “set of rapidly emerging and far reaching new technologies with great 
promise in areas of sustainable food production, nutrition security, health care and 
environmental sustainability.”  DBT hopes to use the tools of biotechnology to help 
convert the country's diverse biological resources to useful products and processes, which 
are accessible to its masses for economic development and employment generation.  
According to a recent publication coauthored by the director of DBT, India’s 
biotechnology sector is at a juncture where on one hand it must serve the nation to seek 
“affordable solutions to the pressing needs in agriculture, health and energy, but on the 
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other, it must be competitive enough to take advantage of the lucrative international 
markets” (Natesh and Bhan 2009, 158).  This statement is indicative of the perceived 
value of biotechnology for Indian policymakers and the policy environment for the Indian 
biotechnology companies will be explored further in this dissertation. 
In presenting the growth of the biotechnology industry in India since 2002 to 
present, Natesh and Bhan (2009) break the industry into five categories: biopharma, 
bioservices, bioagri, bioindustrial and bioinformatics.  A study commissioned by the 
French Embassy in New Delhi (Maria, Ruet and Zerah) on the state of biotechnology in 
India used a similar breakdown of the industry as shown in Table 1.1 and is based on 
industry segmentation done by Ernst and Young.  This categorization will also be used as 
a reference point for this dissertation.  However, the focus of this dissertation will be on 
healthcare biotechnology in India. Overseas travel and primary data collection for this 
research was funded through a grant from the National Science Foundation seeking to 
study health biotechnology sectors in developing countries.  Similar research has already 
been undertaken in China (Malone et al. 2008) under this grant.  As discussed below, the 
healthcare biotechnology segment in India is the single largest component in the industry 
revenues.  
The healthcare biotechnology sector includes medicines, vaccines, diagnostics 
and gene therapy, whereas agricultural biotechnology sector includes hybrid seeds, bio-
pesticides, bio-fertilizers and plant extractions.  There is a lot of interest in biofuels in 
India also which may be categorized under industrial biotechnology.  The bioservices and 
bioinformatics groups also service the healthcare biotechnology segments and together 
with the biopharma segment contributed to 84 percent of the $2.5 billion in revenues 
during 2007-2008 accounting year (Natesh and Bhan 2009). The interest in the life 
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sciences sector of biotechnology is manifested in names of areas with a concentration of 
biotechnology activity like “Genome Valley” located near Hyderabad, Andhra Pradesh 
and “Bangalore Helix” in the State of Karnataka.  This research was conducted primarily 
in Bangalore and the underlying reasons for selecting Bangalore are described in the 
methodology section of this dissertation. 
Table 1.1  
 
Categorization within the Biotechnology Sector 
 
Biotechnology Sub-sector Sub-sector Components 
Healthcare biotechnology Medicines 
Vaccines 
Diagnostics 
Gene therapy 
 
Agricultural biotechnology Hybrid seeds 
Biopesticides 
Biofertilizers 
Plant extractions 
 
Industrial biotechnology Industrial enzymes 
Polymers 
Biofuels 
Fermentation products 
 
Environmental biotechnology Effluent and Waste Water Management 
Bioremediation 
Biosensors 
Creation of Germplasms 
 
While the agribiotech segment constituted only twelve percent of the 2007-2008 
revenues, it is nevertheless a very important business sector in India.  Three of the top ten 
biotechnology companies in India are seed companies.  A genetically modified strain of 
cotton, commonly known as Bt Cotton (crops genetically engineered to express the 
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bacterium Bacillus thuringiensis which increases it resistance to pests), is the fastest 
growing biotechnology-based product in the country in the last few years.  
With a population of 1.1 billion and Gross Domestic Product (GDP) of $3.82 
trillion in purchasing power terms in 2005, India is the fourth largest economy in the 
world (Central Intelligence Agency). India is also one of the fastest growing economies 
in the world with the growth rate of GDP averaging 7.2% from 1998 to 2008 (World 
Bank 2009).  In 1991, the finance minister aggressively advocated economic 
liberalization embracing the twin pillars of market liberalization and deregulation with 
major changes in industrial, trade, and exchange-rate policy.  Economic reforms to 
promote investment in the country through privatization, foreign direct investment and 
trade liberalization were undertaken resulting in significant reduction of import tariff 
rates and up to 100% foreign ownership was permitted in a large number of industries. 
(Kumar 2006; Ray 2008; Vaidyanathan 2008).  The environment for availability of 
funding for indigenous biotechnology companies in India and funding strategies pursued 
by these companies is explored in this dissertation. 
The economically liberalized India, with its abundant supply of English speaking 
highly skilled inexpensive labor, made it an attractive place for U.S. software companies 
to invest. The government of India set up technology parks in cities such as Bangalore for 
the software industry to overcome critical deficiencies in the telecommunications systems 
and to provide these facilities as well as other infrastructure to attract foreign companies 
and to encourage small and medium domestic entrepreneurs to enter the software 
industry.  After the success of the software industry in the last decade, the government of 
India has been actively promoting the biotech sector, which is considered as the next 
major growth sector in India.  This dissertation reviews current literature on various 
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programs instituted including research parks and private-public initiatives by the Indian 
government to support this sector as part of the secondary data analysis.  Literature on the 
change in the Indian patent regime, which took effect in 2005, is also reviewed to 
understand the impact of this policy change on the biotechnology sector. 
According to the DBT’s 2006-2007 annual report the biotechnology industry has 
seen revenues in excess US$ 1.5 billion in 2005-2006.  Although the growth was mainly 
in biogenerics and contract manufacturing, research leading to new product development 
is also taking place. This report points out the positive social impact of such growth is the 
ability to provide indigenously developed and produced vaccines by biotechnology 
companies such as Serum Institute and Biocon to the Indian population at one fourth to 
half the cost of importing them (Narayanan and Rao 2009).  Based on current rate of 
investments and product development in this sector, the DBT predicts an annual turnover 
of US$ 10 billion for the Indian biotechnology industry by 2010 and expects the annual 
revenue growth rate between 2010 and 2015 to be almost twenty five percent.  During the 
year 2006-2007, the impetus was on programs of national relevance with special 
emphasis on strengthening of infrastructure, creation of centers of excellence, capacity 
building and developing mission mode programs and public-private partnerships. DBT 
supported 450 research and development (R&D) projects during this period with 
approximately 200 universities and research laboratories involved in these projects.  
Funding from the Central government has been steadily increasing and is built into the 
national five-year plans.  Table 1.2 shows a 450% funding increase from the tenth five-
year plan to the current five-year plan, which was preceded by a 233% increase between 
the ninth and tenth five-year plans.  The government of India acknowledges the 
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importance of the biotechnology sector and is making significant investments to promote 
this industry. 
 
Table 1.2  
Availability of Funds for DBT through the Plans* (from DBT 2007-2008 Annual Report) 
– National Biotechnology Development Strategy 
 
Five-Year 
Plan Period 
Five-Year 
Time Period Funding Level, Rupees (US$ @ Rs.45/$1) 
9 1997 – 2002   6,210,000,000      (US$ 138 million) 
10 2002 – 2007 14,500,000,000      (US$ 322 million) 
11 2007 – 2012 65,000,000,000**  (US$ 1.44 billion) 
*It is to be noted that Biotechnology sector also receives funding from several sources such as CSIR, 
DST, ICAR, ICMR, MHRD and others 
**Indicative figures at current costs 
 
A common business model in the pharmaceutical industry is that of the fully 
integrated pharmaceutical company (FIPCO) where the research, clinical trials, 
production and marketing are all done by the same company.  Amgen, Genentech, and 
Chiron are examples of now well-established FIPCO’s, but due to the high financial and 
time costs of multiple steps involved in bring a new drug to market, outsourcing of many 
of these steps is an option (Broderson 2005).  Some of the research steps, as well as 
clinical trials and data management maybe outsourced to smaller firms, which have 
developed the capabilities for performing such functions.  Biotechnology industry is one 
of the most scientifically research intensive industries in the world and requires elaborate 
skills on the part of researchers and a technologically advanced infrastructure and 
equipment to support that research.  The researcher studied the level of innovative 
strategies being followed by lesser-known biotechnology companies in India and tried to 
understand the reasons for the products and services being developed by these 
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companies.  The researcher visited Bangalore, Mumbai and New Delhi in 2008 and 2009 
to collect primary data from these companies as well as biotechnology industry 
organizations.  Bangalore along with Hyderabad has evolved as the concentration hub for 
the biotech companies in India.  Personal interviews were conducted with mid to upper 
level biotech company officials, including company founders, to learn more about their 
business practices, product development strategy, sales strategy, methodology for raising 
financial capital, professional networking and strategies for developing and protecting 
intellectual property. 
As mentioned previously, the focus was primarily be on the smaller, privately 
held companies since academic literature on the business strategies on such companies is 
practically non-existent.  Larger Indian biotechnology companies and multinational firms 
operating in India, which have received coverage in main-stream media, will be excluded 
from the interviews.  Many of the companies have generally been labeled as “innovative” 
and researching their level of innovativeness may present an inherent bias in classifying 
them according to a business typology.  Another important reason to interview the 
smaller companies was to understand their methods to raise start-up and operational 
capital.  The researcher wishes to answer such questions as to how well Indian companies 
are innovating in the biotech sector and how they may be leveraging their strengths; what 
are the challenges facing them and have recent changes in government policy and 
intellectual property regulations influenced their operations.  The researcher has 
attempted to categorize the business approaches taken by these companies using the 
Miles and Snow typology and more importantly understand the reasons for these 
companies to follow such approach.  
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Chapter II of this dissertation reviews the current literature in two key areas: (1) 
application of Miles-Snow (M-S) typology (1979) and (2) development of the Indian 
biotechnology sector.  The M-S typology describes four distinct categories of companies: 
prospectors, analyzers, defenders, and reactors based on their approach to allocating 
internal resources and developing new products.  The literature review covers the 
theoretical basis of the Miles and Snow typology and its application to different countries 
and industries around the world including references to developing countries and 
emerging technology industries including biotechnology.  The literature review also 
looks deeper into the current state of the private sector activity in the Indian biotech 
industry as well as government policies and funding mechanisms.  Recent changes in the 
Indian patent law are examined by analyzing secondary data. 
Chapter III of the dissertation discusses the methodology applied to collect 
primary and secondary data starting with selecting the sample of companies to be 
surveyed via on-site interviews.  The value of semi-structured personal interviews is 
discussed along with the pitfalls and the validity threats, which the researcher faced while 
collecting primary data.  Steps to mitigate such threats are discussed.  Secondary data 
collection methodologies such as content analysis and the use of the Internet and other 
on-line sources are also discussed. 
Chapter IV is dedicated to a compilation of results and discussion of the primary 
data and secondary data.  These analyses are presented in the framework of the 
aforementioned literature reviews.  The researcher demonstrates that conducting 
interviews with twenty companies afforded a reasonable sample of Indian biotechnology 
companies to make meaningful, but not necessarily generalizable, inferences about the 
business strategy of smaller biotechnology companies in India.  The reasons for focusing 
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on the smaller companies is also discussed.  This chapter also discusses information 
gleaned from interviews conducted with individuals not directly employed with a 
biotechnology company albeit those associated with pertinent non-profit organizations or 
supporting financial, government and academic institutions.  This chapter presents the 
policy and environmental factors, which have influenced the adoption of a given Miles 
and Snow business type strategy by the companies interviewed during the course of this 
research.  This dissertation attempts to answer the following questions: (1) how well 
Indian companies are innovating in the biotech sector and how they are leveraging their 
strengths; (2) what are the financing mechanisms for these companies facing them; and 
(3) have recent changes in government policy and intellectual property regulations 
influenced their operations.  Based on the responses to these questions, the researcher has 
categorized the companies’ business strategies under the Miles and Snow typology 
framework. 
The dissertation concludes with a summary of the findings and policy 
recommendations for technology development in developing countries and emerging 
industry sectors.  Opportunities for future research are also presented.  It is shown that the 
M-S typology is applicable in the Indian biotechnology industry context and the 
researcher was able to categorize the companies within this framework.  Furthermore the 
researcher has attempted to draw policy recommendations based on observations and the 
results of the interviews.  The research has proposed a qualitative model of inter-
organizational collaboration between five sectors (non-profit, academia, private industry, 
government, and international organizations) for promoting biotechnology sector in 
India.  A brief comparison is made with the biotechnology company strategies in 
neighboring China within the M-S typology framework.   
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CHAPTER II 
LITERATURE REVIEW 
Miles and Snow is an established, well-tested theory for explaining corporate 
strategy.  It has been extensively tested over forty years under multiple conditions; 
however, its applicability in developing nations and emerging technologies is less fully 
understood.  Literature on explaining the environmental effects on the business strategies 
of companies in emerging technologies such as biotechnology and in developing 
countries is still limited.  The researcher has attempted to bridge this gap in the literature 
by specifically testing the Miles and Snow theory in the context of the Indian 
biotechnology industry and the environment in which it operates.  The literature review 
chapter explains the Miles and Snow (M-S) strategic typology and its application first 
followed by a review of the existing literature on biotechnology development in India 
including the impact of recent changes in Indian patent policy. 
Miles and Snow Typology 
Strategic behavior has been defined as managing environmental risks and 
matching organizational capabilities with the opportunities offered by the environment 
(Hofer and Schendel 1978).  The study of strategic behavior is important to understand 
the ways in which companies may become profitable.  Donald C. Hambrick writes in the 
introduction to the 2003 edition of Miles and Snow’s classic text Organizational 
Strategy, Structure, and Process originally published in 1978 that there are only a limited 
number of basic patterns that businesses can choose from to achieve their goals.  
Biotechnology companies face different issues than firms in more established and mature 
industries due to characteristics of the firms and the business environment in which they 
operate, which may be characterized as being turbulent with a rapidly changing 
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competitive landscape (Hynes and Mollenkopf 2006).  Evolution of the Miles and Snow 
typology and its application in developing countries and to the biotechnology industry are 
discussed below. 
 For nearly thirty years the Miles and Snow (1978) strategic typology has been the 
most enduring strategy classification system available (Hambrick 2003).  Many authors 
attribute the longevity of the typology to its lack of dependence on industry factors and 
the actual correspondence to firm behavior and positioning (Blumentritt and Danis 2006; 
DeSarbo, Di Benedetto, Song, and Sinha 2005; Dvir, Segev, and Shenhar 1993; Kald, 
Nilsson, and Rapp 2000; Lei and Slocum 2005; Segev 1987).  The lack of dependence on 
industry specific factors, the firm-level behavior focus and the prolonged existence of the 
Miles and Snow (M-S) typology make it an appropriate behavioral theory in this 
research.  On the other hand, Hambrick (2003), while being one of the strongest 
proponents of the Miles and Snow typology, points out the generic nature of the typology 
tends to ignore the “industry and environmental peculiarities.”  A key objective of this 
research is to understand if the generic nature of the typology is a deterrent in applying it 
to small Indian biotechnology companies. 
 Miles and Snow (2003, 7) propose that organizations develop relatively similar 
patterns of strategic behavior that co-align the organization with its environment.  This 
typology views firms as complete and integrated systems within the dynamic 
environment in which they exist (McDaniel and Kolari 1987).  Miles and Snow (2003, 
21) developed a dynamic model called the adaptive cycle which encompassed a number 
of issues constantly confronting management and the response by organizations to adjust 
to their environment. 
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Miles and Snow (2003, 22) determine that firms make decisions in three main 
areas: entrepreneurial problems, engineering problems, and administrative problems.  
They contend that all three problem areas are addressed almost simultaneously in 
established and mature companies, but new or rapidly growing organizations may loosely 
follow a sequential path with overlap in the three problem areas.  The entrepreneurial 
problems deal with the decisions surrounding a specific product or a target market a 
company should attack.  It is essential for a new company to concretely define the 
product or service offering as early as possible.  The realization of a company’s 
acknowledgement of a “particular product-market domain” is evident by the nature of 
resources deployed by the management to achieve stated objectives (Miles and Snow 
2003). 
The engineering problems involve the mechanisms to operationalize the 
company’s entrepreneurial ambitions.  It deals with the how and methods including the 
selection of appropriate technology to use production resources to deliver the products or 
services to the customers.  Addressing the engineering problems may also be represented 
by a change in approach for an “on-going” or mature organization as their environment or 
market base changes.  Last, administrative problems address how to organize and control 
the business process.  The actual form of the organization is determined during this phase 
as management rationalizes and stabilizes it process controls to effectively deal with the 
environment in which it is operating.  This phase also lays the foundation for future 
innovative actives of the organization based on entrepreneurial and engineering activities 
employed by the company to solve its problems successfully and makes the adaptive 
cycle a closed loop framework. (Miles and Snow 2003). 
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Figure 2.1. The Adaptive Cycle  
From Organizational Strategy, Structure, and Process, by R. E. Miles and C. C. Snow (2003, 24).  
 
Over time the adaptive cycle, the way companies handle fundamental problems, 
leads to defined patterns of solutions.  The behavioral method a firm uses to solve the 
adaptive cycle problems can be grouped into four strategic orientations.  As a result, it is 
possible to distinguish groups of companies within each strategic orientation that deal 
with the three adaptive problems in a relatively similar fashion (Kald et al. 2000).    
The similar patterns, which companies exhibit over time to address the ongoing 
adaptive cycle, form the four basic organizational strategic types defined by Miles and 
Snow (1978, 13-93) as follows. 
Prospector 
A prospector is virtually the opposite of a defender.  A prospector tends to 
compete by looking for new products and markets through technological innovations.  
Prospectors are firms that thrive with a changing market and enjoy being first to market, 
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first to sell and first-move in the respective industry (Miles and Snow 1978).  Prospector 
firms need strong research and development and rely on heavy market research.  
Blumentritt and Danis (2006) write, “We expect the locus of innovation activities in 
prospector firms to be centered around creation of products and services as well as 
customer relationships” (280).  Companies like Sony Corporation, Apple Computers and 
Amazon.com have been exemplified as prospectors (Hougaard and Bjerre 2002). 
Miles and Snow (1978) had reported the existence of relationships across strategic 
types and such firm strategic capabilities. Prospectors, for example, tend to compete by 
anticipating new product or marketplace opportunities and through technological 
innovation. These firms thrive in unstable, volatile environments—those marked by rapid 
technological change such as in the biotechnology, medical care, and aerospace industries 
(Walker et al. 1992, 89). Prospectors use a first-to-market strategy and typically succeed 
by being able to develop new technologies, products, and markets rapidly (McDaniel and 
Kolari 1987; Conant et al. 1990). Walker et al. (1992) note that prospectors require 
strength in product R&D and product engineering, and perform best when the amount 
spent on product R&D is high. They also rely on solid market research and build close 
ties with distribution channels to ensure that the R&D produces products that meet 
customer needs (Hambrick 1983; McDaniel and Kolari 1987; Shortell and Zajac 1990). 
Also, IT capabilities facilitate internal communication and functional integration between 
and marketing that are critical to new product success (Swanson 1994; Moenaert and 
Souder 1996; Griffin and Hauser 1996; Bharadwaj, Bharadwaj, and Konsynski 1999).  
Miles and Snow (1978) have noted that Prospectors need to have the most complex 
coordination and communication mechanisms, as they are most reliant on new product 
development to sustain competitiveness (Robinson, Fornell, and Sullivan 1992). 
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Defender   
A defender attempts to locate and maintain a secure niche in a relatively stable 
product or service (DeSarbo et al. 2005).  Defenders do not look outside their market and 
tend to offer a more limited range of products and services.  Defenders typically use a 
high-level of marketing and constantly look for cost cutting measures to remain 
competitive (Conant, Mokwa, and Varadarajan 1990).  Many long-term established 
airlines would be considered as examples of defenders (Saur 2008) as would fast food 
restaurants like McDonalds (Duane 1996) and firms in the construction industry 
(Hougaard and Bjerre 2002). 
In contrast to prospectors, defenders attempt to locate and maintain a secure niche 
in a relatively stable product or service area.  They do not look outside their established 
product-market domain to identify new opportunities (McDaniel and Kolari 1987; 
Shortell and Zajac 1990).  They tend to offer a more limited range of products or services 
than their competitors, and try to protect their domains by offering higher quality, 
superior service, and lower prices (Hambrick 1983).  Clearly, to be effective in achieving 
these objectives, defenders need to possess a high level of marketing and market linking 
capabilities (Conant et al. 1990; Walker et al. 2003, 76), and have to concentrate on 
resource efficiency, cost-cutting, and process improvements. 
Reactor 
A reactor is a firm that has no established pattern of decision making and usually 
reacts to an ongoing situation.  Usually short-term focused Miles and Snow (1978) 
highlight that this strategy will not be successful unless the company can move to one of 
the other three strategies.  The reactor strategy is not normally a choice but rather a 
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residual strategy, arising when one of the other three strategies is improperly pursued 
(Slater and Narver 1993).   
Analyzer   
An analyzer is a firm that exhibits characteristics of both.  Many analyzers operate 
in one stable market and one changing market.  Analyzer firms usually take a wait-and-
see approach and are not first-movers like what would be expected of prospectors (Miles 
and Snow 1978).  Given their hybrid nature analyzers tend to be the more complex 
entities.  In stable domains analyzers tend to emphasis production and improved 
efficiency while in more turbulent domains they tend to closely monitor key competitors 
and adopt only those innovations which appear to have strong market potential (Conant et 
al. 1990).  Saur (2008) describes a large regional bank that prides itself on a high-level of 
customer service but on not developing new self-service technology but rather allowing 
the larger companies to be the first-mover as a committed analyzer.  Quaker Oats 
Company and Carnation Foods are cited as specific examples of analyzers by Duane 
(1996). 
According to Miles and Snow (1978), successful prospecting will have the effect 
of strengthening technology and R&D capabilities.  In other words, “Prospectors tend to 
want to continue prospecting” (Hambrick 1983, 5), since this is what they do best. 
Similarly, Defenders will likely keep on defending, while Analyzers will build upon both 
prospecting and defending capabilities.  Reactors do not capitalize on the set of 
capabilities they already have built up, but rather they shift strategic orientation in 
reaction to competitive pressures, thus they will usually be at a disadvantage to those 
firms that are competing from an established position of strength. 
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The first three strategies when viewed together exist on the same continuum 
where prospector and defender are on opposite ends with analyzer in the middle.  Miles 
and Snow (1978) and the empirical tests conducted afterwards (Conant et al. 1990) show 
that all three strategies can result in highly successful firms while reactors typically lack 
long-term plan and react to the changing environment thus making them less successful 
(Song, DiBenedetto, and Nason 2007).  An alternative matrix has been presented by 
Hougaard and Bjerre which classifies companies based on their goals of product 
differentiation versus cost reduction focus.  This matrix also places prospector companies 
in the entrepreneurial part of the adaptive cycle (Hougaard and Bjerre 2002).  Elements 
of Hougaard and Bjerre’s matrix have been combined by the researcher with the Miles 
and Snow (1978) and Conant et al.’s (1990) description of the four categories to present 
the continuum in a graphic form shown in Figure 2.2.  The wavy line for reactors 
signifies a lack of focus on either cost or differentiation. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. The Miles and Snow Typology Continuum with Adaptive Cycle Stage and 
Firm Outcome. 
 
Prospector Defender Analyzer 
Highly successful firms 
Cost Focus Differentiation Focus 
Reactor 
Unsuccessful firms 
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In summary, according to Walker et al. (2003), the following environmental 
characteristics tend to favor Prospector strategies: (1) the industry is in the early stage of 
the product development; (2) market segments are still unidentified or undeveloped; (3) 
industry technology is still emerging; (4) there are few established competitors; (5) 
industry structure is still in the process of evolving; and (6) industry concentration is 
high, e.g., one firm holds most of the market share. The reverse conditions tend to favor 
Defender strategies, whereas Analyzer strategies are favored in the “middle ground.”  As 
an example, if a large number of competitors exist, but industry structure is still evolving 
and a shakeout is inevitable, an Analyzer strategy may be more appropriate. 
Characteristics of the four strategy types are summarized below. 
 
Prospectors 
• Compete by looking for new products and markets through technological 
innovation 
• Enjoy being first to market or first to sell 
• Need strong R&D and market research 
• Thrive in unstable, volatile markets – those marked by technological change such 
as biotechnology, medical care, and aerospace (Walker et al. 1992) 
• Examples: Sony, Amazon, Apple (Hougaard and Bjerre 2002) 
 
Defender 
• Attempts to locate and maintain a secure niche in a relatively stable product or 
service (DeSarbo et al. 2005) 
• Do not look outside their market 
• Limited product/service offering 
• Competitiveness through higher quality, superior service, lower prices (Hambrick 
1983) 
• High level of marketing (Conant et al. 1990) 
• Examples: United or American Airlines (Saur 2008), McDonalds (Duane 1996) 
 
Analyzer 
• Exhibit characteristics of Prospectors and Defenders 
• Operate in one stable market and one changing market 
• Wait-and-see approach and not the first movers (as expected of prospectors) 
(Miles and Snow 1978) 
• More complex entities 
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• Adopt innovations which appear to have strong market potential (Conant et al. 
1990) 
• Examples: Quaker Oats and Carnation Foods (Duane 1996) 
 
Reactor 
• No established pattern of decision making 
• Reacts to ongoing situation 
• Short-term focused 
• Company will not be successful unless it moves to another strategy 
• Change course in reaction to competitive pressure and do not capitalize on 
existing capabilities 
• This is normally not a choice, but a residual strategy (Slater and Narver 1993) 
 
Limitations of Miles and Snow Typology 
Hambrick (2003) pointed out that the original M-S model does not seek to predict 
which of strategic types will perform the best; rather, the intent was to develop a typology 
of corporate strategy and not to explore the performance consequences.  As Hambrick 
(1983) noted, little consideration of the environment–strategy link has been given in 
Miles and Snow, and no systematic evidence has been provided on how strategic types 
differ in their functional attributes.  Finally, Hambrick (1983) also criticized such general 
classification schemes in not being quantitatively based, but more a product of the 
researcher’s personal insight which may not accurately reflect reality; thus serving well 
for descriptive purposes but with limited explanatory or predictive power. 
Comparatively few research studies have attempted empirically to support the 
proposed relationships between environment, strategic capability, and Miles and Snow 
strategic types as outlined by Walker et al. (2003).  A need for a greater consideration of 
the effects of the environment and capabilities on strategic choice has been acknowledged 
in the literature (DeSarbo et al. 2005).  Miles and Snow typology (1978) has classically 
been tested primarily in developed nations and in mature industries to study relationships 
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among strategy, firm competence, and organizational performance in the plastics, 
semiconductor, automotive, and air transportation industries (Snow and Hrebiniak 1980). 
In a widely recognized study applying the Miles and Snow typology, Donald Hambrick 
(1983) looked at 1452 business in the “growth and maturity” stages of the life cycle from 
the Profit Impact of Market Strategies (PIMS) database, but acknowledged that 
businesses in the introductory and decline stages of the business life cycle were not 
included.  Researchers have pointed out that the original Miles and Snow research was 
limited in the number of industries and the range of capabilities studied.  They did not 
systematically study all the possible linkages between capabilities and strategic type, nor 
did they attempt to prove the validity of their typology across other industry types.  It is 
unknown, however, whether this observation held true in industries other than the ones 
studied, or in other countries (DeSarbo et al. 2005). 
Carter et al. (1994) have questioned the utility of the Miles and Snow typology for 
new ventures on the basis that this typology does not account for the breadth and 
diversity of new ventures’ activities.  They also showed that type of business also had a 
significant influence on the strategies chosen by management.  Only more recently has 
this theory been applied to developing nations and emerging technology companies such 
as biotechnology.  The following section will review the application of Miles and Snow 
typology in developing countries and then to the biotechnology industry.  These studies 
show the broad range of industries even individual studies have been applied to and the 
points to the dearth of literature in the Miles and Snow typology’s application to 
biotechnology firms world-wide. 
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Miles and Snow in Developing Countries 
In many developing nations, there are factors not broadly present in developed 
nations.  Among these are a significant number of state-owned enterprises.  Peng et al. 
(2004) demonstrated that Miles and Snow typology had applicability in China 
specifically with respect to ownership.  They found state-owned enterprises were 
generally Defenders, whereas privately held companies were Prospectors.  Companies 
that had both state and private ownership were Analyzers (Peng et al. 2004).  A survey of 
150 Brazilian firms’ owner-managers showed evidence in support of Miles and Snow’s 
model of existence of four types of generic strategies in a competitive environment 
composed mainly of small firms (Gimenez 2000).  However, Gimenez (2000) included 
ten business sectors in this survey (computer services, food industry, supermarkets, 
chemical industry, clothing industry, clothes retailers, tourist agencies, metallurgy 
industry, lumber extraction and furniture industry) with 108 respondents located in urban 
area in Southern Brazil and the other 42 from a less developed city in northern Brazil.  
Habaradas’s (2009) conceptual study of Filipino small and medium enterprises (SME’s) 
proposed a link between organizational learning behaviors and the company strategy as 
prescribed by the Miles and Snow typology.  This study categorized reluctant learners as 
reactors or defenders, eager learners as analyzers and dynamic learners as prospectors. 
The current research is not directed at evaluating market success or failure of 
biotechnology small companies in India based on their business strategy; hence it will 
allow the researcher to determine if the application of M-S typology is a suitable 
framework to study the strategic choice for small biotechnology companies in India.  The 
application of M-S typology to developing nations in various parts of the world is 
reviewed next followed by it application to biotechnology companies.  The proposed 
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research will fill a gap in current academic literature, which has only recently begun to 
look at the biotechnology sector in India.  The current research relies on the qualitative 
methodology of personal interviews and acknowledges the deficiency of the Miles and 
Snow typology pointed out by Hambrick (2003).  Research methodology biases will be 
explored in greater detail in the methodology section of the dissertation. 
A study of 13 hotels in Malaysia looked at their adoption and use of the Internet 
depending on their business strategy.  The study concluded that Prospectors were ahead 
of others in the use of Internet with advance website features while Reactors were at the 
other end of the continuum with no adoption (Hashim et al. 2007, 457).  A second study 
in Malaysia was much broader and included responses from 120 companies listed in the 
2003 directory of Federation of Malaysian Manufacturers.  Results suggested that 
Malaysian firms viewed competitive strategy differently than their Western counterparts 
and “the difficulties faced when Western measurement scales are employed in non-
Western emerging nations” (Hashim et al. 2007, 457).  Another study recommended 
strategy researchers to consider using multiple performance measures in assessing firm's 
performance such as financial performance, customer satisfaction and loyalty measures, 
as well as employee satisfaction and training measures (Jusoh and Parnell 2008). 
The largest known study of Asian companies based on the Miles and Snow 
typology, as claimed by DeSarbo et al, is their research on survey data obtained from 709 
firms in three countries: China (245 firms), Japan (248 firms), and United States (216 
firms) (DeSarbo et al. 2005).  The final study sample included the following industries: 
chemicals and related products; electronics and electrical equipment; pharmaceuticals, 
drugs, and medicines; industrial machinery and equipment; telecommunications 
equipment; semiconductors and computer-related products; instruments and related 
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products; and others (air conditioning; transportation equipment, etc.).  The majority of 
participating strategic business units or divisions had annual sales of $11–750 million and 
100–12,500 employees.  DeSarbo et al. (2005, 65) concluded there was preliminary 
evidence that the Miles and Snow model was generalizable across the United States, 
Japan, and China and that “managers from these three countries think alike when reacting 
to similar capability and environmental settings.”  They observed that prospectors were 
technologically innovative and sought out new markets; analyzers tended to prefer a 
“second-but-better” strategy; defenders were engineering-oriented and focused on 
maintaining a secure niche in relatively stable market segments; and reactors lacked a 
stable strategy and were highly responsive to short-term environmental exigencies.  
Since the focus of this dissertation is on Indian companies, a literature review of 
use of the Miles and Snow typology in the Indian context is presented below.  As shown 
below, literature on the application of this typology for Indian companies is limited and 
fragmented.  A study involving 273 Indian managers measured the effects of 
demographic (age, gender, education, nationality, and culture), personality (locus of 
control, achievement need, and ambiguity intolerance), and work-related (organizational 
level, tenure, and organizational size) factors on managerial preference. Regression 
analysis revealed that younger managers, male managers, and managers with high 
ambiguity tolerance were significantly more likely to prefer prospector strategies 
(Williams and Narendran 2000).  This study, however, was distributed geographically in 
India and Singapore and did not focus on any particular industry.   
Another study in India applied the Miles and Snow typology to look at 20 firms 
having design and manufacturing departments and understanding the relationship 
between these two departments.  Bhartia et al. (2008) argued that manufacturing had the 
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“veto” in decision making over design the design department in defender firms and vice-
versa in prospectors. Analyzers tended to use third party “integrators” to coordinate 
activities of design and manufacturing.  This study also covered a broad range of 
industries including footwear, stationary, automotive and industrial firms (Bhartia et al. 
2008). 
A study of 34 Indian software companies used the Miles and Snow Typology to 
understand their business strategic models and linked it to human resource management 
practices and organizational performance (Paul and Anantharaman 2002).  This study 
found that prospectors had a comparative advantage over other strategic types in almost 
all performance parameters.  This study included responses from 370 respondents from 
34 companies, but only 22% of the participants were from small-scale companies.  About 
half were from large Indian companies and almost thirty percent belonged to 
multinational companies.  Paul and Anantharaman (2002) acknowledged the fact that 
most studies on business strategy and human resource practices were conducted in the 
United States. 
The research in this dissertation focuses exclusively on indigenous biotechnology 
companies in India most of them with fewer than 100 employees and helps bridge the gap 
identified in the literature on the Miles and Snow typology in developing countries and 
emerging industries.  This researcher tested the applicability of this typology to both a 
developing country and an emerging industry.  A review of the limited number of 
existing studies on Miles and Snow strategy types application in the biotechnology sector 
is presented below. 
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Miles and Snow in Biotechnology 
While the biotechnology industry may have been conceived almost four decades 
ago (Ebers and Powell 2007), it is believed to be the dynamic growth sector in the first 
half of the twenty-first century (Ruttan 2001).  The field of biotechnology is generally 
considered an early stage or emerging industry and is typically associated with a high rate 
of innovation (Weisenfeld et al. 2001).  Weisenfeld et al. (2001) laid out a proposed 
model of the biotechnology industry highlighting the concept of collaboration to 
demonstrate the various forms of networks along key differentiating characteristics of 
academic disciplines, technologies, company strategies, and target markets.  This view 
was supported in previous research conducted between 1990 and 1995 that biotechnology 
companies in the United States grew by being connected to “benefit-rich networks” and 
biotech firms, which often tended to be small start-ups, acted as sources of innovations 
for large, established pharmaceutical companies (Powell et al. 1996).  Biotechnology is 
an especially young industry in India and is considered to be the sunrise industry of the 
country’s economy (Mueller 2008).  
There have been a few studies conducted to look at the business strategies of 
biotechnology companies, but most of them have focused on the USA or Europe (Müller 
et al. 2004).  Research by Chakrabarti and Weisenfeld (1989) surveyed 64 biotechnology 
firms in the USA about their R&D strategy, marketing focus and sources of technology 
and classified them on the basis of their technology acquisition as (1) internal developer, 
(2) joint developer, and (3) cooperative financed.  Three marketing clusters were 
presented: (1) market penetrator, (2) innovative marketer, and (3) market developer.  The 
R&D clusters were: (1) defensive strategy, (2) aggressive strategy, and (3) research-
intensive strategy.  The researchers concluded that innovative firms were inclined to 
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depend on external sources of technology (Chakrabarti and Weisenfeld 1989).  A 
quantitative study of the business models of the Italian biotechnological firms showed the 
existence of four clusters grouping biotechnological firms namely “service companies,” 
“small research companies,” “traditional integrated firms,” and “industrialized integrated 
firms” (Bigliardi et al. 2005). 
Miles and Snow typology has only been recently applied to the field of 
biotechnology.  One of the earliest and frequently cited studies, which directly applied 
the Miles and Snow typology to the biotechnology sector, was conducted by Ursula 
Weisenfeld-Schenk in 1994.  The objective of this study was to look for different 
strategic types based on the company’s choice of technology strategy, and characterize 
differences in firm performance and willingness to take risks.  Results were based on a 
sample of 41 biotechnology firms in the United Kingdom and Germany.  The study 
concluded that Miles and Snow typology was applicable to biotechnology companies and 
even though prospectors types in this industry were not more inclined to take risks than 
defenders and analyzers; prospectors perceived risks as being “less high” in this industry 
(Weisenfeld-Schenk 1994). 
There appears to be a long chronological gap in the literature on studies applying 
Miles and Snow typology to the biotechnology sector and only a few articles have 
appeared recently since 2006.  Hynes and Mollenkopf (2006) compared strategic, market 
and technological orientations of companies they considered “dedicated biotechnology 
firms” (DBFs) and related that to company performance.  These researchers showed that 
DBFs operate in “turbulent environments” where knowledge creation, alliances, and early 
technical leadership are critical to the success of the business.  They concluded that 
importance of technological orientation for DBF’s not as important.  However, this study 
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was limited to companies in United Kingdom, United States, Australia and Canada.  This 
study proposed a new scale for evaluating DBFs’ firm performance which was based on 
the Miles and Snow typology along with several other strategic orientation typologies 
(Hynes and Mollenkopf 2006).  Another study looked at the business models of Italian 
biotechnology companies and compared the researchers’ classification of “new 
biotechnology firms,” “integrated firms,” “service firms,” and “biotech suppliers,” to the 
Miles and Snow typology (Nosella et al. 2006). 
An interesting study by Gao et al. (2008) examined the IPO (initial public 
offering) prospectuses of 57 biotechnology firms listed on the NASDAQ stock market 
between 1997 and 2002 and attempted to correlate company strategy type to the first-day 
initial and 30-day returns based on how that strategy was communicated.  This study 
found that consistent communication of a prospector strategy negatively impacted 30-day 
initial returns, whereas consistent communication of a defender strategy positively 
impacts 30-day initial returns.  Gao et al. (2008) concluded that consistent 
communication of a prospector strategy by the company limited underpricing of the stock 
and first-day returns would be close to expected returns.  They asserted that a defender 
strategy caused significant underpricing and attributed this to the notion that 
biotechnology firms are expected to be prospectors, or dynamic and flexible in the market 
(Gao et al. 2008). 
The only study to apply Miles and Snow typology to biotechnology companies in 
a developing country was published very recently and looked at 19 medicinal 
biotechnology companies in Shanghai, China.  Most of the companies interviewed 
followed the Miles & Snow analyzer strategy and only two companies were clearly 
prospectors.  Malone et al. (2008) studied the same companies using the Porter Generic 
  
33
Strategy typology also and indicated that most are using cost leadership strategies. The 
researchers conclude that strategic behavior of these companies is could change quickly  
given the dynamics of the global market in which they could participate, but it appeared 
that government-sponsored monopoly policies were driving low-cost strategies rather 
than innovation-based differentiation strategies (Malone et al. 2008).  This strategic 
behavior is in sharp contrast to what is generally expected from biotechnology companies 
in the United States and Europe as described previously in this chapter.  The proposed 
dissertation is expected to be first study of the Indian biotechnology sector to understand 
the strategic orientation of the “home-grown” companies and to understand their 
networking environment.  The Miles and Snow strategy type will be considered in 
conjunction with the technology adopter categories as described in the Diffusion of 
Innovation theory, which is covered in the next section. 
As the Indian biotechnology sector is developing rapidly, it is important to 
understand not only the strategic orientation of these companies, but also these 
companies’ ability to innovate.  A key component in the success of industrial firms is the 
extent of their innovativeness, which implies a firm’s capacity for introducing new 
processes, products, or ideas within the organization (Hult et al. 2004).  Innovativeness is 
one of the factors over which the management has considerable control and enables 
managers to devise solutions to business problems that ensure the survival and future 
success of the firm (Hult et al. 2004).  Innovativeness is viewed as one of the core value-
creating capabilities, which drives market orientation-firm performance relationship.  
Market orientation is defined as the fundamental tenants of organizational behavior with 
respect to a firm’s customers, competitors and internal functions (Han et al. 1998).  A 
strong linkage between market orientation and innovativeness has been proposed by 
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researchers for achieving superior business performance outcomes (Deshpandé et al. 
1993) and more recently they showed that success of Chinese firms in Shanghai 
competing in business-to business markets was related to innovativeness, a high level of 
market orientation and outward oriented organizational cultures (Deshpandé and Farley 
2000). 
Innovation Studies in Biotechnology 
As demonstrated earlier, innovation is considered to be the driver for 
biotechnology and the companies involved in this type of work are generally expected to 
portray Miles and Snow Prospector type behavior.  The following literature review looks 
at articles on the role of innovation in the biotechnology sector.  The studies, which were 
found, dealt again with the developed nations, as was the case with the application of the 
Miles and Snow Typology. 
Research published by the National Academy of Sciences (Zucker and Darby 
1996) showed that diffusion of biotechnology innovations in the United States in the 
1970’ and 1980’s was rather slow because the most productive (“star”) bioscientists were 
very protective of their techniques, ideas, and discoveries in the early years of the 
revolution, tending to collaborate more within their own institution and not with outside 
scientists.  Where and when star scientists were actively producing publications is a key 
predictor of where and when commercial firms began to use biotechnology.  The extent 
of collaboration by a firm’s scientists with stars is a powerful predictor of its success: for 
an average firm, 5 articles coauthored by an academic star and the firm’s scientists result 
in about 5 more products in development, 3.5 more products on the market, and 860 more 
employees.  Zucker and Darby (1996) state that the U.S. scientific and economic 
infrastructure has been particularly effective in fostering and commercializing the 
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bioscientific revolution.  These results show the process by which scientific 
breakthroughs become economic growth and consider implications for policy. 
A qualitative study conducted by Bernstein and Sing (2008) on nine Australian 
biotechnology companies examined the social and behavioral actions, activities and 
practices in order to group them together to create behavior-based profiles that 
characterize the various stages of the innovation generation processes within the 
organizations.  They used the five DI theory adopter categories to broadly identify and 
classify the types of companies.  Furthermore, these researchers applied Moore’s 
metaphor of “chasm” to explore the nature of difficulties that organizations face in 
converting innovative ideas into commercially successful products and services. 
Bernstein and Sing (2008) found that the use of the labels from the categories of the 
adopter categorization model enabled suitable behavior-based profiles to be developed 
and the categorization model provided a fuller and richer insight into the innovation 
generation process.  They concluded that the model could also be used to assess more 
holistically the viability of innovations as they progress from inception to 
commercialization (Bernstein and Singh 2008). 
A study by Bartholomew (1997) explored the relationship between national 
institutional context and the development of biotechnology in the United States, United 
Kingdom, Japan and Germany. Bartholomew demonstrated that in biotechnology, the 
integration of basic and applied research that is required for innovation takes place 
largely between firms and research institutions, rather than within firms.  Accordingly, 
biotechnology innovation may be conceptualized as the product of the accumulation of 
scientific knowledge in research institutions and firms (stocks) and the diffusion of that 
knowledge between them (flows).  Each national system may be seen to embody a set of 
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technical, institutional and organizational capabilities, which represents that society’s 
“preferred solution” for advancing biotechnology and provides compelling motivation for 
international technological cooperation.  Tapping into foreign innovation systems by 
forming cross-border alliances thus may be one of the most important means for firms to 
enhance their innovative capability in biotechnology, underscoring the growing 
significance of inter-firm partnering (Bartholomew 1997).  Bartholomew emphasized the 
need for inter-connectedness and networking for biotechnology firms as a means to spur 
innovation in biotechnology at the national level.  
The concept of National Innovation Systems has been applied to the United 
Kingdom (Cooke 2002), Brazil (Marques and Neto 2007), and India (Chaturvedi 2007) as 
well.  The researchers have linked the National Innovations Systems to Sectoral 
Innovation Systems.  In the case of biotechnology, universities are key knowledge 
sources, but to transfer science from the laboratory bench to the market involves 
complex, interactive chains of transactions among scientists, entrepreneurs, and various 
intermediaries including investors and lawyers. Proximity to such services and research 
hospitals for clinical trials creates an innovation system for biotechnology, which is best 
analyzed regionally and locally (Cooke 2002).  Chaturvedi (2007) studied the policy 
regime facilitating this new era of major expansion in the Indian pharmaceutical industry 
and the new efforts to incorporate strategies targeting biotechnology innovation and 
discusses the future growth prospects of the Indian biopharmaceutical industry.  The 
Brazilian study suggested that even though Brazil had a scientific tradition in 
biotechnology and financing, there was still a long way to go as start up company 
financing and the cultural aspect of business aversion by researchers seem to be the main 
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obstacles for Brazil to become a significant player in this sector (Marques and Neto 
2007). 
As mentioned previously, networks in the biotechnology industry play an 
important role in the diffusion of innovations.  Some of the studies have focused the 
collaboration aspect and spatial clustering of biotechnology companies and a result on 
firm performance (Powell et al. 1996).  This study stressed that the locus of innovation 
will be found in networks of learning, rather than in individual biotechnology firms, yet 
on the other hand saw an issue with the large-scale reliance on inter-organizational 
collaborations in the biotechnology industry reflected a fundamental and pervasive 
concern with access to knowledge.  Another study by the same core group of researchers 
examined the relationship between position in a network of relationships and 
organizational performance and study highlighted the critical role of collaboration in 
determining the competitive advantage of individual biotechnology firms (Powell et al. 
1999).  A third, and more recent study by Powell et al. (2002) looked into the spatial 
clustering of biotechnology firms and their ability to seek venture capital.  The 
importance of tacit knowledge, face-to-face contact, and the ability to learn and manage 
across multiple projects are critical reasons for the continuing importance of geographic 
propinquity in biotech.  The researchers found that over the period 1988-99, more than 
half of the US biotech firms received locally based venture funding.  They concluded that 
biotechnology is unusual in its dual dependence on basic science and venture financing; 
other fields in which product development is not as dependent on the underlying science 
may have different spatial patterns.  Their other studies were also focused primarily on 
U.S. based biotechnology companies. 
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A study on the formation of the biotechnology cluster in San Diego, California, 
showed support for the notion that sustainable clusters are linked to the existence of 
dense social networks across key personnel supporting career mobility (Casper 2007),  
but as in the case of San Diego sustainable social networks emerge relatively slowly.  
Casper’s (2007) research showed it took about 15 years for this cluster to become 
sustainable, at least in terms of social network organization.  The dominant role in 
seeding the development of subsequent generations of biotechnology companies in San 
Diego was attributed to managers associated with a single successful start-up company 
called Hybritech (Higgins 2005), and in doing so established the core of social networks 
linking managers during the formative stages of the cluster.  The successful trajectory of 
San Diego’s biotechnology cluster may not have materialized without the presence of a 
group of experienced biotechnology managers willing to embrace and commercialize 
local university technologies (Higgins 2005). 
Much of the biotechnology innovation studies in India have focused on 
agriculture and the adoption of various agricultural practices or products such as 
genetically modified seeds or crops.  Some of the studies date back to the early 1970’s.  
Dasgupta (1989) surveyed three hundred publishded studies, theoretical and empirical 
research, covering a 25 year period of on the agricultural diffusion of innovations in rural 
India.  In summarizing Dasgupta’s findings, Vail and McIntosh (1990) noted that early 
adopters of agricultural biotechnology in India tended to have higher literacy and 
education levels, and non-adopters had a stronger orientation to the sacred and traditional. 
Policy and Finance Environments in India 
The policy environment in India has gone through some important milestones 
over the last twenty years that may have potentially impacted the biotechnology sector in 
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this country either directly or indirectly.  On a macro level, the major economic reforms 
instituted by the government starting in 1991 have impacted all sectors of the economy 
and the era since then has been dubbed as the “post-reform India” (Chakraborty and 
Nennenjamp 2008).  On a micro level, the change in patent regime instituted in 2005 is 
expected to impact the biotechnology sector directly and is explored in greater detail 
below.  Even though there is a big difference in the revenues of the IT and biotechnology 
sectors, the Indian policy makers often refer to biotechnology as the industry of new 
opportunities in the current millennium and more specifically a driver the country’s 
export sector.  Despite the policy maker rhetoric, many challenges exist before India can 
achieve exports with sustained high growth in excess of twenty percent every year 
(Chadha 2000). 
The economic reforms were started in the 1980’s and India’s real gross domestic 
product per capita more than doubled between 1980 and 2000, which prompted Martin 
Wolf, author of Why Globalization Works (2004), to call India and China’s liberalization 
and move away from self sufficiency to an international exchange as one of the most 
important events of the last two decades of the twentieth century.  Low productivity of 
investment after the independence in 1947 till 1980 was a product of “four interconnected 
characteristics of economic policy: inappropriate and excessive state interference in the 
market mechanism, the dominant role of public sector, fiscal deformities, and neglect of 
critical social sectors” removing India from the benefits of international division of labor 
and more importantly diffusion of technology (Joshi 1998, 334).  Since 1991, the 
philosophy of trade protectionism has given way to the removal or lowering of import 
restrictions and tariffs on many producers’ goods.  The average tariff rate in the post-
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1991 era was brought down to 35% from an average nominal rate of 125% with a peak 
rate of 355% (Joshi 1998), making imported goods much less expensive. 
Foreign Direct Investment 
During the reform period, the stock of foreign direct investment (FDI) in India 
also rose steeply from less than US$ 2 billion in 1991 to about US$ 45 billion in 2005 
(UNCTAD, online database) as the Indian economy opened up the to world markets. FDI 
is widely regarded as a composite bundle of capital inflows, knowledge, and technology 
transfers (Balasubramanyam, Salisu, and Sapsford 1996).  Hence, the impact of FDI on 
growth is expected to be manifold (de Mello 1997).  In line with expectations that it was 
mainly the manufacturing sector that benefited from trade liberalization, financial 
liberalization and human-capital formation in post-reform India, and the complementary 
process of technological diffusion these industries have become more closely integrated 
into world markets in terms of exports and imports as well as in terms of technology 
transfers.  The services sector has seen a rising share of inward FDI since the mid 1990’s 
and may have also contributed to the stimulation of the manufacturing sector.  
(Chakraborty and Nennenjamp 2008).  However, the regulatory attitude to foreign direct 
investors, who could be the fuel for India’s export drive, continues to be ambivalent.  The 
government promotes FDI on the one hand, but then maintains regulations against full 
foreign ownership, or insists on lengthy approval processes, on the other hand (Bajpai 
and Sachs 2000).  The government’s goal of attracting greater levels of foreign direct 
investment (FDI) by enacting stronger intellectual property legislation, which is 
discussed later in this chapter, appears to be working in the biotechnology sector; for 
example, DuPont recently announced plans to build a $23 million research and 
development center in Hyderabad that will focus on biotechnology and bioinformatics 
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innovation (Mueller 2008).  Another example of pharmaceutical related FDI is the recent 
inauguration of GlaxoSmithKlein (GSK) new facility near New Delhi.  The facility was 
built at a cost of Rs. 1.5 crore (about $35 million) and will be able to produce one-eight 
of GSK’s global medicine output when the facility is fully operational later this year.  
Andrew Witty, company CEO, referred to India as “a great economic story for the next 
50 years” (Som 2010, n.p.). 
Patent Regulations in India 
Another major policy change in India took effect in 2005 and was driven by the 
global Agreement on Trade-Related Aspects of Intellectual Property Rights (the TRIPS 
Agreement).  India became a party to the TRIPS Agreement in April 1994 and effected a 
change to the Patent Act of 1970.  Upon coming into effect on January 1, 1995, TRIPS 
set out transitional periods for the World Trade Organization (WTO) members to 
introduce legislation complying with the obligations under TRIPS.  For developing 
countries, like India, the deadline for complying with TRIPS was the year 2000 with a 
special five-year transitional provision for those countries that did not grant product 
patents. India took advantage of this extra transition period and a major shift was the 
recognition of product patents for “food,” “drug,” and “pharmaceuticals” on January 1, 
2005.  The Act repealed the controversial Section 5(1) of the Patents Act, 1970, which 
provided for process patents in this field, and also removed the definition of food.  A 
chronology of Indian patent regulations is presented in Figure 2.3. 
The Indian domestic pharmaceutical industry flourished in the absence of product 
patents. The competitive generic market resulted in production of generic versions of 
blockbuster drugs at very low prices.  These generic drugs cost about 5% of the price of 
similar drugs sold by American and European pharmaceutical firms.  Apart from the 
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large domestic consumption, cheap Indian generic drugs have been favored by many 
millions of AIDS patients across the Third World.  Generic drugs from India played a key 
role in lowering the price of antiretroviral treatment by as much as 98%, making it 
feasible to scale up treatment more rapidly for 3.7 million Africans with AIDS lacking 
access to treatment.  Since the new law came into effect on January 1, 2005, there have 
been serious concerns regarding the role of the domestic Indian generic industry in the 
new product patents regime, and the continued availability of essential medicines at 
affordable prices.  For India’s domestic consumers, medicines patented pre-1995 would 
continue to be available at the same prices.  Prices for medicines that are the subject of 
patents issued after 2005 would probably be higher (Ram 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Chronology of Indian Patent Regulations  
Adapted from The Impact of Higher Standards in Patent Protection for Pharmaceutical Industries 
under the TRIPS Agreement – A Comparative Study of China and India, by X. Li (2008) 
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The Patent Act of 1970 had specifically excluded pharmaceuticals and 
agrochemical products from eligibility for patents.  This exclusion was introduced to 
break India’s dependence on imports of bulk drugs and formulations and provide for 
development of a self-reliant indigenous pharmaceutical industry.  However, on account 
of lack of capital and the prohibitive expense associated with fundamental research, the 
Indian pharmaceutical companies avoided this segment and instead opted for generics 
manufacture.  The process patent system in vogue had encouraged Indian companies to 
undertake cost effective and efficient methods of developing alternate processes for 
existing drugs. TRIPs commands tremendous potential as a constructive tool for 
scientific, technical and economic progress in countries like India.  The product patent 
regime compels pharmaceutical companies to aggressively explore drug discovery 
options as a part of their survival bid.  This shakes off the complacency that had crept in 
under the process patent regime (Bhaduri and Mathew 2004).  Biotechnology patenting in 
India is still in its infancy in 2007 and India’s patent laws were amended in 2002 to 
explicitly include “biochemical, biotechnological, and microbiological processes” within 
the definition of potentially patentable “chemical processes” (Mueller 2008, 2). 
There are conflicting views in the literature related to legal systems and economic 
growth.  On one side, there has been a long held view that strong patent protections 
dampen growth in less developed countries (Penrose 1951; Greer 1973; Vaitsos 1972).  
Because these countries use more R&D intensive products than they develop, they are 
hurt by the increase in prices due to patent related monopoly protection.  On the other 
side, there are those that suggest that strong patent protection is important for strong 
economic performance.  Maskus (2000) argued that patent protection promoted 
innovative activity, even in less developed nations.  Mazzoleni and Nelson (1998) 
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surveyed the literature related to patent protection and identified four broad theories.  
First, patent protection stimulates invention.  Second, patent protection promotes the 
commercialization of inventions.  Third, patents reward the disclosure of inventions.  
And fourth, patents promote a wider exploration of wider uses of inventions. 
This research was interested in looking at the second theory related to the 
commercialization of inventions, as Indian patent protection is improving (Chaudhuri 
2007).  In essence, the holding of a patent allows an inventor to ensure to outside 
financing sources that the invention they are investing in will not be commercialized by 
another firm.  This promotes the commercialization (and the larger economic growth 
benefits) of inventions because inventors and investors are rewarded through economic 
rents associated with the exclusive rights to their technology. 
On a larger scale, the relationship between property rights and economic growth 
has been shown at the national level in many studies.  De Soto (2000) states that there is 
an “economic subconscious” at work in the West, where the importance of capital and its 
accumulation is taken for granted, where an “implicit legal infrastructure” is “hidden 
deep within their property systems –of which ownership is but the tip of the iceberg”  (8).  
For De Soto this is a key differentiator between the developed and less developed world.  
Johnson, McMillan and Woodruff (2002) put it more bluntly: “Property rights are 
fundamental: entrepreneurs will not invest if they expect to be unable to keep the fruits of 
their investment. Country level studies consistently show that less secure property rights 
are correlated with lower aggregate investment and slower economic growth” (1335).  
They found evidence in Eastern Europe and the former Soviet Union that weak property 
rights made it less likely for firms to reinvest profits back into the business.  LaPorta, 
Lopez-di-Silanes, Shleifer and Vishny (1997, 1998, 2000) found that countries with 
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better legal protections for investors and better financial institutions have better financial 
outcomes, both at the micro and macro levels.  The stronger protections, primarily found 
in countries with English common-law origins, promote firms’ use of external capital 
markets.   
As noted earlier, with no indigenous firm engaged in drug discovery a decade 
ago, this change is considered a significant strategic shift towards full integration into the 
global pharmaceutical industry.  However, the new IP regime appears to have changed 
the emphasis of pharmaceutical innovation in India.  From less than 2 per cent of industry 
sales spent on research and development (R&D) a few years ago, leading Indian firms 
have now increased their R&D expenditure to around 10 per cent of their annual sales 
revenue.  The Indian industry’s R&D expenditure, now estimated at around $250 million 
annually, is expected to grow to $500 million by 2010. In addition, the contract research 
organizations’ and MNCs’ expenditure of $100 to $150 million on R&D is expected to 
grow to $500 to $600 million by 2010.  Taking into account the low costs in India, the 
estimated expenditure would be an equivalent of $3 to $4 billion spent in US or Europe. 
Special Economic Zone (SEZ) Policy 
One of the policy tools being used by the Indian government to promote 
biotechnology is the formation of Special Economic Zones or more commonly known as 
SEZ’s.  An SEZ is considered a duty free enclave that is not under the national import-
export regulations and economic laws which are less restrictive.  More specifically, 
licenses are not required for import of capital goods and raw materials, and consumables 
are exempt from custom duties.  The sales taxes on domestic purchases are reimbursed on 
economic activity in the SEZ’s and customs duties are not levied on manufactured goods 
exported from these zones (Wheelwright and Bagaria 2008).  Three SEZ’s involved in 
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biotechnology acitivity were identified by Wheelwright and Bagaria (2008), with two of 
them located in Bangalore and one in Pune.  There is a severe lack of academic literature 
on biotechnology related SEZ activity as indicated by the search results shown in Table 
2.1.  The results from both databases were mostly newspaper article citations and often 
duplicated. 
Table 2.1 
 
Results of Literature Review on Special Economic Zones (SEZ) 
Database: EBSCO Host 
India SEZ  373 (1969 – 2010) 
India SEZ Biotech* 5 (2001 – 20009) 
Database: JSTOR 
India “Special Economic 
Zone” 
 121 
India “Special Economic 
Zone” 
Biotech* 0 
India SEZ  504 
India SEZ Biotech* 24 
Note: * implies a wildcard character 
 
According to policy makers quoted in the Times of India, SEZs are a vehicle for 
investment and increased employment opportunities (2006).  These geographic areas are 
designed to encourage exports, have speacial rules for IT and biotech, but critics 
complain that they still need to be too big for these industries.  While several news stories 
were available related to biotechnology SEZ through on-line databases, no academic 
literature on this subject was discovered.  The news items are summarized below.  One of 
the largest issues dealing the use of SEZ’s for both information technology and 
biotechnology was the minimum allowable size of these facilities.  As reported by the 
Times of India newspaper (2006), the government officials agreed to lower the 
requirements to ten hectares (approximately 25 acres) from 25 hectares (approximately 
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75 acres) of land area and built area of 40,000 square meters for biotechnology and non-
conventional energy.  Interestingly, these changes still allow the SEZ developers to 
earmark up to 65 percent of the area for residential plots, malls, hotels, schools and 
hospitals, although that set aside was decreased from the 75 percent allowable previously 
for such infrastructure.  The IT industry is still complaining about the size of these 
facilities and claims that these requirements will need employment in the range of 10,000 
people; a requirement which industry leaders say is not feasible in second tier cities like 
Jaipur (Rajasthan) or Bhubaneswar (Orissa) due to a lack of sufficient skilled labor 
(Rajawat 2006). 
The SEZ policy has prompted some major groups in India to announce their entry 
into biotechnology SEZ’s and has created joint venturing opportunities with foreign firms 
such as the alliance between the Videocon Group and a French company.  This SEZ is 
expected to attract on an investment of Rs. 150 crore or about $33 million (Mukherji 
2007); however, more recent news was not found on the Internet since the initial 
annoucement.  That same year Reliance Industries, backed by the globally renowned and 
prominent Ambani family, also expressed interest in a biotechnology SEZ.  Times of 
India reported 386 proposals for various industry sector SEZ’s were approved by 
September 2007 and another 149 were notified of pending status.  A more recent 
announcement proclaimed a three billion dollar investment over the next three yeas in a 
390-acre pharmaceutical and chemical manufacturing SEZ located in the state of Gujarat.  
The promoter of this SEZ, Dishman Pharmaceuticals and Chemicals, intends to only 
include mid-size and large companies operating in these two sectors, even though the 
SEZ is expected to accommodate 50 to 60 companies (Ramesh 2009). 
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VC Funding and Biotechnology Entrepreneurship 
Biotechnology is a knowledge-intensive industry that requires a large amount of 
capital for research and development.  The Biotechnology Industry Organization (2006) 
indicates that approximately one fourth of the industry financing comes from venture 
capital, which provides not only money but also managerial guidance to biotechnology 
firms.  Data gathered in 2006 by The Biotechnology Industry Organization found that 
biotechnology venture activities were highly clustered in urban centers with socio-
economic diversity.  Such firms are also located in close proximity to research 
universities, institutes and/or hospitals, where there was a strong life science research 
base and a large pool of life scientists.  These firms also clustered in areas with large 
pharmaceutical companies, venture capital providers and entrepreneurial spirit as well 
(Chen and Marchioni 2008). 
The term “bioentrepreneur” is commonly used in the literature to describe 
enterprising individuals in the field of biotechnology.  Hurwitz (1999) tends to believe 
that most biotechnology companies are headed by a bioentrepreneur—“an individual with 
patentable dreams and the conviction to turn these dreams into a commercial success” 
(35). Hurwitz further describes the personal attributes of a bioentrepreneur as typically 
coming from the upper echelons of academia where they may have conducted pioneering 
scientific research or made important discoveries.  However, this individual most often 
has more than technical expertise driving him or her and are fearless and strongly self-
motivated.  From the set of profiles described above, it may surprise many 
bioentrepreneurs that millions of dollars change hands in this industry based on people 
issues rather than on a cold objective analysis.  To be sure, the analytic aspect of the 
industry is well supported—millions of dollars are spent on due diligence.  But at the end 
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of the day, when one is forced to make a decision, this industry has found that what it is 
really investing in is people: individuals who have the capacity to make things happen in 
the face of adversity (Hurwitz 1999). 
A survey (Richard et al. 2009) of the financing methods of 19 Shanghai medicinal 
biotechnology companies revealed a lack of private venture capital fund participation.  
Alternatively, these companies have obtained financing from government sources based 
substantially on the reputation and relationships of the companies’ officers with 
government officials.  This aligns with recent literature suggesting that China is an 
exception to the dominant body of literature on the relationship of strong legal and 
financial institutions to the commercialization process.  The dominant body of literature 
suggests that strong legal and financial institutions are needed to provide patent 
protection to promote inventions and their commercialization, which in turn protects 
investors and promotes financing of the commercialization process (Richard et al. 2009). 
While many banks and other financial institutions provide conventional debt 
financing, they have pursued very conservative lending practices.  Consequently, new 
entrepreneurs have faced difficulty in obtaining project financing in and a lack of venture 
capital was identified for areas such as information and communication technology, 
healthcare and medicine, non-conventional energy and biotechnology.  Venture capital 
activity was formalized only as late as 1988 when the central government announced 
guidelines for the establishment and functioning of the industry (Mitra 2000).  The 
government itself got into the action by sponsoring several VC firms.  The central 
government introduced new and improved guidelines in 1996 for regulating India’s VC 
industry, but the growth of this industry has been hampered by conservative government 
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policies, limited availability of funds and an inadequate equity market infrastructure 
(Mitra 2000). 
Development of Biotechnology in India 
Reviewing the prior literature, most scholars studied the Indian biotechnology 
industry from the perspective of the larger firms, which are mentioned in the mass media.  
Information from the manager’s perception or of the market structure and their 
market/business development strategy is lacking.  Most of the research has focused on 
identifying and categorizing the companies based on their products and services (Feller 
and Wolff 2003; Kumar et al. 2004; Frew et al. 2007; Kumar 2007; Frew et al. 2008; 
Suresh and Rao 2009), and a limited number of studies have discussed them from the 
viewpoint of technology and business management (Arora 2005; Kale and Little 2007; 
Bagchi-Sen and Smith 2008; Konde 2009). 
Over the past few years, India has earned a spot on the global map of the 
biotechnology industry.  India currently has close to 400 biotechnology companies, with 
total expenditures rising from $150 million in 1988 to $300 million in 1998 to $500 
million in 2003.  International companies such as Monsanto, Pfizer, AstraZeneca, 
Unilever, DuPont, Bayer, Novaritis, and Eli Lily have all located in India.  Outside of the 
recognized biotechnology hubs such as San Diego, San Franciso, Boston, Cambridge, 
UK and Munich, Germany (Casper 2007), a recent article by the trade publication 
Business Facility, named Bangalore, in the state of Karnataka, India as one of the most 
active biotechnology areas in the world along with St. Louis (Missouri), Texas, Arizona 
and Saskatoon (Vickers 2008).  A report by the accounting firm Ernst & Young states 
that Bangalore as well as Hyderabad (located in the state of Andhra Pradesh) are using 
the enclave city approach by building biotechnology parks which feed companies, and 
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solve infrastructure problems, with their own sub-economy, state-of-the art infrastructure, 
and friendly regulatory and business environment (Giovannetti and Jaggi 2008). 
In order to give a systematic impetus to the development of this very important 
field of science – biotech – during 1981-1982, the then Scientific Advisory Committee to 
the Cabinet, had detailed deliberations with the scientific community, and a National 
Biotechnology Board (NBTB) was set up in 1982 to look into scientific programs in the 
are of biotech, which required financial support for strengthening indigenous capabilities.  
Based on the progress in the areas of creating infrastructure, human resource 
development and specific research initiatives as well as the need for a major effort in this 
field, the Government decided to set up a separate Department of Biotechnology in 
February 1986.  The mandate of the Department is to support research and development, 
technology validation and demonstration, set up centers of excellence, build a strong 
human resource and promote industry-academia interaction and technology transfer.  To 
fulfill the mandate, a number of programs have been supported in different fields of 
agriculture, health, environment and industry (Ghose and Ghosh 2003). 
During the last 15 years, since the DBT came into being, a strong infrastructure 
for biotechnology research and services has been created in the national laboratories and 
academic institutions across the country.  An integrated human resource development 
program, support to basic and applied and product oriented research has resulted in 46 
technologies have been developed and transferred to the industry in addition to numerous 
technical and research publications.  A unique feature of the DBT has been to promote 
strong interaction between scientists and institutes across the country to promote 
biotechnology research and development efforts for commercialization and also to benefit 
the rural population for socio-economic development.  Another important feature has 
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been the interaction at the State government level to promote biotechnology to meet the 
needs of the various regions.  The investment in the area of biotechnology has increased 
from 750 million rupees (Rs.) in 1992-93 (about US$ 16.7 million) to Rs. 2,250 million 
(about US$ 50 million) in 2002-2003 (Ghose and Ghosh 2003). 
The Indian Government has been playing an important role in the development of 
the Biotech sector from the very beginning, and there are large numbers of R&D 
institutions (scientific, medical, industrial and agricultural) that have been set up by the 
Government during the past two to three decades.  The Indian Biotechnology industry is 
advancing towards new heights in alignment with the growth and progression observed 
globally.  The past performance of the industry indicates that it has surpassed the growth 
rate of many other industries and favorable national policies have facilitated the 
collaborations in the biotechnology sector (Konde 2008). 
Another factor driving India’s biotechnology boom is the rapidly expanding 
worldwide market for generic versions of bio-pharmaceuticals, also referred to as 
“generic biologics” or “bio-generics.”  “Bio-generics” are copied versions of 
biopharmaceuticals, which are “the drugs/vaccines/biologicals derived from living 
organisms through biotechnological tools” (Dey 2009, n.p.).  Biopharmaceuticals are 
more complex molecules than traditional pharmaceuticals and hence “difficult to 
consistently manufacture in quality and quantity” (Dey 2009, n.p.).  As an international 
leader in the manufacture of generic versions of traditional synthetic, small-molecule 
chemicals, India appears uniquely situated to supply the demand for generic biologics.  
India has a history of producing generic medicines at low cost and high quality.  The 
reverse engineering and process development skills set of India’s traditional generic 
manufacturers are already being transferred to copying off-patent biologics.  The 
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companies involved in generic biologic manufacture are recognizable names in the Indian 
pharmaceutical industry and some researchers fear that given the demand for bio-
generics, Indian companies may not invest in new drug development.  Under this 
scenario, the enhanced incentives provided by India's newly strengthened patent regime 
would not be of much value for further developing human capital and research skills 
(Mueller 2008). 
Table 2.2  
Chronological Review of Scholarly Works on Biotechnology in India 
Year Authors Title Publication Methodology & Analysis 
2001 Mehra, K. Indian system of innovation in 
biotech−A Case study of 
Cardamon 
Technovation National system of 
innovation framework, 
case study 
2002 Ramani, S. Who is interested in biotech? 
R&D strategies, knowledge  
base and market sales of Indian 
biopharmaceutical firms 
Research Policy Secondary data and 
interviews, company 
R&D activities and 
personnel makeup, 
quantitative analysis 
2002 Visvanathan, S., 
Parmar, C. 
A Biotechnology Story: Notes 
from India 
Economic and Political 
Weekly 
Qualitative narrative on 
the foundation of Indian 
biotechnology industry 
2003 Chaturvedi, S. Biotechnology: Need for 
reliable statistics 
Economic and Political 
Weekly 
Secondary data analysis 
2004 Kumar, N., 
Quach, U., 
Thorsteinsdottir, 
H., Somsekhar, 
H., Daar, A., 
Singer, P. 
Indian biotechnology - rapidly 
evolving and industry led 
Nature Biotechnology Industry analysis based on 
interviews and secondary 
data 
2004 Srinivas, S. Technological learning and  
the evolution of the Indian 
pharmaceutical and 
biopharmaceutical sectors 
Doctoral Dissertation, 
Massachusetts Institute 
of Technology 
Personal interviews, 
sector-wide indicators, 
firm level learning 
approach 
2004 Thorsteinsdottir, 
H., Quach, U., 
Daar, A., Singer, 
P. 
Conclusions: Promoting 
Biotechnology Innovation in 
developing countries 
Nature Biotechnology Qualitative policy 
analysis of biotech in 
seven countries 
2004 Wilkie, D. India wants to be your biotech 
source 
The Scientist Secondary data, 
outsourcing potential 
2005 Arora, P. Healthcare biotechnology firms 
in India: Evolution, structure 
and growth 
Current Science Secondary data analysis 
based on BCIL industry 
directory 
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Table 2.2 (continued). 
Year Authors Title Publication Methodology & Analysis 
2005 George, D. S. Global and Local Determinants 
of Entrepreneurial Growth in 
India: Evidence from the 
Biotechnology Industry, 1980-
present 
ASA Conference 
Proceedings, 
Philadelphia 
Personal interviews; 
entrepreneurship and 
globalization, networking
2005 Moza, M. Collaborations to Improve 
Biotech industry in India 
(News) 
Current Science Brief about Indian 
companies seeking 
partnerships in the US 
2005 Palnitkar, U. Growth of Indian biotech 
companies, in the context of  
the international biotechnology 
industry 
Journal of Commercial 
Biotechnology 
Market segmentation, 
product differentiation, 
partnering 
2005 Parmar, H. Biotechnology in India: 
Emerging Opportunities 
Journal of Commercial 
Biotechnology 
Secondary data, policy 
analysis, market 
segmentation 
2005 Peet, N. Biotechnology in India Drug Discovery Today Market segmentation by 
industry consultant 
2005 Ramani, S.V., 
Pradhan, P.,  
Ravi, M. 
Biotech in post-TRIPS India Nature Biotechnology Policy analysis from 
patent regulation 
standpoint 
2005 Shroff, S., 
Robinson, D. 
India's Biotech and Software 
Renaissance 
Managing Intellectual 
Property 
Policy analysis from 
patent regulation 
standpoint 
2006 Clark, N., 
Reddy, P., 
Hall, A. 
Client-driven biotechnology 
research for poor farmers:  
A case study from India 
International Journal of 
Technology 
Management and 
Sustainable 
Development 
Policy debate on status of 
biotechnology for 
international 
development, case study 
of a specific program 
2006 George, D. S. Adapting science, building 
capabilities: the emergence of 
healthcare biotechnology in 
India 
Doctoral Dissertation, 
Duke University 
Personal interviews, 
regional innovation 
systems approach, 
partnerships 
2006 Saberwal, G. New Pharma-Biotech  
Company formation in India 
Nature Biotechnology Interviews and secondary 
data; company formation 
mechanism 
2006 Singh, M. Will India become the global 
center for pharma research & 
development? 
Journal of Generic 
Medicines 
Market segmentation and 
strengths, policy analysis 
2007 Athreye, S., 
Chaturvedi, S. 
Industry associations and 
technology-based growth in 
India 
The European Journal 
of Development 
Research 
Qualitative analysis of 
biotechnology industry 
organizations 
2007 Bower, D.,  
Sulej, J. 
The Indian challenge: the 
evolution of a successful new 
global strategy in the 
pharmaceutical industry 
Technology Analysis 
and Strategic 
Management 
Focus on business models 
of top Indian 
pharmaceutical firms, 
relied on publicly 
available secondary data 
on selected firms 
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Table 2.2 (continued). 
Year Authors Title Publication Methodology & Analysis 
2007 Chataway, J., 
Tait, J., Wield, D. 
Frameworks for  
pharmaceutical innovation in 
developing countries—The  
case of Indian pharma 
Technology Analysis & 
Strategic Management 
Policy analysis on 
innovation in 
pharmaceutical companies 
India 
2007 Chaturvedi, S. Exploring interlinkages  
between national and sectoral 
innovation systems for rapid 
technological catch-up: Case  
of Indian biopharmaceutical 
industry 
Technology Analysis & 
Strategic Management 
Mostly qualitative look at 
Indian biotech sector and 
policy, innovation system 
framework 
2007 Chaudhuri, S. The gap between successful 
innovation and access to its 
benefits: Indian  
pharmaceuticals 
The European Journal 
of Development 
Research 
Policy analysis on drug 
marketing and distribution
2007 Frew, S., Rezaie, 
R., Sammut, S., 
Ray, M., Daar, A., 
Singer, P. 
India's Health Biotech Sector at 
a Crossroads 
Nature Biotechnology Face-to-face interviews 
with company 
representatives; product 
and services 
classification, 
collaborations 
2007 Kale, D., 
Little, S. 
From imitation to innovation: 
the evolution of R&D 
capabilities and learning 
processes in the Indian 
pharmaceutical industry 
Technology Analysis 
and Strategic 
Management 
Industry level interviews 
with academics, 
consultants and patent 
experts; case study of six 
pharma companies via 
interviews 
2007 Kumar, A. Indian biotech bazaar: SWOT 
Analysis 
Biotechnology Journal Secondary data qualitative 
analysis 
2007 Maiti, R., 
Raghavendra, M. 
Clinical Trials in India Pharmacological 
Research 
Technical, financial, 
policy and infrastructure 
opportunities and 
challenges for outsourcing 
clinical trials to India 
2007 Newell, P. Biotech Firms, Biotech Politics: 
Negotiating GMOs in India 
The Journal of 
Environment 
Development 
Company ownership and 
industry organization, 
trade groups 
2007 Scoones, I. The contested politics of 
technology: Biotech in 
Bangalore 
Science & Public Policy Qualitative look at 
biotechnology policy in 
the state of Karnataka 
2007 Thorsteinsdottir, 
H. 
The Role of the Health System 
in Health Biotechnology in 
Developing Countries 
Technology Analysis & 
Strategic Management 
Semi-structured 
interviews and publication 
data analysis to   study 
role of users in the health 
biotechnology innovation
2007 Thorsteinsdottir, 
H., Singer, P., 
Daar, A. 
Innovation Cultures in 
Developing Countries: The  
Case of Health Biotechnology 
Comparative 
Technology Transfer 
and Society 
Technology transfer and 
innovation system 
framework, case study 
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Table 2.2 (continued). 
Year Authors Title Publication Methodology & Analysis 
2008 Bagchi-Sen, S., 
Smith, H. 
Science, Institutions, and 
Markets: Developments in the 
Indian Biotechnology Sector 
Regional Studies Used "environmental 
selection pressures" 
framework developed by 
McKelevey (2004); case 
study of four large bio-
pharma companies 
2008 Fan, P., 
Watanabe, K. 
The rise of the Indian biotech 
industry and innovative 
domestic companies 
International Journal of 
Technology and 
Globalization 
Case study of three 
biotech companies in a 
late-industrializing 
economy 
2008 Frew, S., Kettler, 
H., Singer, P. 
Indian and Chinese health 
biotechnology industries: 
Potential champions of global 
health? 
Health Affairs Indian and Chinese 
biotechnology policy 
analysis 
2008 Joseph, J. Entering the contract research 
industry in India 
Contemporary Clinical 
Trials 
Market segmentation, 
product differentiation, 
partnering 
2008 Khattar, K. The face of partnering in India Applied Clinical Trials Western industry 
perspective on 
outsourcing to India 
2008 Konde, V. Biotechnology in India: Public-
Private Partnerships 
Journal of Commercial 
Biotechnology 
Policy analysis, biotech 
park development, 
secondary data analysis 
2008 Kumar, S., 
Chandra, A., 
Pandey, K.C. 
Bacillus thuringiensis (Bt) 
transgenic crop: An 
environment friendly insect-pest 
management strategy 
Journal of 
Environmental Biology 
Technical, business and 
policy and biosafety 
issues for 
commercialization of Bt 
crops in India 
2008 Mueller, J. Biotechnology Patenting in 
India: Will Bio-Generics Lead  
a “Sunrise Industry” to Bio-
Innovation? 
U. Pittsburg Legal 
Studies Working Papers 
Patent data, policy 
analysis, case study 
2008 Vaidyanathan, G. Technology parks in a 
developing country: The case  
of India 
Journal of Technology 
Transfer 
Role of government in 
biotechnology park 
creation; policy analysis 
2009 Gupta, S., 
Woodside, A., 
Dubelaar, C., 
Bradmore, D. 
Diffusing knowledge-based  
core competencies for 
leveraging innovation strategies: 
Modelling outsourcing to 
knowledge process 
organizations (KPOs) in 
pharmaceutical networks  
Industrial Marketing 
Management 
Knowledge outsourcing in 
pharmaceutical industry 
and India's role in it. 
2009 Konde, V. Biotechnology business models: 
An Indian perspective 
Journal of Commercial 
Biotechnology 
Business models of major 
Indian biotech companies 
based on the value-chain 
structure, secondary data 
analysis 
2009 Narayanan., S., 
Rao, S. 
Profiles of top four biotech 
companies in India 
Biotechnology Journal Market information on 
four companies 
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Table 2.2 (continued). 
Year Authors Title Publication Methodology & Analysis 
2009 Ray, M., Daar, A., 
Singer, P., 
Thorsteinsdottir, 
H. 
Globetrotting firms: Canada’s 
health biotechnology 
collaborations with developing 
countries 
Nature Biotechnology Survey of 181 Canadian 
firms to identify number 
of types of collaborations 
2009 Saberwal, G. Seeding a skilled workforce Nature Biotechnology Qualitative analysis of 
biotechnology workforce 
development 
 
The frequency of publication of peer-reviewed literature listed in Table 2.2 is 
shown in Figure 2.4, and it is interesting to note that all these documents were published 
within the last ten years.  In order to bridge the gaps in the previous research efforts, this 
study used personal interview data collected from biotechnology companies in India to 
understand the business strategies of the companies and the attitudes of upper level 
managers of these companies towards innovation.  The researcher expected to gain 
insights regarding the strategic orientation and innovativeness of Indian biotechnology 
companies.  More importantly the researcher sought to demonstrate the applicability of 
the Miles and Snow typology in the context of this emerging industry sector in India.  
These studies may be applicable to other parts of the world for analyzing the growth of 
emerging technology sectors.  The methods used to collect and analyze primary and 
secondary data are discussed in the next chapter. 
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Figure 2.4. Frequency of Peer-Reviewed Publications on the Business and Intellectual  
Property Aspects of Indian Biotechnology Sector. 
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CHAPTER III 
METHODOLOGY 
The research question for this dissertation is to determine if Miles and Snow 
typology (M-S) provides an adequate framework to study the business strategy choice at 
the firm level in the setting of an emerging technology sector in a developing country.  
There has been limited application of the M-S typology in both these settings and these 
criticisms have been discussed in the previous chapter.  Miles and Snow (2003) state that 
strategy choices of companies are influenced by external factors during the adaptive cycle 
of an organization.  The goal of this dissertation was to gain an understanding of the 
strategic business orientation of biotechnology companies in India and understand the 
influence of the policy and financial environments on the strategy choices of the 
companies.  In starting with the Miles and Snow theoretical framework, this dissertation 
follows the “theory before research” (TBR) model (Nachmias and Nachmias 1992, 46) 
and subsequently develop a research design which will allow the incorporation of 
pertinent data for testing this theory.  The TBR model is beneficial in assisting the 
researcher in selecting the appropriate cases to be studied and developing a more 
complete description of the research experiment (Yin 2003, 4-5).  The TBR model has 
been laid out by Berg (2007) in a linear manner as shown in Figure 3.1.  Berg goes a step 
further and states the value of a spiraling research approach which allows a researcher to 
reconsider and refine the idea as well as reexamine the two theoretical assumptions.   
 
 
Figure 3.1. Theory Before Research Model for Social Science Research. 
From Qualitative Research Methods for the Social Sciences, 6th ed., by B. L. Berg (2007, 23) 
 
Ideas Theoretical Framework 
Research 
Design 
Data 
Collection 
Data 
Analysis 
Results 
Dissemination 
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It was not the intent of this research to formulate a new theory to describe the 
operation of the high technology based industries such as biotechnology in India; 
however, the researcher attempted to develop policy recommendations based on the 
research design while validating the use of the Miles and Snow model.  The M-S 
framework is also not concerned with the performance of the companies, hence this 
research has not attempted to correlate company performance with it strategy choice.  
The approach of this dissertation was to collect primary data from various sources 
including indigenous biotechnology companies in India on internal parameters such as 
their product offering, marketing, and networking to classify their strategy choices and 
supplement that with secondary data to understand the financial and policy environments 
in India.  More specifically, the research attempted to understand the external 
environment by looking at a recent landmark change in the patent regime, the 
biotechnology promotional policies of the Indian government, the broad national 
economic reforms over the last two decades, and venture capital deal flow.   
This dissertation took a qualitative approach to focus on the emerging 
biotechnology industry in India and narrowed the scope of study to companies operating 
in the life sciences subsector.  For the purpose of this dissertation the words life sciences 
and medical sector are used interchangeably.  The geographic focus of the field research 
was concentrated on the south Indian city of Bangalore for reasons discussed below.  A 
series of open-ended, personal interviews were conducted in October 2008 and May 2009 
with small to medium sized enterprises (SMEs) and related institutions in India to gather 
primary data.  The following chapter discusses the rationale behind the methods and sites 
selected for primary data collection.  The chapter also discusses the “investigator 
inference” methodology for analyzing these data within the M-S framework.  Several 
  
61
sources including company websites and government and trade publications were utilized 
for secondary data.  Majority of the field research for this study was undertaken as part of 
the National Science Foundation’s Integrative Graduate Education and Research 
Traineeship (IGERT) grant entitled “Entrepreneurship at the Interface of Medicinal 
Chemistry & Polymer Science” awarded to The University of Southern Mississippi.  The 
scheme for data collection and analysis is shown in Figure 3.2 and is discussed in the 
subsequent sections of this chapter. 
 
Figure 3.2. Qualitative Data Collection and Analysis Scheme. 
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Research Methods 
This dissertation relies solely on qualitative methods to gather primary data as 
shown in Figure 3.2.  Some of the secondary data used to understand the nature of the 
external environment is quantitative in nature and helps bring specificity to the 
biotechnology sector in India, but the research does not delve into any statistical analyses 
of these numerical data.  As O’Sullivan and Rassel (1999) note, “The qualitative study is 
defined by its extensive use of verbal information, its preference for developing full 
information on relatively few cases, and its consideration of the unique features of each 
case” (36-37).   The following section summarizes the strengths and weakness of 
qualitative research methods (Johnson and Christensen 2008).   
 Qualitative studies may include information on the unique features and the 
environment of each case.  Qualitative studies describe specific features of each 
individual, organization, jurisdiction, or program.  Typically, the researcher studies few 
cases and obtains extensive information on each case and its setting.  Qualitative studies 
may involve extensive fieldwork; the researcher goes to where the cases are located and 
obtains information on them in their natural setting.  In this way the researcher does not 
attempt to manipulate any aspect of the situation being studied but takes it as it is.  
Nevertheless, the qualitative researcher’s background and personality influence data 
collection and interpretation.  Qualitative studies are often conducted by researchers who 
are participants or close observers of the phenomena studies.  Such researchers are more 
likely to have the knowledge and interest to design and conduct a sound qualitative study.  
The researchers use their experiences and insights to design a study and to interpret the 
findings.  A researcher’s interactions with subjects affect what he is told and what 
information he is given. 
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 In qualitative studies the researcher usually works with a flexible design.  
Although the studies may have a clearly defined methodology and a plan of action, the 
researcher usually has great flexibility.  He may alter the design as the research 
progresses.  Typically, the researcher uses several sources of information.  Multiple 
sources give a fuller picture of a case and its setting and help to verify other information. 
 Researchers using qualitative techniques need different skills than those using 
quantitative designs.  An interviewer in a quantitative study receives a list of questions 
which is asked of every respondent.  All other interviewers would use the same set of 
questions and ask them in the same way.  In a qualitative study, the interviewer may have 
a suggested set of questions but asks them as the situation dictates.  Based on the 
response to one question, the interviewer asks another question; the researcher needs to 
ask the question, listen, interpret, and phrase a proper follow-up question.  A researcher 
using qualitative methods must be able to record information accurately, write clearly, 
divide trivial from important details, and draw appropriate conclusions from the 
information.  Since data from qualitative studies tend to be descriptions, observations, 
and responses to interview questions, a great deal of information is obtained.  To make 
sense out of it may be difficult.  Rather than doing statistical analysis of numerical data as 
in quantitative studies, the researcher looks for themes and concepts in the analysis of 
qualitative data. 
The most important components of any qualitative research design are the 
conceptual framework, research questions, methods, and validity of the design, which are 
interconnected with each other in multiple ways (Berg 2007).  These four components are 
driven by the researcher’s goals as discussed in the previous question. The process is 
defined with a slight variation by Berg (2007) as the components of the qualitative 
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research design being the spiraling approach starting with the ideas, leading to theory, 
design, data collection and organization, analysis and findings and dissemination.  The 
conceptual framework referred to by Maxwell (2005) is essentially the theoretical basis 
of the research as well as the existing body of literature that will support or refute the 
hypothesis or the research question. Maxwell (2005) states that both “qualitative and 
quantitative methods are not simply different ways of doing the same thing.  Instead they 
have different strengths and logics, and are often best used to address different kinds of 
questions and goals” (22).   
The research question in a qualitative research setting must be framed such that 
“they can be potentially answered by the study” and should not have an open-ended 
nature (Maxwell 2005, 21).  Research questions in social science inquiry should meet two 
important criteria: (1) they should be related to real world of politics and social 
phenomena and issues that shape people’s lives and (2) they should be based on the 
scholarly literature of social science and seek intellectual puzzles not yet posed or solved 
but have theories and methods to solve them (King, Keohane, and Verba 1994).  Maxwell 
(2005) writes that questions with “can” and “should” cannot be adequately addressed 
with even large amounts of data or analysis.  This concept is in strake contrast to the 
physical sciences, this researcher’s prior academic background, where a technical 
research a question such as “can” this material withstand a temperature of 1000 degrees 
without deforming, will have a definite yes or no answer based on empirical data.  The 
research question in social science qualitative studies strives to achieve the practical goals 
rather than rephrasing the goals as the questions themselves (Maxwell 2005).  The 
conceptual framework is very important and as suggested by Maxwell (2005, 35) should 
be “constructed” and not simply “found.”  It should be built with the knowledge of 
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existing theories and their potential strengths and limitations as applicable to one’s 
research.  It is also important to discard or be aware of personal biases towards or against 
a certain position.  Research bias, as pertinent to the current research, is discussed at the 
end of this chapter.  The strengths and weaknesses of qualitative research are outlined in 
Table 3.1.  The methods used for this research and the target subjects are summarized in 
Table 3.7 towards the end of this chapter. 
Table 3.1  
Strengths and Weaknesses of Qualitative Data Collection and Analysis 
Strengths Weaknesses 
Data based on the participants’ own 
categories of meaning 
Knowledge produced might not generalize 
to other people or other settings 
Useful for studying a limited number of 
cases in depth 
Findings might be unique to the relatively 
few people included in the research study 
Useful for describing complex phenomena It is difficult to make quantitative 
predictions 
Provides individual case information to 
vividly demonstrate a phenomenon 
It is more difficult to test hypotheses and 
theories with large participant pools 
Can conduct cross-case comparisons and 
analysis 
It generally takes more time to collect the 
data when compared to quantitative 
research 
Provides understanding and description of 
people’s personal experiences of phenomena 
(i.e., the insider’s viewpoint) 
The results are more easily influenced by 
the researcher’s personal biases and 
idiosyncrasies 
Can describe in rich detail phenomena as 
they are situated and embedded in local 
contexts 
Data analysis is often time consuming 
The researcher almost always identifies 
contextual and setting factors as they relate 
to the phenomenon of interest 
Researcher may only know roughly in 
advance what he/she is looking for.  
The researcher can study dynamic processes 
(i.e., documenting sequential patterns and 
change) 
The research design may emerge or 
change as the study unfolds.  
Can determine how participants interpret 
constructs (e.g., intellectual property in this 
case) 
The researcher is the data gathering 
instrument, hence data collection may be 
prone to human error 
Qualitative approaches are especially 
responsive to local situations, conditions, 
and stakeholders’ needs 
Researcher tends to become subjectively 
immersed in the subject matter. 
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Table 3.1 (continued). 
Strengths Weaknesses 
Qualitative researchers are especially 
responsive to changes that occur during the 
conduct of a study (especially during 
fieldwork) and may shift the focus of their 
studies accordingly 
 
Qualitative data in the words and categories 
of participants lend themselves to exploring 
how and why phenomena occur 
 
Determine idiographic causation (i.e., 
determination of causes of a particular event) 
 
 
Operationalizing Miles and Snow 
 
A literature review of the Miles and Snow framework examined in the previous 
chapter shows multiple ways in which researchers have chosen to categorize 
organizations within the P-A-D-R typology.  There are four main methods to determine 
the type of organization: (1) self-typing, (2) investigator inference, (3) objective 
indicators, and (4) external assessment (Conant et al. 1990).  Self-typing involves the use 
of survey instruments which are completed by the respondents to classify their own 
organizations.  This approach is useful with large sample population and lends itself to 
statistical analysis.  However, it may lead to over-simplification of the archetype 
constructs and may not capture all dimensions of the framework.  The idea of self-typing 
as a measure to categorize an organization was first introduced in Snow and Hambrick 
(1980) and has been used for research in Finland (Woodside, Sullivan, and Trappey 
1999), Israel (Dvir, Segev, and Shennar 1993) and Brazil (Gimenez 2000) in addition to 
the United States, Japan and China (DeSarbo et al. 2005).  Investigator inference has 
been demonstrated as a viable technique by Ruekert and Walker (1987) who used data 
from interviews conducted with company executives from three divisions of a Fortune 
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500 industrial products manufacturer.  Each division had separate marketing and research 
and development departments and operated in different industries. 
Miles and Cameron (1982) used investigator inference along with external 
assessment and objective indicators.  They elaborate on the question “whether 
environmental determinism or organizational choice best explains the process of strategic 
organizational adaptation” (5) and conclude that it is not either/or issue, but elements of 
both volition and determinism will be present.  The drawback pointed for this 
methodology is the time and monetary commitment required to undertake the study can 
be significant.  However, this approach is useful for small samples and is capable of 
capturing all four types of strategic choices based on in-depth analysis.  A number of 
researchers have advocated the use of multiple approaches to operationalize and measure 
the organizational constructs as suggested by Hambrick (1981, 1982) but the approach 
has to be balanced with the available resources of the researchers.  Various approaches 
are summarized in Table 3.2.  The “investigator inference” methodology used for this 
research is summarized in fifth measurement approach listed in Table 3.2.  Given the 
objective of this research was to seek privately held, lesser known, small-to-medium 
sized life-science biotechnology related businesses in India, the researcher was not 
expecting objective indicators such as percentage of sales derived from new products 
(Hambrick 1983) to be readily available publicly for analysis.  Annual reports for these 
companies were also not available since they were not publicly traded.  In-depth analysis 
was only deemed possible by collecting primary data through interviews with company 
executives such as founders or chief executive officers, and using the researcher’s insight 
in conjunction with information obtained from company websites and interviews with 
individuals affiliated with this sector to classify the companies within the M-S 
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framework.  The survey instrument used for interviews was organized into specific areas 
of importance to this research and served as a guide for the interviewers for asking the 
questions, most of which were open-ended.  The interviewees were directly asked about 
their intent to produce a differentiated product, if they intended to enter a new market, 
and how they viewed their competitive advantage. 
 
Table 3.2  
Methodologies for Operationalizing Miles and Snow Framework 
Measurement 
approaches Measurement description 
Illustrative 
studies Strengths  Limitations  
1A. Self-typing  
Respondents are asked to 
classify their organization as 
defender, prospector. 
analyzer, or reactor based 
on paragraph descriptions of 
the four strategic types 
Snow and 
Hrebiniak (1980) 
McDaniel and 
Kolari (1987) 
Segev (1987a) 
Zahra (1987) 
Easy to 
complete and 
interpret All 
four types can 
be captured 
Useful with 
large samples 
Single-item scale 
Over-simplification 
of archetypes  
1B. Self-typing, 
complemented by 
investigator-
specified decision 
rules  
Multi-item, close-ended 
Likert-type scale to gauge 
the overall degrees to which 
a firm's strategy conforms 
one of the four strategy 
types. May be combined 
with cluster analysis to 
classify firms  
Segev (1987b) 
Smith et al. (1986) 
Multi-item 
scale All four 
types captured 
Useful with 
large samples 
Simplification of 
archetype 
constructs 
Scale 
inconsistencies 
Interpretation 
challenges 
2. Objective 
indicators  
Percentage of sales derived 
from new products. Interval 
measure transformed into 
ordinal measure 
Hambrick (1983) Useful with 
large samples; 
easy to 
interpret 
Unidimensional 
conceptualization 
of a multi-
dimensional 
construct; only 
prospectors and 
defenders can be 
typed 
3. External 
assessment 
Expert panel assessment and 
typing 
Meyer (1982)  Impartial 
assessments 
All four types 
capable of 
being captured 
Potentially 
useful with 
large samples 
Time consuming 
Experts must be 
identified and their 
involvement 
secured A process 
by which 
classification 
decisions will be 
made must be 
developed 
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Table 3.2 (continued). 
Measurement 
approaches Measurement description 
Illustrative 
studies Strengths  Limitations  
4. Investigator 
inference 
Investigator inference based 
on interviews with company 
executives 
Ruekert and 
Walker(1987) 
Somewhat 
objective All 
four types 
capable of 
being captured 
Time-consuming 
Usefulness 
restricted to small 
samples 
5. Investigator 
inference, 
tempered by 
external 
assessment, and 
objective 
indicators 
Interviews with company 
executives and industry 
experts, and review of 
annual reports, government 
documents, and press 
releases 
Miles and Cameron 
(1982) 
All four types 
captured 
In-depth 
analysis 
Multiple 
measurement 
approaches 
Expensive and 
time- consuming 
Usefulness 
restricted to small 
samples 
6. Objective 
indicators, 
external 
assessment, and 
investigator 
inference 
Quantifiable published data 
from annual industry source 
books on product/market 
additions, assessments by 
expert panels, and 
investigator inference based 
on interviews with CEOs 
Hambrick (1981) 
Hambrick (1982) 
Use of 
multiple 
measurement 
approaches 
facilitates 
identification 
of' relatively 
pure' strategic 
types 
Unidimension-ality 
of objective 
indicator 
Time-consuming 
Usefulness 
restricted to small 
samples Sample 
attrition and 
limited strategic 
typing  
Note. Adapted from Conant et al. (1990) 
 
Primary interview data were supplemented with an examination of the contents of 
each company’s website.  A similarly fashioned research study was conducted on 
Chinese biotechnology enterprises by some members of this research team (Malone et al. 
2008) under the same IGERT grant.  The final sample size of interviews for this study 
was nineteen companies and the survey instrument for the research in India was drawn 
from the one used in China.  Details of the survey instrument used to conduct interviews 
in India are discussed in a later section.  A much larger study in China, albeit across a 
multitude of industry sectors, relied on a multi-step instrument development procedure 
for measurement items for each capability type using relevant measurement scales from 
marketing and management literature (DeSarbo et al. 2005).  A combination approach of 
evaluating product portfolio and self typing by companies as product innovative, 
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primarily production innovative or both product and production innovative was used to 
classify 55 manufacturing companies in Australia, Denmark and Norway (Laugen, Boer, 
and Acur 2006).  Studies by DeSarbo et al. (2005) and Laugen et al. (2006) were in 
developed countries or in mature industry sectors.  
Development of the Survey Instrument 
The survey instrument used to query the biotechnology company managers for 
primary data collection relied on a combination of open-ended questions as well as 
specific questions with both “yes/no” answers as well as numerical responses.  The main 
topic areas of the survey instrument and a breakdown of themes within those subjects are 
presented in Table 3.3. 
Table 3.3  
Survey Instrument Categories and Parameters 
Interview Category Parameters 
Business background Company and employee demographics 
Product/Service profile Product or service offering, sales information, product 
innovativeness 
Management team 
 
Founder profile, decision making process; future plans 
with the firm, networking profile 
Marketing Target market and marketing strategy; value proposition 
Intellectual property Patent protection, competitive advantages 
Government involvement Assistance, grants, loans, tax incentives, other 
Finance Startup and ongoing financing strategy 
 
As discussed previously, the field of biotechnology is generally associated with 
innovation in a multitude of scientific disciplines including biology, chemistry, and 
engineering and market sectors such as pharmaceuticals, agriculture and chemical 
manufacturing.  Biotechnology has become a globalized industry with sales of industrial 
biotechnology products alone exceeding $140 billion in 2007 (Economist 2009) and it is 
anticipated to create the next generation of innovations and surpass the Information 
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Technology (IT) revolution in terms of economic prosperity (Zucker and Darby 2003).  It 
has been observed that biotechnology companies around the world have tended to 
develop and grow in close proximity to each other.  Geographical biotechnology clusters 
are evident in the US in California, Massachusetts, and Washington/Oregon regions with 
names like BioBay, GeneTown and BioForest and Biopolis in Singapore (Hine and 
Kapeleris 2007).  Certain regional characteristics are thought to be necessary for a 
biotechnology cluster to develop.  A strong research capacity, the ability to convert 
research into successful commercial activity, access to private sector funds, and a 
supportive entrepreneurial context are commonly thought to be critical components of 
successful biotechnology clusters.  There is a general consensus in the literature that 
certain conditions are necessary for a biotechnology cluster, particularly the 
biopharmaceutical sector, to arise.  Prevezer (1997) found a strong science base with 
specialized labor, specialized inputs, and specialized knowledge that spills over as the 
greatest explanatory factor for biotech clustering in the US.  Audretsch  (2001) found that 
world class scientific talent, venture capital and other forms of finance, the existence of 
an entrepreneurial culture, and appropriate regulations fostering the start-up and growth 
processes were biotech cluster success factors.  Su and Hung’s (2009) biotech success 
factors include a strong scientific and industrial base, funding availability, 
entrepreneurship, social capital, and scientific/industry networking.  Cortright and Mayer 
(2002) put together composite measures of biotechnology activity for 51 metropolitan 
areas in the US and found that biotechnology is highly concentrated within those 
metropolitan areas that combine a strong research capacity with the ability to convert 
research into substantial commercial activity coupled with an entrepreneurial 
environment and the availability of venture capital.  In a study published by The Milken 
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Institute the researchers  used 44 measures of the biotechnology innovation pipeline (i.e., 
the infrastructure that allows a region to capitalize on its biotech knowledge and  
creativity) including R&D inputs, risk capital, human capital, and biotech workforce to 
judge a biotechnology cluster (DeVol et al. 2004) . 
Chiesa and Chiaroni (2005) conducted in-depth analysis of biotech clusters in 
nine developed countries.  The four main driving forces or external factors influencing 
the growth of biotechnology companies they identified were (1) the availability of funds 
such as venture capital or government funds, (2) the presence and exploitation 
mechanisms of scientific research, (3) industrial characteristics such as a critical mass, 
integration, and mechanisms to attract key managerial and commercial people, and (4) 
supporting factors such as a legal framework, public acceptance, and promotion.  These 
studies, mostly in developed countries, found the availability of experienced venture 
capital, experienced management, and a serial entrepreneurial culture as common 
ingredients for successful biotechnology centers.  These preconditions have been 
operationalized in various ways.  Cortright and Mayer (2002) used quantitative measures 
that are readily available in the U.S. (see Table 3.4), whereas Chiesa and Chiaroni (2005) 
used a combination of numerical indicators and more nuanced indicators such as public 
acceptance of biotech activities to measure regional biotechnology characteristics (see 
Table 3.5).  
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Table 3.4   
Key Elements to Grow a Biotechnology Cluster  
Research capacity and 
activity 
Commercialization 
activity Investment capital Entrepreneurial capacity 
? Employment and 
education  
? NIH funding levels  
? Number of 
biotechnology patents 
issued  
? Research centers 
 
? Level of venture 
capital funding  
? Value of research 
contracts with 
pharmaceutical 
companies  
? Level of initial stock 
market offerings  
? Number of 
biotechnology firms 
with 100 or more 
employees  
? Firms’ membership in 
industry associations 
? Venture capital 
investments 
? Venture capital firms 
? IPOs 
? Number of new 
biotechnology firms  
 
Note. Adapted from Cortright and Mayer (2002) 
 
Table 3.5   
Four Main Driving Forces of Biotechnology  
Financial driving forces, 
which concern the 
availability of funds for 
the biotech companies 
Scientific driving forces, 
which concern the 
exploitation mechanisms 
of scientific research 
Industrial driving forces, 
which concern the 
exploitation mechanisms 
of industrial research 
Supporting driving 
forces, which concern 
the presence of a 
favorable general 
context 
? Pre-seed capital;  
? Seed capital;  
? Venture capital  
? Governmental funds;  
? Exit strategies. 
? Scientific base;  
? Technology transfer 
mechanisms;  
? Networking culture;  
? Entrepreneurial 
culture;  
? Mechanisms to attract 
key scientific people 
? Industrial base;  
? Existence of success 
stories in biotech;  
?  Attraction of new 
sites of other 
companies  
?  Integration among 
industrial actors;  
? Support to R&D 
outsourcing 
processes: 
? Mechanisms to attract 
key people 
? The legal framework;  
? The attractiveness of 
the area;  
? The presence of 
dedicated support 
infrastructures;  
? The public 
acceptance of biotech 
activities;  
? The international 
promotion of the 
cluster 
 
Note. Adapted from Chiesa and Chiaroni (2005) 
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Studies of the emerging Indian biotechnology sector under the theoretical 
frameworks discussed above are very limited and partial.  A chronological review of 
articles published in academic journals pertaining to the medical related biotechnology 
subsector in India is presented in Table 2.2.  While a significant increase was observed in 
the number of publications starting in 2005, most of the articles have attempted to 
categorize the companies and have furthermore focused on the top five to ten companies.  
Two doctoral dissertations (Srinivas 2004; George 2006) were among the publications, 
which were helpful in validating the use of research methods to study this sector.  It is 
apparent that personal interview is the method of choice for collecting primary data due 
to the lack of sufficient literature at this point.  The average number of interviews 
conducted per study in the eight studies, which utilized this methodology, is about 
twenty.  Interviews have been conducted with state and national government officials, 
company officials, university researchers and government scientists.  The Government of 
India’s Department of Biotechnology (DBT), state government websites and policies, 
patent information and company website were the main sources of secondary data. 
A major shift occurred in India’s patent laws in 2005, which were revised to 
comply with the requirements of the World Trade Organization.  In doing so, India now 
recognizes product patents in addition to process patents and a few articles have appeared 
in the literature to study this shift and its impacts on the biotechnology industry (Mueller 
2008; Singh 2009; Sampath 2007).  These articles, which rely primarily on secondary 
data, have been used as such for this research also to understand the policy environment 
for the Indian biotechnology companies.  Other sources of secondary data look 
specifically at the Indian national government’s policy to promote tax-free economic 
areas called “special economic zones” or SEZ’s as well as their efforts to promote the 
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biotechnology sector including biotech parks.  As seen from the exhaustive literature 
review in Chapter II, there is a lack of scholarly information based on established 
theoretical frameworks of strategic business typologies such as the Miles and Snow, 
hence it important to understand the drivers behind the recent rise of the biotechnology 
industry in India and understand the external factors which may influence the business 
strategies being adopted by these companies.   
Location Selection: Why Choose Bangalore? 
Bangalore is often called the Silicon Valley of India because of the large number 
of Information Technology companies and this export oriented service software industry 
formed the structure of the developing biotechnology industry.  In the 1940s, industrial 
visionaries played an important role in the development of Bangalore's manufacturing 
and industrial base.  Bangalore’s secure location and dust-free environment proved 
conducive for setting up large public sector undertakings specializing in electronics, 
aerospace, machine tools, and telephone equipment.  One of India’s premier research 
centers, Indian Institute of Science, and direct satellite links were established.  In the 
1970s, Bangalore business leaders proposed the development of an “electronics city” to 
attract more private sector companies, but it was Indian national government’s policy 
reforms of the 1980s and 1990s that allowed the emergence of an export oriented IT 
industry.  When large international IT companies started to look for a presence in 
liberalized India, Bangalore’s industrial base and infrastructure coupled with a low-cost 
educated workforce and an attractive lifestyle for expatriates made Bangalore the main 
choice for electronics-related industries.  
The IT cluster in Bangalore comprises over 1,500 IT firms and most of the large 
IT firms are headquartered in Bangalore.  Initially, firms were principally involved in 
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range of “body shopping” services including customer software application development, 
maintenance, call centers, counter cyclical work and other outsourced information 
services.  Recently, Indians have started to return from the west and greater value-added 
is being conducted by the Bangalore IT firms.  An innovative region is starting to 
develop.  Networks and entrepreneurism are on the rise.  A study found that almost all the 
domestic and foreign firms located in the technology parks had some form of 
professional contact with research laboratories or institutions in Bangalore.  Parthasarathy 
and Aoyama  (2006) argue that Bangalore is entering a new phase of technological 
upgrading “facilitated by active local entrepreneurship and supported by the gradual 
thickening of institutions, both formal and informal” (1281).  However, a recent 
Brookings Institute report found that inadequacies in basic governmental functions such 
as tax collection and land records still discourages general entrepreneurship in Bangalore 
(Cortright and Mayer 2002). 
In order to diversify from IT, the state government of Bangalore, Karnataka, was 
active in promoting Bangalore as a knowledge hub for biotechnology that links private 
and public science.  The state government established a “Vision Group on 
Biotechnology” and funded a biotechnology institute in Bangalore’s technology park, 
declared a biotech development corridor in Bangalore, linked a number of public science 
institutions, granted tax concessions for importing inputs and capital goods along the 
lines already offered to the ICT sector, and created a biotech fund to be co-financed by 
private venture capital.  Thus, the regional government is attempting to develop a policy-
driven biotechnology cluster built on the success of the more spontaneous Bangalore IT 
cluster.  In 2004, the Karnataka government set up “Bangalore Helix,” a 106-acre 
biotechnology park that includes the Institute of Bioinformatics and Applied 
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Biotechnology, the Center for Human Genetics, an incubation center, a greenhouse, and 
an animal care facility.  Bangalore has grown as a biotechnology center by focusing 
mostly on innovation in biopharmaceuticals, with companies such as Biocon—which 
developed Insugen, a proprietary process for manufacturing human recombinant 
insulin—leading the way.  Bangalore is also starting to see multinational corporations 
conduct clinical trials in the city, relying upon Indian contract research organizations to 
manage these trials.  For example, Merck and Pfizer (USA), AstraZeneca (UK), and 
others have contracted Bangalore-based Clinigene, the first lab in India certified by the 
College of American Pathologists, to conduct trials for them. 
Company Sample Selection 
 
The companies and institutions were selected from biotech industry association 
lists and government contacts.  The criteria used to form the sample pool of companies 
were: self-identification of the company being in the medicinal or lifescience 
biotechnology sector, principally Indian owned (rather than multinationals with 
operations in India) and located in Bangalore.  The focus was primarily on small 
biotechnology companies typically with fewer than 50 employees, doing 
pharmacological, diagnostics, or bioinformatics business.  It was important to speak with 
locally owned small-to-medium sized enterprises (SMEs) rather than multi-national 
companies because the former would be more sensitive to the regional context and the 
local environment rather than large multi-nationals. 
Another reason to select small companies is the prevalence of SMEs in the 
biotechnology sector in the United States and Europe.  Small biotechnology companies 
have been associated with developing innovative products and processes and have served 
as a pipeline for the larger more established companies.  Furthermore, there is limited 
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research on the Miles and Snow concepts which have studied technology intensive 
industries such as biotechnology, optics, medical devices and telecommunications (Dvir, 
Segev, and Shenhar 1993).  It will be very interesting to understand if this progression 
will take place in the Indian biotechnology sector and how it is reflected in the business 
strategy.  The Miles and Snow typology is being used to understand the strategic business 
orientation of these companies.  
Company names were identified through Internet searches, government 
documents, industry trade organizations publications and existing academic literature.  A 
team consisting of multi-disciplinary faculty and student researchers from the University 
of Southern Mississippi carried out these searches.  Members of this team are listed in 
Table 3.6 along with their departmental affiliations.  These team members also conducted 
field research in the cities of Bangalore and Mumbai in India.  Two of the faculty 
members, Malone and Hales, had prior experience conducting very similar research in 
China.  Companies were also targeted for interviewing during the Asia Pacific 
BioProcess International Conference & Exhibition, which was held in Mumbai from 
October 20-22, 2008 and coincided with the field research trip.  Only two team members 
visited this conference as indicated in Table 3.6 and the other eight conducted interviews 
in Bangalore.  Two of the research team members, Arora and Schwartz, were of Indian 
origin and all the rest were Caucasians.  All team members were citizens of the United 
States of America.  The influence of the presence of Indian and Caucasian researchers on 
the interview team was not explored in depth in the research design; however interactions 
with the interviewees favoring one race or the other were noted. 
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Table 3.6  
India Research Team Members 
Member Name USM Status Department/Major Interviewed at 
Brent Hales Faculty Economic and Workforce 
Development 
Mumbai, 
Bangalore 
Ken Malone Faculty Economic and Workforce 
Development 
Bangalore 
Chad Miller Faculty Economic and Workforce 
Development 
Bangalore 
Brian Richard Faculty Economic and Workforce 
Development 
Bangalore 
Sumesh Arora Doctoral student International Development Mumbai, New 
Delhi 
Irene Gorman Doctoral student Polymer Science and 
Engineering 
Bangalore 
Megan Powell Master’s student Polymer Science and 
Engineering 
Bangalore 
Chris Sahagun Doctoral student Polymer Science and 
Engineering 
Bangalore 
Antony Schwartz Doctoral student Microbiology Bangalore 
James Whitmore Doctoral student Polymer Science and 
Engineering 
Bangalore 
 
An attempt was also made to contact individuals in the financial sector, more 
specifically managers with venture capital firms, to better understand the types and levels 
of funding available for small-to-medium sized biotechnology companies in India.  
Meetings were scheduled in Mumbai with a group active in venture capital (VC) 
investing both in India and the United States, but were cancelled due to local riots, which 
erupted unexpectedly on the day of the meeting in connection with the imprisonment of a 
prominent political figure.  Most parts of the city were in a lock down mode and the 
researchers were confined to the hotel premises.  The VC group with whom the meeting 
was scheduled had also made arrangements for the researchers to meet members and 
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officers of the Mumbai chapter of the entrepreneurship group The Indus Entrepreneurs, 
now simply known as TiE.  This meeting was also cancelled due to the riots.  
Coincidentally there was a bombing on a train in the northeastern part of India also that 
very same morning, but the two events were unrelated.  The research team stayed at the 
hotel and monitored the situation through television news and timely and useful updates 
from the hotel staff.  Things were back to normal in the city the following day and the 
researchers were able to visit the companies as scheduled. These two violent events gave 
the researchers a first hand sense of the political environment in which all business in 
India continues to take place.   
Telephone and e-mail were the primary means of initiating communication with 
the companies.  The ten hour and thirty minute time difference between Indian Standard 
Time and the United States Central Time zone posed some challenges in contacting the 
companies by telephone and the team members had to be persistent in making multiple 
phone calls sending multiple emails to the companies targeted for interviews.  
Furthermore it was realized that several companies were not really active in scientific 
endeavors related to biotechnology even though they have direct use of the prefix or 
suffix “bio” in their name.  Some companies, which surfaced during Internet searches, 
were active in the renewable energy area with interest in products such as biofuels such 
as biodiesel, biobutanol or bioethanol.  These companies were excluded from the present 
research, but could serve as a sample for future research.  Sample emails crafted to seek 
appointments with these companies in Bangalore and Mumbai are included in 
Appendixes B and C respectively.  
 
 
  
81
Table 3.7  
Company Location and Title of Officials Interviewed 
Company City Located 
Interview 
Location Title of official interviewed 
A Bangalore Bangalore Head of business development-contract 
research; Deputy Manager of Business 
Development 
B Bangalore Bangalore Chief science officer/Chief operating 
officer 
C Bangalore Bangalore Chief executive officer 
D Bangalore Bangalore Director 
E Bangalore Bangalore Chief executive officer 
F Bangalore Bangalore Chief executive officer 
G Bangalore Bangalore Senior management 
H Bangalore Bangalore Director 
I Bangalore Bangalore Founder and Chief executive officer; 
Co-Founder and Chief technology 
officer 
J Bangalore Bangalore Senior Manager of Strategic Planning 
K Bangalore Bangalore  
L Bangalore Bangalore  
M Bangalore Bangalore Managing Director 
N Bangalore Bangalore Managing Director 
O Bangalore Bangalore Managing Director 
P Hyderabad Mumbai President 
Q Hyderabad Mumbai Head of Sales 
R Mumbai Mumbai Director 
S Mumbai Mumbai Founder/Director 
T Mumbai Mumbai Managing Director 
U Mumbai Mumbai Director; Senior General Manager for 
Reserch and Regulatory Affairs; senior 
members of technical and quality 
assurance departments 
V Chennai Mumbai General Manager 
 
As a result of the research team’s combined efforts, the following meetings were 
scheduled in Bangalore prior to arriving in India (see Table 3.7).  Companies P, Q, and V 
were approached during the BioProcess International conference and the interviews were 
conducted at the Mumbai Grand Hyatt Hotel where the conference was taking place.  The 
survey instrument was used for company interviews in Mumbai and Bangalore.  Several 
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additional interviews were conducted in Mumbai at this conference venue as shown later 
in this chapter.  Meetings in Mumbai with companies R, S, U were scheduled through 
email and telephone while still in the United States and company T was introduced to the 
researchers through company S as it happened to be located in the same building and the 
same floor.  Interestingly enough, this was the first contact for the director of company S 
with the managing director of company T even though company S had been for quite 
some time.  It must be noted that company T is a publicly traded pharmaceutical 
company and not actively pursuing any efforts in biological-based therapies.  Similarly 
company U is also a publicly traded generic pharmaceutical company, but is actively 
seeking biobased vaccines and therapies through a wholly owned subsidiary, which is 
treated as a separated entity, and is designated as company R for the purposes of this 
research.   
The overall response to the scheduling interviews for companies in Bangalore was 
about fifty percent as the research team had identified a list of about 30 potential 
companies.  Setting up appointments with companies in New Delhi was more difficult.  
The researcher visited New Delhi on a family trip in May 2009 and used the opportunity 
to collect additional data.  Six companies were contacted prior to departure, but none of 
them responded favorably.  Three of these companies were only peripherally affiliated 
with the healthcare sector and two had no real connection to biotechnology despite 
having the word “biotech” in their company names.  An official from another company 
appeared suspicious about the research goals and did not want to participate.  New Delhi 
and surrounding areas of satellite cities such as Gurgaon, Faridabad and NOIDA, 
commonly referred to at the National Capital Region, do not have a high concentration of 
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biotechnology firms as shown in the next chapter. Not surprisingly though, the NCR has 
a higher than average ratio of organizations and government agencies located there.  
Interview Methodology 
The following paragraphs describe the various methods used in this research 
along with benefits and pitfalls.  
Survey  
Briefly defined, a survey is “a system for collecting information from or about 
people to describe, compare, or explain their knowledge, attitudes, and behavior”  (Fink 
2003, 1).  Fink lists seven integral activities for conducting a survey as follows: (1) 
determine objectives for information collection, (2) design the study, (3) prepare a 
reliable and valid survey instrument, (4) administer the survey instrument, (5) manage 
data, (6) analyze survey data, and (7) report results.  Berg (2007) equates a pencil and 
paper survey to a standardized interview, which has a set number and order of questions 
being asked of all the respondents.  Picking the appropriate population is also a critical 
part of the survey process as is the number of participants to have a statistically valid 
response (Fink 2003).  The survey for this research was conducted via in-person 
interviews as described below.  Oishi (2003, 1) lays out the five W’s of in-person 
interviews: Who? What? When? Where? Why?  These five parameters for this research 
are listed in Table 3.8.  Following the 5 W’s is a description of the “how” of the interview 
process, which according to Oishi (2003, 11) is the next logical step in the conduct of 
research. 
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Table 3.8   
The 5 W’s of In-Person Interviews 
Who participates in the 
interview? 
Participants are interviewer (USM research team members) 
and responder (biotechnology company senior manager).  
Researchers conducting qualitative interviews personally may 
also conduct analyses of their own findings. 
What does the interview 
consist of?  
The survey instrument was constructed around content 
determined by survey objectives (instrument is attached in 
Appendix A and its outline is shown in Table 3.3. The format 
is designed to “create a flowing conversation” 
When is in-person 
interview mode used? 
When surveyors need to ask complex questions, the physical 
presence of an interviewer enhances the interviewer-
respondent rapport which was deemed necessary to overcome 
any cross-cultural gaps and build trust with the respondents; 
allows for observation of non-verbal cues; useful for long 
interviews, While such interviews are monetarily expensive, 
most of the field research costs were covered by a grant, 
which also was limiting factor on the duration of stay in India 
and consequently the number of interview that could be 
conducted an 
Where are in-person 
interviews conducted? 
Interviews were conducted on site in India at the locations of 
the biotechnology companies 
Why are in-person 
interviews done? 
The role of the interviewer was to help the respondents guide 
through the survey instrument and clarify meanings of 
responses; the surveyor also wanted to keep control of the 
questions being answered by the highest ranking officers of 
the respective companies and not be delegated to junior staff 
or not being answered at all. 
 
Interview and Data Analysis Procedure  
The interview conducted for this research was conducted in an unstandardized 
manner as described by Berg (2007).  In contrast to the rigidity of the standardized 
interview with specific questions in a given order (as is the case with the survey 
instrument) the unstandardized interview does not utilize any schedules and there is no 
pre-set wording for any questions.  The interviewer may add or delete questions 
depending upon the circumstances during the interview and make seek clarifications from 
the subject.  In short, no two interviews may be alike.  Berg (2007) states, “in an 
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unstandardized interview, interviewers must develop, adapt, and generate questions and 
follow-up probes appropriate to each given situation and the central purpose of 
investigation” (94).  Unstandardized interviews were conducted with individuals listed in 
Table 3.10.  
Existing literature was reviewed thoroughly to determine the best approach to 
study small Indian biotech companies.  As apparent for the literature review presented in 
Table 2.2 in the previous chapter, an on-site interview was the methodology of choice 
and deemed the most suitable approach in extracting information from such companies.  
A semi-structured face-to-face interview format at the interviewee’s facility was utilized 
and the discussions typically last one hour.  Other interviews of associations, institutions, 
research centers, and universities involved with biotech were also conducted to better 
understand the regional context as well as the environment in which these companies 
were operating. 
The data were collected by PhD candidates in the fields of Medicinal Chemistry, 
Polymer Science, and International Development, each having received extensive 
technology commercialization training including the development of original 
biotechnology business plans.  These students were teamed with economic development 
and entrepreneurship faculty to perform the data collection and at least one faculty 
member was present at each interview.  This combination of technical, business and 
research competency was needed to obtain a deep understanding of the companies 
interviewed.  Names of research team members are listed previously in Table 3.6. 
The advantages and caveats of conducting interviews are described below.  The 
canonical preconditions of biotechnology clusters have been operationalized in various 
ways.  For this research, primary frameworks used are from two well-known studies of 
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biotech clusters. Cortright and Mayer (2002) used quantitative measures, whereas Chiesa 
and Chiaroni (2005) used a combination of numerical indicators and more nuanced 
indicators (e.g., the public acceptance of biotech activities) to measure regional 
biotechnology characteristics.  These frameworks are merged together and used to 
develop the survey instrument to be utilized during the interviews.  
The blended frameworks resulted into a series of open ended interview questions 
organized into four broad categories of preconditions: (1) research capacity, (2) the 
ability to convert research into successful commercial activity, (3) access to funds, and 
(4) entrepreneurial and innovative environment (see Table 3.9).  In order to gauge the 
region’s research capacity, a series of questions are included on their intellectual property 
origin, development, and protection.  An additional series of questions focusing on 
marketing efforts shed light on the region’s ability to convert research into successful 
commercial activity.  Another group of open-ended questions is designed to seek 
information on the company’s financing in order access the availability of private and 
public funding.  A discussion of the management teams’ background sheds light on the 
region’s entrepreneurial and innovative environment.  “Networking is key to 
biotechnology companies as biotechnology strives on knowledge exchange and contacts,”  
(Hine and Kapeleris 2007, 48) hence questions were included on their local, national, and 
international networks.  Finally, several questions regarding the role of government 
provided insights for a number of regional characteristics.  A total of thirty-two 
interviews were conducted in India and the United States during the course of this 
research.  A semi-structured face-to-face interview format at the interviewee’s facility 
was utilized for the company interviews in Bangalore and the discussions typically lasted 
one hour.   
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Table 3.9 
Interview Protocol 
 
General 
Questions  
 
Does the region have 
a strong research 
capacity from a small 
company’s 
perspective? 
Did resources of 
the region help the 
companies convert 
research into 
successful 
commercial 
activity?  
Did being in 
the region 
provide access 
to funds? 
Does the region 
have an 
entrepreneurial and 
innovative 
environment? 
 
Specific 
interview 
questions 
Where did their ideas 
and technology come 
from?  
 
How did the 
company utilize the 
scientific resources 
in region? 
How did the 
company convert 
research into 
revenue and how 
did being located in 
region help or 
hinder this? 
 
Discuss the regions 
technology transfer 
mechanisms? 
How was the 
company start-
up funded? 
 
How is growth 
and product 
development 
funded?  
 
What regional 
networks and 
associations assist 
you? 
 
Did you receive 
government 
assistance? 
 
 
Finding upper level managers in small to medium sized Indian biotechnology 
companies is not without its unique challenges.  Robert Thomas (1995, 3) discusses the 
challenges of interviewing “business elites” and indicates that top executives in 
corporations are usually easy to identify but gaining access to them is usually difficult 
due to the layers of management and gatekeepers the researcher would have to go 
through.  In other words, executive “visibility is not the same as accessibility” (Thomas 
1995, 4).  While this section was written mainly with the American corporations in mind, 
it also holds true for Indian companies.  Several articles in the mainstream media have 
been written about Kiran Mazumdar Shaw who is the founder of India’s pioneering 
biotechnology company, Biocon.  She has a highly visible profile, and a search on 
Google Images using her full name and the company name as key words yielded several 
thousand links, yet the company website does not show her direct contact information.  
Only those of managers at the division level are listed.  The problem with lesser-known 
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companies in foreign countries may be compounded, as they may be both less visible and 
less accessible, due to lack of readily available information about the company.  Selecting 
the companies to interview in Bangalore was a time consuming task as the information 
was scattered in multiple locations on the Internet. 
Given that the opportunities for data collection were limited and not easily 
repeated, it was important for the researcher to feel at ease with who he or she is in with 
relation to the interview subject, and the interview setting.  Thomas (1995) states that 
even the researcher’s attire is important such that it should not distract from the principal 
goal of gaining insights about the subject.  These details will be kept into account while 
meeting with officials at Indian biotechnology companies and other organizations.  Two 
of the research team members were born in India although they are both naturalized 
citizens of the United States of America, but in some cases it appeared that it was easier 
to build a rapport with the interviewee by being an Indian.  The researcher’s Indian origin 
was further helpful in understanding the cultural context of conducting surveys and 
interviews in urban India. 
This research trip was a unique opportunity for the entire team and it was 
imperative for everyone on the team to be intimately familiar with the survey instrument.  
Everyone on the team was required to familiarize themselves with the research 
publications resulting from the China trip in 2006.  Additional briefings were held on site 
in Bangalore before the research teams split up to follow the pre-assigned interview 
schedule.  Multiple email and telephone correspondence with the respondents prior to 
even arriving in India was a key part of building trust with the interviewees since the 
actual time during the on-site interview would be limited.  Given the length of the 
instrument it was critically valuable to have a minimum of two individuals on the 
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interview team.  As a show of courtesy towards the company managers, an electronic 
device was not used to gain an audio recording of the interview.  The interview teams 
gathered at the end of each day to compare notes and fill in any information provided 
during the interview which may not have been written down on the hard copy survey 
instrument, which each member of the research team had in their possession during the 
interview.  Generally the instructor was the one asking more questions while the student 
members of the team wrote the responses.  The research team met on multiple occasions 
in Hattiesburg, Mississippi in 2009 to go over the progress in transcribing the data and 
readying it for peer-reviewed publications.  A master spreadsheet was complied for the 
purpose of this dissertation, which aggregated completed survey instruments from all 
members of the research team and also added secondary data about the companies 
available from industry directories and the respective company websites. 
Table 3.10  
List of Interviews Conducted in an Unstandardized Format 
Interviewee Interviewee Position Organization 
Organization 
Location 
Interview 
Location Interviewer
C.E. Veni 
Madhavan, PhD 
Chief Executive 
and Professor 
Society for Innovation & 
Development, Indian 
Institute of Science (IIS) 
Bangalore Bangalore Full team 
Paturu Kondaiah, 
PhD Professor 
Department of Molecular 
Reproduction, IIS Bangalore Bangalore Full team 
Vinod Kumar Program Manager BCIL New Delhi New Delhi Arora 
Dr. Suryakumar 
Suryanarayan Director ABLE Bangalore Mumbai Arora, Hales
Mr. Larry 
Cummings 
Consulting 
Scientist Bio-Rad Laboratories 
Hercules, 
California Mumbai Arora, Hales
Mr. Nagraj Bhat President PDP India Mumbai Mumbai Arora, Hales
Mr. Mike Hobby Distribution Sales Director Genetix 
Hampshire, 
United Kingdom Mumbai Arora, Hales
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Table 3.10 (continued). 
Interviewee Interviewee Position Organization 
Organization 
Location 
Interview 
Location Interviewer
Chip Skowron, 
MD PhD Partner FronPoint Partners, LLC
Greenwich, 
Connecticut by phone Arora 
Mr. Ramneek 
Gupta Partner Battery Ventures 
Menlo Park, 
California by phone Arora 
Ms. Banashri Bose 
Harrison 
Minister 
(Commercial) Embassy of India 
Washington 
DC 
Washington 
DC Arora 
Henry Daniell, 
Phd 
Professor 
Biotechnology 
University of Central 
Florida 
Orlando, 
Florida By phone Arora 
 
Secondary Data Collection 
Secondary data was used mainly to (1) gain additional specific information about 
the companies interviewed, (2) to understand the current state of the biotechnology sector 
in Indian and (3) understand the external environment of these companies.   
Unobtrusive Methods 
Unobtrusive research methods were used for this dissertation as well.  The idea 
behind unobtrusive research is learn about human patterns and behaviors without 
questioning the subjects directly (Berg 2007).  The researcher’s intent was to collect 
secondary data to determine the patterns of company ownership and performance.  These 
techniques were combined with some direct (obtrusive) research methods such as surveys 
or interviews to determine the operational experiences of the company managers.  Of all 
the unobtrusive research methods described by Berg (2007), the use of archival data is a 
very powerful tool.  Berg discusses several archival strategies that include public and 
private archives.  Public archives span the range of commercial media accounts, actuarial 
records and official documentary records whereas private archives cover solicited and 
unsolicited documents such as comprehensive, topical and autobiographies.  Given the 
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limited information available from the company websites directly, the researcher used 
data archived by pertinent industry organizations and the government of India. 
Content Analysis 
 Two definitions of content analysis from Leedy and Ormorod (2005) and 
Neuendorf (2002) who define “content analysis as a “careful, detailed, systematic 
examination and interpretation of a particular body of material in an effort to identify 
patterns, themes, biases, and meanings” are presented by Bruce Berg (2007, 304).  Berg 
(2007) states that fields chosen to define the subject matter should “not be merely 
arbitrary or superficial applications of irrelevant categories, but the inclusion or exclusion 
of content is done according to consistently applied criteria of selection; this requirement 
eliminates analysis in which only material supporting the investigator’s hypotheses are 
examined (306).  The Google Alerts tool was used for gathering information for content 
analysis.  The keywords chosen for this alerting service were: biotech, India, and 
innovation, which were combined with “and” as a Boolean operator for the search 
algorithm.  These search terms below typically yielded fewer than five alerts per day and 
was indicative of the narrowness of the search term combination.  Another source of 
content analysis was a daily electronic newsletter published by Venture Capital Circle.  
Content analysis on such large amounts of information can be a time consuming task and 
one has to learn to separate the pertinent information from the noise or extraneous 
information.  A summary of the various research methods used for this dissertation and 
the respective targets are described in Table 3.11. 
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Table 3.11 
Summary of Methods Used and Target Audience 
Methods Targets 
Survey Small to medium sized life science biotechnology related 
companies in India  
Survey methodology: Open-
ended interviews (mostly 
qualitative) 
Senior management at Indian biotechnology SME’s (15 
in Bangalore and six in Mumbai who are be present at 
the International BioProcessing Conference) 
Academic professionals 
Indian government officials at the Indian Embassy in the 
U.S. 
Representatives of biotechnology industry and trade and 
industry groups in India (ABLE and BCIL), 
Biotechnology industry equipment vendors 
Unobtrusive methods 
(secondary quantitative data 
collection) 
Gather information on current status of the biotechnology 
industry in India from national and state government 
documents, industry reports by private consulting groups 
and non-profit organizations 
Background information on companies from industry 
directories published by BioSpectrum and Biotechnology 
Consortium of India (BCIL) 
Content Analysis 
(quantitative information 
has to be extracted from the 
alerts and statistical analysis 
is possible, but mostly 
qualitative) 
Use the free, daily “alerting” service provided by Google 
to obtain current information on pertinent search-term 
keyword combination (India & biotech & innovation) 
Analysis of newsletter published by a venture capital 
(VCCircle) group in India 
Indian Patent Office database 
 
Research Bias 
For primary data to be valid it must be free of bias.  The final section of this 
chapter deals with the various types of bias, which may be encountered in this research, 
and addresses how the bias may be minimized.  The section on bias is drawn from the 
work of Alreck and Settle (1994).  Systematic bias (or just bias) is to push or pull (skew) 
the results in one specific direction or another (p. 58) and given that the research will take 
in a foreign country, a researcher may easily be misled on basic factual information as 
well as cultural contexts of the conversation.  Given the Indian nationality of the primary 
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researcher for this dissertation, the systematic bias could be minimized by having a better 
understanding of the culture and expressions used by the survey respondents. 
For purely quantitative research, which relies on statistical analysis, selecting a 
large random sample is very important but also often quite difficult (Alreck and Settle 
1994).  However, the primary research in this case was qualitative and relied on open-
ended questions in the companies interviewed using the standardized survey instrument.  
Due to the physical distance between the United States and India, and a relatively limited 
pool of companies to pick from, it was difficult to pick a truly random sample of small 
biotechnology companies.  It is understood that making generalizations about business 
strategies and innovativeness of the Indian biotechnology sector as a whole will be 
difficult to make based on the primary data collected.  It was also possible, and somewhat 
expected, that companies who are eager to establish overseas networks and broaden their 
connectedness may self-select for agreeing to be interviewed.  This may lead to what is 
know as accessibility bias where some respondents are more readily selected or included 
in the sample so they are over selected.  When all units aren’t equally accessible, controls 
and incentives are necessary to ensure there will be no overrepresentation or under 
representation of some types of respondents.  Similarly, respondents who are most 
attractive to the interviewer are more often selected so they are overrepresented leading 
to affinity bias that can be avoided by providing fieldworkers with very precise 
specification of who is to be contacted and selected and by strict supervision and 
enforcement of the instructions.  This research excluded large companies with 
communications departments which are used to providing media interviews.  A cluster 
bias in this research is inherent for most of the companies surveyed as the respondents 
selected are geographically closely clustered and they may be more similar to one another 
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than to the population as a whole.  In effort to reduce cluster bias, a limited number of 
interviews will be conducted in Mumbai at a biotechnology related conference.  These 
meetings were not set in advance, but respondents were chosen on the site of the 
conference from among the conference attendees.  Additionally, while the 
recommendation to reduce cluster bias is to not have respondents directly interconnected 
in order to gain independent responses, researching the connectedness of biotechnology 
companies, which is a measure of innovativeness was actually needed.  As discussed 
earlier this research was prone to “non-response bias” due to the limited amount of 
information available in the public domain on these small biotechnology companies.  
Some of the firms were not reachable and others felt they were not the appropriate 
candidates to be interviewed.  Alreck and Settle (1994) contend that non- response is 
almost impossible to avoid and it is the researchers’ responsibility to access the degree of 
direct and indirect interaction that may exist between the survey issues and topics on the 
one hand and the propensity to respond on the other. 
The two other types of bias, which the researcher sought to avoid, were 
instrument bias and response bias.  Instrument bias can creep in from the way questions 
are asked or expressed and subsequently introduce systematic bias, random error, or both 
(Alreck and Settle 1994).  Types of instrument bias include unstated criteria, inapplicable 
questions, example containment, over demanding recall on the part of the interviewee, 
over generalization or over specificity of information being asked, ambiguity of wording, 
double-barreled questions or questions which may lead the respondent an unintended 
path.  Instrument bias was minimized in this case by modifying an existing survey 
instrument which was used for similar research in China in 2007.  The survey instrument 
(see Appendix A) was approved by the University of Southern Mississippi Institutional 
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Review Board (see Appendix D) since the interviews were conducted on human 
participants.  The biggest drawback of this survey instrument is the length of the 
questionnaire, but these instruments were not filled by the respondents, and used as a 
guide to ask a series of open-ended questions in the sequence listed in the instrument.  
Since these were semi-structured interviews, there was room for both the interviewer and 
the interviewee to deviate from a strict order of questioning.  The expectation was that 
such deviation would add to the richness of the interview data rather than take away from 
the limited time available to conduct each interview on site in India. 
The researchers had to be extra careful to avoid response bias (Alreck and Settle 
1994) especially due to the cultural differences between the interview team and the 
respondents.  Response bias can take the form of social desirability with responses being 
provided based on what’s perceived as being socially acceptable or respectable.  
Acquiescence, or a response based on respondent’s perception of what would be 
desirable to the research sponsor could potentially be an easy trap for the respondents to 
fall in with the best of intention to “help” the sponsor.  
The researchers were mindful of responses which may be intended to enhance the 
image or prestige of the respondent in the eyes of others; for example exaggerated claims 
to show that Indian companies are just as good, or better than their Western counterparts.  
Questions which may be perceived as threatening or appearing to seek sensitive company 
information were handled carefully to as to not illicit a response influenced by anxiety or 
fear instilled by the nature of the question.  A semi-structured approach allowed the 
flexibility to limit response bias and even ask the same question in a different manner if it 
appeared threatening to the subject.  A university faculty member was paired with one or 
more graduate students on all primary data collection teams, which were thoughtfully 
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assembled to bring credibility to the interview team status as well as limit response bias 
from the interviewee. 
Methodology Summary 
In summary, the primary benefits of the use of qualitative research are: the free 
form/non-scripted gathering of information (which provides the greatest amount of 
information/data that represents the respondents’ point of view), the ability for the 
researcher to identify and study dynamic processes and to identify event root causes.  The 
primary weaknesses associated with the research are the time needed for the gathering, 
review and analytical processes (“time consuming”), sampling is limited to a relatively 
small number of respondents, and the biases of the researcher may affect the respondent’s 
observations in a free form/non-scripted environment that is controlled by the researcher.  
In-person interviews using a standardized set of questions seem to be best suited for the 
proposed data collection followed by a qualitative analysis of the responses.  A few of the 
responses on the survey instrument have quantitative responses, but these will only 
considered for statistical analysis if the sample size is large enough to represent a five 
percent of the target population of small Indian biotechnology companies. 
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CHAPTER IV 
RESULTS AND DISCUSSION 
Interviews with high ranking officers of these companies as well as other 
individuals related to policy, finance, and technical aspects of this industry were 
conducted to develop the M-S typology matrix shown in Table 4.1.  Primary data from 
the interviews was supplemented with secondary information available on the websites of 
all twenty-two companies and additional multiple sources presented below.  The 
classification of these companies within the M-S framework was based on the following 
parameters:  
• type and innovativeness of their product or service offering 
• value proposition 
• marketing strategy 
• extent of professional networking 
• market competition 
• financing strategy 
• research and development activity 
• intellectual property creation. 
This research found that firms pursuing the analyzer strategy formed the single 
largest group of companies (45%) in the survey sample of 20 companies.  There were 
only six prospectors (30%), four defenders (20%) and one reactor.  This was contrary to 
general expectations that most companies operating in a rapidly changing field of 
technology with underdeveloped markets, such as biotechnology should be prospectors. 
However, research showed that the Miles and Snow theoretical framework was 
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applicable in the case of the Indian biotechnology sector.  The implications of this 
research are to provide a structural framework for managers in biotechnology or other 
emerging industries to analyze product development and marketing decisions.  Detailed 
results from interviews and secondary data compiled for this research are presented 
below, which support the categorizations of the companies presented in Table 4.1. 
Table 4.1  
Miles and Snow Categorization of Companies 
Company Prospector Analyzer Defender Reactor 
A  1   
B  1^   
C  1   
D  1   
E 1    
F  1^   
G  1^   
H  1   
I    1^ 
J  1#   
K 1    
L  1   
M   1  
N   1  
O 1*    
P   1*  
Q 1    
R 1    
S 1    
V   1  
Total (20) 6 (30%) 9 (45%) 4 (20%) 1 (5%) 
     
Generic Pharmas 
T   1   
U    1  
Note. The researcher viewed the M-S framework (1978) as a continuum; hence some companies had 
the potential to move across categories and are identified as such:  
# Could be classifed as a Defender; 
* Could be classifed as an Analyzer; 
^ Could be classifed as a Prospector 
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The primary objective of this dissertation was to test the Miles and Snow theory 
in a developing country and in the context of an emerging technology.  The secondary 
objective was to see if a better understanding of the growth of the biotechnology sector in 
India can be explained within the Miles and Snow framework.   The Miles and Snow 
framework looks at how companies adapt to their environment and prescribes strategic 
orientations of companies which fit that environment and are also based on the stage of 
the company within the adaptive cycle.  The researcher sought to the lay out the 
landscape for the policy and financial environments in India within with biotechnology 
companies have to operate through literature reviews and secondary data.  Primary data 
were used to collect information from the management of biotechnology companies in 
order to determine the type of strategic orientation they are following.  The discussion in 
this chapter is focused on developing a qualitative relationship between the policy and 
financial environments in India and the strategic orientation of the companies. 
To summarize, the four strategies identified by Miles and Snow (1978) are: (1) 
Prospectors focus on business growth  through the development of new products and new 
markets; (2) Defenders concentrate on maintaining market share in established product 
markets with new product development taking a back seat; (3) Analyzers have a hybrid 
approach of both Prospectors and Defenders attempting to maintain a strong position in 
its core product market but looking for expansion opportunities in new, but usually 
closely related product markets; and (4) Reactors have no clearly defined strategy for the 
firm’s product-market development and are most likely to fail unless they adopt any one 
of the other three approaches.   
The research on biotechnology companies in India demonstrated that Miles and 
Snow framework is broadly applicable for understanding the process by which 
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organizations in these settings adjust to their environments in order to attain positive 
outcomes.  Twenty two companies operating within the life sciences sector in India were 
studied for this research. Fifteen interviews were conducted in Bangalore on the premises 
of the respective companies, and seven companies were interviewed in Mumbai during 
the 2008 BioProcess International – Asia Pacific Conference & Exhibition.  All 
interviews in Bangalore were scheduled prior to departing for India, but companies were 
selected on-site at the Mumbai conference.  Two companies were generic drug 
manufacturers and were excluded from the sample of companies used for quantitative 
analysis since the intention of this research was to study Indian biotechnology companies.  
Some companies may be weak prospectors and could slide towards being an analyzer.  
Similarly, two companies were identified which may be weak analyzers and could slide 
towards behaving as a defender if their focus became on doing things cheaper, faster and 
better only.  Only one company was identified as reactor, although it had the potential to 
actually be a prospector.  This company was developing new products, pursuing different 
markets segments and trying to capitalize on the significant technical knowledge of the 
founders, but did not appear to have a coherent strategy choice.  According to Miles and 
Snow (1978), if a company does not adopt one of the three strategies, their survival as a 
business may be questionable. 
An interesting point to note in contrast to the Chinese biotechnology field 
research conducted in 2007 by some of the members of the present team (Malone et al. 
2008), language was not a barrier in India as all companies conducted business in 
English.  An English-fluent translator accompanied the research team on all the 
interviews in China.  All individuals in the public, private and academic sectors 
encountered during the field research in India spoke good English and were able to 
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understand the context of the interviews.  The only question, which yielded out-of-
context responses, was related to protection of intellectual property and is discussed later 
in this chapter.  All of the company websites in India presented their information in 
English whereas some of the websites belonging to Chinese companies required 
translations.  The websites belonging to the Indian central government such as the 
Department of Biotechnology gave an option to view the site in English and Hindi.  
Having English as the default language for business in many parts of India, irrespective 
of the regional language in a given state, is a tremendous advantage for Indian businesses 
in the global marketplace, and even more so in the field of biotechnology, which is 
technologically complex and highly export oriented in India. 
The following sections of this chapter go into the detailed presentation of primary 
and secondary data.  The secondary data are present first to provide the reader an 
overview of the Indian biotechnology sector.  As described earlier in the methodology 
section, industry data published by CyberMedia (BioSpectrum) and Biotech Consortium 
India Limited (BCIL) were used to gain a better understanding of the current state of this 
industry in India.  Data were mined from BCIL’s 2007 Directory of Biotechnology 
Industries and Institutions in India (5th Edition) and the BioSpectrum India Life Sciences 
Resource Gide 2008.  Results from these industry publications are shown below.  
Biotechnology related activity in India is concentrated in and around the cities of 
Bangalore, Hyderabad, Mumbai and the National Capital Region (NCR).  The NCR 
region consists of the Delhi metropolitan areas consisting of the National Capital 
Territory (NCT) of Delhi and New Delhi as well as the neighboring satellite towns of 
Faridabad and Gurgaon in Haryana state and NOIDA, Greater Noida and Ghaziabad in 
the state of Uttar Pradesh. Subsector breakdown used by BioSpectrum and BCIL are 
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somewhat different as seen in the following tables and graphs. Specific information for 
Bangalore is provided as most of the primary data collection was conducted in that city. 
As seen previously, the two major areas of biotechnology in India’s life sciences 
are healthcare and agriculture.  Data gathered from the India Brand Equity Foundation 
(IBEF) and BioSpectrum’s annual biotechnology industry survey show an average annual 
growth rate of almost thirty percent since 2002 to the present.  These data are presented 
in Table 4. 2 and show the average annual growth rate since 2002 till present is about 
thirty percent each year. This growth appears to have been tempered due to the downturn 
in the global economy in 2008-2009.  It is also important to note that according to the 
market segmentation by BioSpectrum, the bio-services and bioinformatics sub-sectors are 
involved in primarily supporting the biopharma sub-sector.  Given the significance of the 
life sciences biotechnology activity in India, this dissertation is focused primarily on 
studying firms in the medical related sub-sectors. 
Table 4.2  
Growth of Indian Biotechnology Industry 
Time 
Period Biopharma 
Bio-
Services BioAgri BioIndustrial BioInformatics Total 
Annual 
Growth 
2002-03  $       437   $        33   $      27   $            57   $             18   $       572   
2003-04  $       671   $        67   $      32   $            58   $             20   $       848  48.25% 
2004-05  $       781   $        93   $      72   $            70   $             21   $    1,037  22.29% 
2005-06  $    1,030   $      157   $    130   $            82   $             26   $    1,425  37.42% 
2006-07  $    1,457   $      269   $    226   $            96   $             35   $    2,083  46.18% 
2007-08  $    1,725   $      393   $    300   $          103   $             48   $    2,568  23.28% 
2008-09  $    1,677   $      439   $    318   $          101   $             47   $    2,582  0.55% 
 
The two main industry groups in India, which maintain information on the 
biotechnology sector, are Association of Biotechnology Led Enterprises (ABLE) and 
BCIL.  The researcher met with officials of both organizations and gleaned valuable 
information about various aspects of this industry.  Secondary data compiled from 
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publications obtained from both organizations are presented below.  ABLE along with 
the Department of Biotechnology (DBT) and the Confederation of Indian Industry (CII) 
supported the BioSpectrum Resource Guide 2008 focused on the life sciences sector in 
India.  BioSpectrum covers the “business of biotech” and is published monthly by 
Cybermedia.  The 2008 Resource Guide listed 651 companies loosely affiliated with the 
biotechnology sector as shown in Table 4.3.  Many companies were active in more than 
one sub-sector; hence the number exceeds the total.  For example a company may be a 
maker of medical diagnostic kits, but also perform research on a contractual basis.  Figure 
4.1 shows the percentage breakdown of companies by sub-sector.  Table 4.4 provides a 
more detailed breakdown of the subsectors as well as the cities in which these companies 
are located.  The number of companies in each type of business sub-sector and their 
location by city was counted manually from the printed copy of the BioSpectrum 2008 
Resource Guide as this information was not published in any format. 
Table 4.3  
BioSpectrum Listing by Sub-Sector 
Types of Companies  Number 
Pharmaceutical companies 270 
Medical Diagnostic companies 270 
Biotechnology companies 145 
Contract Research Organization (CRO) - Drug Discovery 43 
Contract Research Organization (CRO) - Clinical Research 47 
Equipment and Chemical Suppliers 125 
Total 651 
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BioSpectrum Biotechnology Company Listing by Sub-sector
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Figure 4.1. BioSpectrum Biotechnology Company Listing by Sub-Sector. 
 
Table 4.4  
BioSpectrum Listing by Sub-Sector and Location 
Company Listings Bangalore Hyderabad Mumbai Delhi-NCR Other Total 
BioPharmaceutical 7 7 4 4 13 35 
BioInformatics 16 6 5 3 6 36 
BioIndustrial 4  8  7 19 
BioAgri 11 8 6 4 20 49 
CRO-Drug Discovery 10 10 7 1 15 43 
CRO-Clinical Research 11 3 11 7 15 47 
Total Listings 59 34 41 19 76 229 
Percent Total 25.8% 14.8% 17.9% 8.3% 33.2% 100.0%
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It is evident from the sub-sector listing that Bangalore, Hyderabad and Mumbai 
are emerging as major clusters of biotechnology related activity in India.  Cities with 
respectable numbers of companies in the other category are Chennai, Pune and 
Ahmedabad.  Corresponding to Table 4.4 is Figure 4.2, which shows the percentage 
breakdown of biotechnology companies by city.  Bangalore is home to just more than a 
quarter of all companies listed in the BioSpectrum 2008 Resource Guide. A map of India 
is included in Appendix E for reference purposes, but also shows areas of venture capital 
investments and singles out Bangalore and the state of Karnataka as the leaders in 
biotechnology. 
Bangalore, which has a heavy concentration of information technology (IT) 
companies, is also the clear leader in bioinformatics with 44% of all such Indian 
companies listed.  The IT hub lends itself as a strong base to expand into bioinformatics.  
The bioinformatics companies form the largest group in the Bangalore (26%) followed by 
a strong focus on contract research (19%) and agricultural biotechnology (19%). 
Bangalore is also emerging as hub for drug development and discovery activities with 
17% of the companies engaged in related activities (see Figure 4.3) although it appears 
they are mostly performing these functions on a contractual basis rather than developing 
novel molecules.  Data compiled from the 2008 BioSpectrum Resource Guide was 
compared to those extracted from the 2007 BCIL Industry Directory.  This directory was 
in CD-ROM format and was searchable by the following subsectors.  However, the report 
generation capabilities of this CD-ROM were limited, and Table 4.5 was compiled by 
manually searching each sub-sector.  A similar process was followed for compiling 
Tables 4.6–4.8. 
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BioSpectrum Biotechnology Company Listings by Location
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Figure 4.2. BioSpectrum Biotechnology Company Listings by Location.  
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Figure 4.3. BioSpectrum Company Breakdown in Bangalore.  
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Table 4.5  
BCIL Listing by Sub-Sector and Location 
BCIL Industry Sector 
(Sub-sector) 
Number of 
Companies 
Percentage 
Agriculture 209 29.6% 
Animal Biotechnology 18 2.5% 
Associations 2 0.3% 
Bioinformatics 56 7.9% 
Contract Research 16 2.3% 
Software tools 28 4.0% 
   
Biotech Parks 5 0.7% 
Environment 30 4.2% 
Healthcare 232 32.9% 
Antibiotics 17 2.4% 
Diagnostics 67 9.5% 
Herbal extracts 12 1.7% 
Monoclonal antibodies 5 0.7% 
Novel drug delivery 
system 13 1.8% 
Nutraceuticals 6 0.8% 
Recombinant Therapeutics 41 5.8% 
Vaccines 35 5.0% 
   
Marine Biotechnology 9 1.3% 
Nanotechnology 2 0.3% 
   
Process Industries 71 10.1% 
Enzymes 28 4.0% 
Fermentation 5 0.7% 
   
Services 225 31.9% 
Clinical Trials 21 3.0% 
Contract Research 
Organization 63 8.9% 
Equipment, Instruments, 
Media 84 11.9% 
 
 A total of 706 companies were listed in the 2007 BCIL directory, which is about 
eight percent more than the number of companies listed in the 2008 BioSpectrum 
Resource Guide.  While the BCIL directory has many fields described for a company 
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record, an in-depth search of these records indicated that data for many fields especially 
those related to company finances and revenue were missing for several companies.  
Gaps in these data also point to the need for conducting personal interviews in an 
industry which is still emerging and lacks sufficient and consistent market information.  
Another observation was the inconsistency in terms used to name the biotechnology 
subsector.  None of these companies were identified by any standardized industry code in 
either the 2007 BCIL directory or the 2008 BioSpectrum Resource Guide.  The 
researcher’s suggestion is for the DBT to issue a set of guidelines and industry codes to 
define the nature of business of various enterprises involved in the Indian biotechnology 
sector.  Such codes will greatly improve the quality of data collected by trade groups, 
industry consultants as well as future researchers.   
Table 4.6  
BCIL Industry Listings by State 
State Name Number of Companies Percentage 
Andhra Pradesh 111 15.7% 
Delhi (without NCR) 71 10.1% 
Gujarat 43 6.1% 
Haryana 26 3.7% 
Karnataka 125 17.7% 
Maharashtra 175 24.8% 
Tamil Nadu 55 7.8% 
Uttar Pradesh 20 2.8% 
Other 80 11.3% 
 
 The number of listings by geographical regions in the BCIL directory were 
consistent with ratios in the 2008 BioSpectrum Resource Guide with Bangalore having 
the maximum number of listings (see Figure 4.5).  Cities such as Faridabad and Gurgaon 
in the state of Haryana and NOIDA in Uttar Pradesh are often included in the Delhi-NCR 
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region but are shown separately in the state listings in Table 4.6.  They are, however, 
combined into NCR for the listings by cities in Table 4.7. 
Table 4.7  
BCIL Industry Listings by City 
Name of City (State) Number of Companies Percentage 
Ahmedabad (Gujarat) 23 3.3% 
Chennai (Tamil Nadu) 39 5.5% 
Delhi-NCR 97 13.7% 
Hyderabad (Andhra Pradesh) 78 11.0% 
Mumbai (Maharashtra) 105 14.9% 
Bangalore (Karnataka) 120 17.0% 
Other 244 34.6% 
 
The contract research organization (CRO) is a rapidly emerging business 
opportunity in India as evident by the 3000% growth between 2003 and 2007 listings in 
the BCIL industry directory shown in Table 4.8.  Data for 2003 were obtained from a 
publication by Arora (2005) and not sourced originally from that year’s industry 
directory.  This table also shows the emergence of biotechnology parks in India. There 
were no such entities listed in the 2003 directory, but five biotechnology parks are listed 
in the 2007 version.  These changes are represented graphically in Figure 4.4.  The state 
governments of Karnataka and Andhra Pradesh, home to cities such as Bangalore and 
Hyderabad respectively, have actively pursued policies to promote the formation of 
biotechnology parks.  BioSpectrum’s 2008 Resource Guide lists thirteen biotechnology 
parks.  It is not apparent from data at hand if these parks were omissions in the BCIL 
database or whether new ones were actually announced in 2008. The state with the 
maximum overall listings is Maharashtra due to the concentration of industry in Mumbai 
and Pune (see Figure 4.6).   
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Table 4.8  
Change in the Number of BCIL Industry Listings 
Change in BCIL Directory Listings 2003* 2007 Increase in Listings
Agriculture 130 209 60.8% 
Bioinformatics 20 56 180.0% 
Biotech Park  5 n/a 
Environment 15 30 100.0% 
Healthcare 142 232 63.4% 
Marine Biotechnology  9 n/a 
Nanotechnology  2 n/a 
Process Industries 37 71 91.9% 
Clinical Trials (Services)  21 n/a 
Contract Research Organizations 2 63 3050.0% 
Equipment, Instruments, Media Suppliers 36 84 133.3% 
* from Arora (2005) 
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Figure 4.4. Change in BCIL Directory Listings. 
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BCIL Company Listings by Location
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Figure 4.5. BCIL Company Listings by Location. 
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Figure 4.6. BCIL Company Location by State. 
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BCIL Company Listings by sub-sector
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Figure 4.7. BCIL Company Listings by Sub-Sector. 
 
 As mentioned previously, twenty-two companies were interviewed for this 
research.  The research team did not have access to either the BCIL directory or the 
BioSpectrum Resource Guide at the time the companies were selected for interviews. 
Table 4.9 presents the list of companies interviewed and identifies the publication in 
which they were included.  Only 41 percent of the companies were listed in both 
publications, but six companies were not found listed in either directory.  Among the 
latter six companies, half of them were defenders and one was a reactor.  While it may be 
difficult to draw statistical correlation between a missing company listing and its strategy 
type, it may be indicative of the lack of company networking and inclusion in industry 
circles. 
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Table 4.9  
Listing of Companies Interviewed in Industry Directories 
Company Year 
Formed 
BCIL Listing 
(5th Edition - 
2007 Industry 
Directory) 
BioSpectrum 
– Resource 
Guide 2008 
Listing in 
both 
directories 
Listing in 
neither 
directory 
M-S 
Type
A 2005 1 1 1  A 
B 2006    1 D 
C 1994 1 1 1  A 
D 2000 1 1 1  A 
E 2008    1 P 
F 2005 1    A 
G 2006     A 
H 1998* 
(2001) 
1 1 1  A 
I 2006    1 R 
J 2004    1 A 
K 2003 1 1 1  P 
L 1991* 
(2005) 
1    A 
M 1998    1 D 
N 2001    1 D 
O 1993 1 1 1  P 
P 2004 1    A 
Q 2000 1 1 1  P 
R 2006 1    P 
S 2000 1    P 
T 1986  1   D 
U 1973 1 1 1  A 
V 1988 1 1 1  D 
Total  14 (64%) 10 (50%) 9 (41%) 6 (27%)  
Note. * Year started biotechnology related operation is in parenthesis 
 
A comparison was made between the listings of BCIL and BioSpectrum to look 
for common listings.  Less than half of the companies interviewed (41%) were listed in 
both resources, but no inference can be drawn whether one or the other M-S type of 
company was listed in multiple directories. Six companies were not listed in any one of 
these resources and one of these six was typed as a prospector.  All companies were 
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found through Internet searches.  The 2007 BCIL industry directory, which was still the 
most recent at the time this research was published, was purchased by the researcher in 
CD-ROM format during the visit to New Delhi in May 2009.  The print copy of the 
BioSpectrum Resource Guide was obtained at the BioProcess International – AsiaPacific 
Conference in Mumbai in October 2008.  These documents served as valuable resources 
for secondary information about the companies.  Having these resources at hand could 
also serve as a valuable tool for conducting future research with a much larger company 
sample and may lend itself to statistical analysis based on self-typing methodology to 
classify companies according to the M-S typology. It is interesting to note all 
biotechnology companies were formed after 1990 (see Figure 4.8) and 16 companies 
started their biotechnology operations in the year 2000 or later.  The three companies 
formed prior to 1990 were the two generic drug firms and an equipment supplier.  The 
activity of company formation as seen in Figure 4.8 mirrors that of research publication 
frequency shown previously in Figure 2.4. 
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Figure 4.8.  Year of Formation of Companies in the Interview Sample. 
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Interviews with the two generic pharmaceutical companies were coincidental and 
were not a part of the planned course of research.  One of them took place as a result of 
the interview scheduled with the biotechnology business unit of company U.  The 
biotechnology unit of Company U is operated as a separate entity by the parent company 
although it is wholly owned by the parent company.  The second generic drug company 
(Company T) was interviewed as result of its co-location with one of the biotechnology 
companies scheduled to be interviewed, and an introduction by the director of the 
biotechnology company.  The two generic drug companies have not been included in the 
research sample of biotechnology companies to determine the P-A-D-R mix.  However, 
based on the information obtained during the interviews, it was apparent that there were 
differences in the strategy choices of the two companies.  Company T was identified as a 
defender while company U was typed as an analyzer.  Company U was actively seeking 
to play a role in the biotechnology arena and pushing forward into more conventionally 
regulated drug markets around the world, while maintaining their core competency in the 
generic drug business.  Company T was also in the process of expanding their product 
offering, but still within the realm of therapies based on chemistry rather than 
biotechnology. 
A common approach mentioned during the interviews by both generic drug-
manufacturing companies for expansion was the use of special economic zone (SEZ) 
legislation passed by the national government.  Both companies, T and U, have acquired 
land to construct facilities to expand their pharmaceutical operations.  Company U 
expects to include some biotechnology related activities at its new facility in the SEZ, but 
company T has no plans to delve into biotechnology products or services.  It is 
noteworthy that only large companies, such as these two generic pharmaceuticals, are the 
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ones able to capitalize on the SEZ legislation.  Even though the government has 
attempted to promote biotechnology as one the key industries through the SEZ 
development, none of the biotechnology companies interviewed for this research 
mentioned SEZ policy as a form of government assistance they were able to use.  This 
confirms the criticism found in the news media that SEZ development has a very high 
threshold from an investment standpoint and these requirements pose a significant barrier 
for the smaller biotechnology companies.  A better approach within the SEZ policy may 
be to encourage the construction of biotechnology incubators by incentivizing larger 
business, more established to construct laboratories and other required infrastructure, 
which may in turn attract smaller, early stage companies.  Four biotechnology-focused 
SEZ’s were identified through literature review in a trade journal (Wheelwright and 
Bagaria, 2008).  Two out of the four were located in Bangalore, one in Pune and one in 
Hyderabad.  The Biocon SEZ in Bangalore is captive to its own operations, while 
Kemwell Pvt Ltd, a contract manufacturer of formulations for multinational 
pharmaceutical companies, developed the second one.  SEZ’s anchored by Biocon and 
Kemwell were not listed in eith of the company directories, but the other two SEZ’s were 
listed in the BCIL directory and the BioSpectrum Resource Guide.  This again points to 
the lack of consistency of data available on the Indian biotechnology sector. 
As mentioned previously, a primary objective of this research was to interview 
senior managers at smaller Indian biotechnology companies.  This was done in order to 
(1) gain a perspective of home-grown companies, (2) understand the management 
strategies of companies in the early stages of formation, and (3) bridge the gap in the 
academic literature since there is practically no research on these companies.  Table 4.10 
and Table 4.11 show the number of employees at half the biotechnology companies in the 
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interview sample was less than 50.  A majority of these companies were founded by 
scientists and individuals with business or pharmaceutical industry backgrounds (see 
Table 4.12). 
Table 4.10  
Company Employee Profile 
Company Number of Employees Founder Background 
Average 
Employee age 
Expats on 
the team 
A 450 Business & pharma 34 1 
B 120 Chemistry, engineeering, 
biotech, biology 
35  
C 200 Scientist/professor at at U.S. 
university 
35 1 
D 59 Software, marketing and finance young  
E 10 Mathematics and 
semiconductors 
young  
F 12 Former top-five Indian biotech 
company employee, 
microbiology, engineering, IT 
young  
G 220 Information technology young 1 
H 400 Medicine, finance, computers, 
pharma, consulting 
 1 
I 4 Scientist/business govt official; 
scientist in India & US 
35+ 1 
J 230 Business, IT  1 
K 45 U.S. based scientist 25-30 1 
L 40 (biotech) 
total ~ 500 
Chemistry, pharm, biotech, 
business 
30’s 1 
M 57 Industrial production   
N 43 Chemistry, pharmacy young  
O 18 Scientist for a multinational drug 
firm; genetics 
  
P 20  26-28 1 
Q 300 US educated scientist; business 27-35 1 
R 15 Business, science  1 
S 15 US educated scientist 30’s 1 
T > 1000 Business, pharma   
U 270 (R&D) 
total > 1000 
Business and science R&D 30-33; 
Sales < 25 
 
V 70 Business 27-28 (sales)  
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Table 4.11  
Number of Employees at Companies Interviewed 
Number of Employee Range Number of Companies 
< 50 10 
< 100 3 
100 < 200 1 
200 < 300 3 
300 < 400 1 
400 < 500 2 
> 500 2 
 
There were twelve companies with expatriates on their teams, with some of them 
being founders who returned to India to start the ventures and others who have some 
operations overseas.  Average age of employees of the 16 companies providing this 
information is between 25 and 35 years old indicating the youth of the workforce in this 
sector.  The age range of the sales force for information provided by two companies was 
between 20 and 30 years old.  Collectively all twenty-two companies represent about 
4000 employees, with over half of these individuals employed by the two generic drug 
manufacturers included in the survey (Companies T and U). 
Table 4.12 
Company Founders’ Backgrounds 
Discipline Number of Companies with Founders in each discipline 
Science (chemistry, biotechnology, 
biology, genetics) 
12 
Pharmaceuticals 7 
Business (Finance, marketing) 11 
Engineering 4 
Information Technology 5 
Mathematics 1 
Medicine 2 
Note: Several companies had two or more founders
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 Interviewees at most companies indicated some type of networking activity.  
IBAB and IISC, both located in Bangalore, were the most commonly cited academic 
institutions with whom these companies had interaction.  Association of Biotechnology 
Led Enterprises (ABLE) and The Indus Entrepreneurs (TiE) were also cited a few times, 
although the director of company S indicated that their local chapter of TiE was very IT 
centric and they did not feel at home at the organization’s events hence stopped attending 
them.  Some of the other organizations mentioned were Association of Contract Research 
Organizations and NASSCOM.  Only one company cited working with an international 
NGO; company O was connected with the Bill and Malinda Gates Foundation.  Data 
presented in Table 4.13 were sorted in ascending order based on the column with values 
for LinkedIn connections.  This table represents a combination of primary data gathered 
during the interviews by the respondents identifying the organizations they associate with 
and secondary data by visiting the LinkedIn profile of each interviewee and determining 
the number of connections.  It is interesting to note that individuals at prospector 
companies tended to have the maximum number of connections.  The individual 
interviewed at company G was a foreign national and the researcher found out through 
his LinkedIn profile that he was no longer in India.  The CEO of company Q had more 
than 500 connections as did its CFO, but data in the table is only for individuals 
interviewed.  Similarly there were individuals at other companies also who had a higher 
number of connections than those listed above.  While the sample of companies 
interviewed may not be large enough to perform statistical analysis on the relationship 
between M-S strategy type and the number of LinkedIn connections, this may be an area 
for future research.  The use of social networking websites such as LinkedIn could 
provide valueable insights on the level and types of networking into interactions between 
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professionals in a given industry or business sector.  Such website may also be beneficial 
in bringing individuals together from different geographic regions for sharing relevant 
technical and business information.  Interestingly, the Jeff Weiner, chief operating officer 
(CEO) of LinkedIn, stated in a recent interview that India represented a highly networked 
professional society (Frazier 2010) and with a user base of about 3.4 million unique 
accounts, India is the fastest growing market for this business-to-business networking 
site. 
Table 4.13  
Company Networking Profile 
Company TiE ABLE Academia Other 
Linked IN 
connections 
M-S 
Type 
M    1 0 D 
N     0 D 
V     0 D 
L   1 1 1 A 
F   1 1 2 A 
C  1   9 A 
P 1 1   18 A 
H    1 23 A 
T    1 37 D 
S 1   1 40 P 
O  1 1 1 57 P 
D  1  1 64 A 
A    1 69 A 
B   1  76 D 
J    1 101 A 
E   1 1 149 P 
R   1 1 149 P 
U   1 1 149 A 
I 1 1   165 R 
Q    1 176 P 
K  1  1 308 P 
G     500 A 
Company Count 3 6 7 15   
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ABLE was the most often cited organization with which these companies were 
affiliated.  Surprisingly none of the companies indicated any links with BCIL.  TiE is a 
global, not-for-profit network of entrepreneurs and professionals dedicated to the 
advancement of entrepreneurship. TiE provides a platform for mentoring, networking  
and education, to entrepreneurs and professionals and was launced in California in 1992 
by Silicon Valley entrepreneurs of Indian origin.  Company S indicated its links with TiE 
were weak as their local chapter catered more towards IT professionals and they felt out 
of place at the area TiE events and meetings.  LinkedIn is an online service provided to 
connect professionals in a business-like environment as opposed to FaceBook or 
MySpace, which are geared more towards social networking.  Table 4.13 shows the 
number of connections for the individuals who were specifically interviewed at these 
companies.  The LinkedIn profile showed an interesting trend. In general, individuals 
with prospector companies had a larger number of connections while those with defender 
companies had fewer connections.  The individual noted for companies R and U is the 
same as he served as the director of company R, which was wholly owned by company 
U.  He was also company U’s founder’s son.  Another person with 27 connections left 
company F but the person still had a LinkedIn account and referenced Company F as a 
previous employer.  The person who provided interview for company G was a foreign 
national and was no longer with this company.  The CEO of company Q had over 500 
connections and the CFO had more than 300 connections.  This research has used the 
number of LinkedIn connections to look at the networking profile of individuals within 
the companies interviewed on a semi-quantitative basis and has not attempted to draw 
any statistical conclusions.  However, there may be opportunities for future research to 
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understand the use of LinkedIn to study the use of this tool as a quantitative measure of 
company and individual connectedness. 
This research looked at who the decision makers were in the company and were 
responsible for guiding the business strategy for their firms.  Since all companies 
interviewed, except for the two publicly traded generic drug manufacturers, were 
privately held, it was not surprising that the founders and company owners were the 
primary decision makers as well.  What was surprising was that almost half of the 
biotechnology companies indicated the involvement of a board of directors or advisors in 
the decision making process.  The companies with larger number of employees had more 
collective decisions made by their management teams whereas the company founders 
were the primary decision makers at the smaller firms with fewer than 50 employees.  
This research was not able to identify any clear patterns whether unanimous or collective 
decisions yielded any particular M-S type company.  A recommendation for future 
research is to exclude this parameter from the survey instrument. 
Table 4.14  
Company Decision-Making Process 
Company Decision Makers (DM) 
DM 
Ownership 
1=complete 
2=partial 
Unanimous/ 
Collective 
1=unanimous 
2=Collective 
M-S 
Type 
A Management team and 
advisory board 
2 2 A 
B Management team and 
advisory board 
2 2 D 
C Founder/CEO 1 1 A 
D Director and board 1 2 A 
E CEO 1 1 P 
F CEO, his spouse (co-
founder), advisory board 
1 2 A 
G Management team 2 2 A 
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Table 4.14 (continued). 
Company Decision Makers (DM) 
DM 
Ownership 
1=complete 
2=partial 
Unanimous/ 
Collective 
1=unanimous 
2=Collective 
M-S 
Type 
H Management, foreign owned 
since 2005 
2 2 A 
I Founders 1 1 R 
J Founders and management 
team 
2 2 A 
K Management and board 2 2 P 
L Chariman, board of directors 2 2 A 
M Founder and management 1 2 D 
N Director 1 1 D 
O Directors 1 2 P 
P Company board 1 1 A 
Q Board, management, 
investors 
2 2 P 
R Company board 1 1 P 
S Director 1 1 P 
T Used to be founders, but now 
bringing in outside managers 
2* 2 D 
U Board of directors and senior 
management 
2* 2 A 
V Directors 1 2 D 
* These companies are publicly traded generic drug manufacturers in India. 
 
The product offering of each company was profiled as one of the key parameters 
for typing the company within the M-S framework.  Managers were asked to describe the 
originality or the innovativeness of their products or services.  Table 4.15 breaks down 
the offerings by biotechnology sub-sector, and Tables 4.16−4.17 show the actual offering 
and indicate whether their product of service required a new way of doing things for their 
customers.  Majority of the companies interviewed provided contract research services 
followed by bioinformatics as the second largest group.  Only five companies indicated 
their product was innovative and required their customers to adopt a new technique.  All 
of these five companies were classified as prospectors.  Companies which had multiple 
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and diverse product and service offerings were also classified as prospectors.  Company 
G produced equipment used by three unrelated sectors including healthcare, but did not 
think that they were a part of the biotechnology supply chain.  This could explain the fact 
that they were not listed in either of the business directories analyzed for this research. 
Table 4.15  
Company Offering by Biotechnology Sub-Sector 
Company Offering Category Number of Companies 
Bioinformatics 6 
Contract Research Services 7 
Diagnostic Kits 4 
New biotechnology products 3 
Equipment manufacturer or supplier 2 
Chemicals manufacturer or supplier 3 
Generic chemical drug manufacturer 2 
Note: some companies offered products or services in multiple categories  
 
Table 4.16  
Company Product Profile 
Company Product Service Both Does it require a new way of doing things M-S Type 
A  1   A 
B  1   D 
C 1    A 
D 1    A 
E  1  1 P 
F  1   A 
G 1 1 1  A 
H  1   A 
I  1   R 
J  1   A 
K 1 1 1 1 P 
L 1 1 1  A 
M 1 1 1  D 
N 1    D 
O 1    P 
P  1   A 
Q 1 1 1 1 P 
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Table 4.16 (continued). 
Company Product Service Both Does it require a new way of doing things M-S Type 
R 1   1 P 
S 1   1 P 
T 1    D 
U 1    A 
V 1    D 
Company 
Count 
14 13 5 5  
 
Table 4.17  
Company Offering Details and Product Development Inspiration 
Company Company Offering Product Inspiration 
A Fee based contract services for 
drug development and discovery 
Coincidental (networking) tie up with 
entrepreneurs and TATA Group 
B Contract research Founder thought something was 
missing in contract research 
C Hand-held diagnostic kits Wanted to come back and do 
something for community of India 
D Hand-held diagnostic kits Was looking to start a company in 
emerging tech and India's unique rural 
med requirements 
E Two algorithms for computational 
processing of biological data 
 
F Database creation, manipulation 
and tools for analysis, informatics, 
gene identification 
Founders desire to be entrepreneur 
G Software and hardware for short 
range information transfer 
Founder left HP and started company - 
his vision 
H Clinical trials/contract research for 
Phase III trials - considered R&D 
company 
Saw an opportunity in market 
I Bioinformatic services, scientific 
software and computing 
Low cost option 
J Pharma market consulting and 
analysis 
Market opportunity 
K Diagnostic kits, research services Wanted to come back to India and do 
something for the community 
L Nutraceuticals, contract research, 
probiotics, herbal extracts 
Started in herbal products since 1991, 
entered into biotech services ~ 2002 
(CRO) 
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Table 4.17 (continued). 
Company Company Offering Product Inspiration 
M Reagents for solid state peptide 
systhesis, contract work on 
speciality chemicals 
Toll chemical manufacturing - depends 
on what customer wants 
N Reagents and analytical equipment Started with chemical reagents but 
more money in equipment 
O Diagnostic kits for various diseases 
including HIV 
Initial market need, but now looking at 
products for non-government customer 
base for Hepatitis-C, Dengue; as 
cheaper Chinese tests have come in 
P CRO-service; outsourced 
preclinical, < Phase I trials 
Wanted to conduct R&D 
Q Three segments: (1) Bio research-
CRO- third party services for 
genotyping; (2) BioIT; (3) Bio- 
molecules 
Founder's vision - bioinformatics grew 
from IT; driving factor for growth 
were scalability and low-cost 
outsourcing 
R Vaccines and therapies based on 
plant gene modification 
trying to reduce cost in producing 
enzymes thru fermentation- produce 
them in plants 
S Naturally occurring 
microorganisms used in 
agricultural biocontrol and 
environmental water remediation 
Founder's research in USA in pharma 
and tried to kill microorganisms, but 
later saw how they could be used to 
perform new uses- looking for green 
solutions 
T Generic/non prescription drugs; 
injectible medicines for other drug 
makers - contract tolling 
production 
Injectibles since 1997; got into R&D 
in 2004-driver for their new 
innovations; in the process of setting 
up a SEZ 
U Generic drug maker with their own 
brands-about 200 products 
marketed in over 50 countries 
Company had humble beginnings 35 
years ago as drug distributor; in the 
process of setting up a SEZ which will 
include biotech activities 
V Instrument supplier - distributor for 
major brands 
Long time in business- market 
opportunity 
 
  
127
Table 4.18  
Company Marketing Strategy 
Company Target Market Marketing Strategy M-S Type 
A Large pharma companies 
around the world with targets 
in pipeline 
Established marketing center in 
Research Triangle Park, NC; direct 
sales including cold calls 
A 
B US, EU, Japan - but not India 
(don’t feel there is a market for 
their services in India yet) 
Customer loyalty-came with him 
when left previous job-word of 
mouth/connections 
D 
C Medical supply distributors; 
40% export to developing 
countries 
Sales force and direct sales target  A 
D Doctors and hospitals in rural 
markets, Indian government 
Through government networking A 
E Large instrument companies 
such as Agilent 
No formal process- only personal 
networking 
P 
F Various market segments Website, cold calls, random business 
visits 
A 
G Plan to market to health-care, 
logistics, automotive 
companies in US, EU and 
Japan 
Sales force, website A 
H Expanding contract research 
operations into regulated drug 
markets 
Now a subsidiary of a foreign firm 
and able to market on a wider basis 
in the west 
A 
I Scientific research groups 
around the country 
Word of mouth  R 
J Big pharma is target market Tradeshows and sales calls; offices 
in two foreign countries 
A 
K Health care providers 
diagnostics and diagnostic labs 
Technical sales, word of mouth with 
extensive network of connections 
P 
L Consumers for nutraceuticals 
and big pharma for research 
Has a US marketing team; totally 
export oriented - no sales in India 
A 
M Drug distributors and hospitals Agreement with German company D 
N Medium and large sized 
diagnostic labs in India 
Outside sales team D 
O Indian government and big 
pharma 
Through personal networks P 
P Big pharma in India and US Personal contacts, overseas partners, 
conferences, trade-shows, and 
existing customers 
A 
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Table 4.18 (continued). 
Company Target Market Marketing Strategy M-S Type 
Q Three target markets in 
contract research, 
bioinformatics and molecular 
research 
Acquisition of existing firms and 
using their networks (science, 
research and IT 
P 
R Developed countries Products still under development P 
S Platform technology for agri-
biotech and environmental 
applications 
education component to get 
customers to try new products - 
getting them to make the initial 
investment is challenging-word of 
mouth, trade organizations, web 
P 
T Focusing on injectibles now 
and contract manuf for drug 
cos worldwide 
Personal connections, word of 
mouth based on marketplace 
repuatation, sales force 
D 
U 50% India, 50% export - own 
brand in 52 countries-mostly in 
semi-regulated markets 
1300 sales force in India and 2100 
worldwide 
A 
V Customers are leading research 
establishments in life sciences 
labs, universities, and hospitals 
Six branches in major Indian cities, 
exhibitions and trade shows 
D 
 
Table 4.19  
Company Value Proposition 
Company Value Proposition M-S Type 
A Low cost for high quality drug dev (accredited by 2 
organizations – AALAC (Germany); GLP (India)) 
A 
B Cost basis and service A 
C Cost effectiveness and suitable for local conditions A 
D Multi-disciplinary team to translate science into market ready 
products for healthcare sector at best cost 
A 
E Quicker, cheaper, simpler methodologies and tools P 
F Strong technical team with academia and industry experience, 
but lower cost solutions for clients 
A 
G Products and partnerships with capabilities to serve multiple 
markets 
A 
H Established reputation for quality data provider A 
I Low cost option with high quality R 
J Innovative, but low cost option for data analysis and consulting A 
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Table 4.19 (continued).  
Company Value Proposition M-S Type 
K Simplicity and cost effective solutions P 
L Diversified product range; relies on core product development 
strength to provide contract research services 
A 
M Capable of meeting international manufacturing  standards at a 
very competitive price point 
D 
N Locally produced semi-automated equipment and test kits at 
competitive prices 
D 
O Wide range of products which simplify disease detection; 
strong research base to provide contract services 
P 
P R&D in ¼ time with high quality; 30%-35% cheaper than US; 
ie faster and cheaper. 
A 
Q Diverse, rapidly growing  organization with strong research 
base to provide contract services, data analysis and drug 
discovery opportunities 
P 
R Relying on new platform technology to develop new products P 
S Better products and cheaper cost per application-increasing 
yield and profit for producer 
P 
T Low cost generic products; now developing new formulations D 
U Generic drugs - lower cost; but expanding research and 
development capabilities and seeking new international markets 
A 
V Provider of full range of scientific instruments to Indian 
establishments with long-term reputation 
D 
 
Table 4.20  
Company Intellectual Property Data 
Company Intellectual Property 
A Internal & external with drug discovery and development team 
B Not their own - trade secret if any; protect customer's work 
C None 
D Indian, world patents- PCT, attys in Germany 
E Internal, with help from IBAB and IISc student interns 
F Internal-developed with student interns from IBAB & employees- 
protected by phyical security measures 
G Trade secrets 
H Non disclosure agreements with employees – appeared weak 
I Possible Indian patent 
J External IP, customer confidentiality 
K Internal (prototyping and market feedback based) & external-US, Indian, 
international patents 
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Table 4.20 (continued). 
Company Intellectual Property 
L 22 US patents, 8 international patents; no Indian patents because no 
sales in India 
M Not concerned with patents as they are expired for products they are 
developing 
N None and not worried about patents 
O Original patent developed by company founder and gifted to founder by 
previous employer 
P None 
Q 65 process patents filed - but mostly trade secrets 
R Company seeking to license multiple U.S. Patents from U.S. based 
collaborator 
S Developed  platform technology-using trade secret to protect it; 
indicated patent process is flawed due to corruption in IPO (Indian 
Patent Office). IPO  controled by large drug firms and there is potential 
to pirate original intellectual property as it is submitted 
T None 
U Few Indian patents for generic drugs 
V None 
 
Table 4.21  
Company Intellectual Property Status (S=Strong; W=Weak) 
Company Internal External Patent Trade Secret License NDA None 
S=1 
W=2 
M-S 
Type 
A 1 1      2 A 
B  1    1  2 D 
C       1 N/A A 
D   1     2 A 
E 1   1    1 P 
F 1       2 A 
G 1   1    1 A 
H  1  1    2 A 
I 1  1     2 R 
J  1    1  2 A 
K 1  1     1 P 
L 1  1     1 A 
M       1 N/A D 
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Table 4.21 (continued). 
Company Internal External Patent Trade Secret License NDA None 
S=1 
W=2 
M-S 
Type 
N       1 N/A D 
O 1  1     1 P 
P  1    1  2 A 
Q 1  1 1    1 P 
R  1   1   1 P 
S 1   1    1 P 
T       1 N/A D 
U 1  1     1 A 
V       1 N/A D 
Company 
Count 11 6 7 5 1 3 5   
 
Bangalore Interview Analysis 
Bangalore’s Research Capacity 
Most of the companies interviewed provided some form of outsourced contract 
biotechnology services so it was the skilled Indian workforce that provided the science 
base. Over a third of the companies interviewed were bioinformatics enterprises that were 
started by entrepreneurs who left IT companies to start companies that service the biotech 
and pharmaceutical sectors.  They took the skills and practices they learned providing 
outsourced IT services and applied them to the biotechnology sector.  They hire the 
scientifically trained students coming out of the universities or lure them away from 
Bangalore’s IT companies.  
Bangalore’s Ability to Convert Research into Successful Commercial Activity  
In Bangalore, commercial activity is converted into research because most of the 
companies interviewed were able to turn their technology into revenue generation 
through contracted service.  Bangalore has firms that offer to do any aspect of the 
biopharmaceutical business cheaper, quicker, and with equal quality to what can be done 
in developed countries making a virtual biopharmaceutical not inconceivable.  The 
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companies interviewed could provide the market research, discovery, testing, and 
development.  They could even provide the back office services. Significant changes in 
India’s patent law in 2002 specifically included processes which produced a live product 
through biochemical, biotechnological and microbial processes.  In 2005, the laws were 
further amended to include product patents in order to comply with the World Trade 
Organization’s agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS).  These changes in the patent regime have the potential to increase the 
commercial development of new biotechnology-based products which would benefit 
from market exclusivity for the duration of the patent (Mueller 2008). 
Access to Funds in Bangalore  
Despite the availability of external private funds and government assistance, most 
of the start-up companies relied on their own funds or revenues from services for their 
funding.  The revenue earning business model and “bootstrap” financing was the norm. 
For initial funding, eight of the fifteen started by doing contract services. Several of the 
companies received bank and government loans, but none of these companies had 
positive experiences with these loans.  Many noted extensive bureaucratic hassles in their 
attempts to get financial assistance from the government.  For example, to be eligible for 
the Small Business Innovation Research Initiative (SBIRI) grant a company needed a wet 
lab of a certain size so some companies would set up a wet lab even though they did not 
need such a lab for their bioinformatics research.  A similar situation was also observed 
by Frew et al. (2007) in their study of the large biotechnology companies in India.  
Nevertheless, two of the companies in the interview sample had received grants from the 
Indian Department of Biotechnology.  Most of the companies were interested in venture 
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capital, but only one, with a well known Indian-American serial entrepreneur a president, 
received venture capital.  
Bangalore’s Entrepreneurial and Innovative Environment   
The entrepreneurial environment for biotechnology is still in its formative stage. 
There are formal (e.g., Association of Biotechnology Led Enterprises (ABLE)) and 
informal networks promoting entrepreneurship and innovation.  Biotech oriented parks 
and incubators such as Institute of Bioinformatics and Applied Biology (IBAB) have 
been developed.  Success stories abound and scientists returning from the west are 
bringing back Silicon Valley concepts.  However, the geography and poor infrastructure 
of the city limit some of the important personal interaction.  Many of the executives that 
we interviewed mentioned spending several hours per day in traffic which limited non-
work networking opportunities.  
Another measure, which implies the technology-oriented nature of Bangalore, is 
the number of nominations from this city in a competition conducted by National 
Entrepreneurship Network (NEN) to identify the “hottest startup” companies across 
several industrial sectors.  According to NEN’s website, it is “India’s leader in 
entrepreneurship education and works with over 380 top tier academic institutes, has 
created a pool of over 700 entrepreneurship faculty, and reaches over 300,000 young 
people across 30 cities in India.”  NEN was started by the Wadhwani Foundation, a 
foundation funded and chaired by Romesh Wadhwani, a serial IT entrepreneur based in 
Silicon Valley, California.  Wadhwani is a graduate of the Indian Institute of Technology 
(IIT)-Bombay and received a doctoral degree from Carnegie Mellon University in the 
United States.  The co-founding academic institutions of NEN include well known and 
respected schools from across the country: IIT-Bombay, Indian Institute of Management 
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(IIM)-Ahmedabad, Birla Institution of Technology and Science (BITS)-Pilani, SP Jain 
Management Institute, Institute of Bioinformatics and Applied Biotechnology (IBAB)- 
Bangalore and Indian School of Business, Hyderabad.  Data presented in Table 4.22 
show the majority of the biotechnology startup company nominations came from 
Bangalore even though the overall number of these companies was a small percentage 
(1.2%) of the total nominations. 
Table 4.22  
Company Nominations by Sector and City for the NEN Hottest Startup  
Industry Sector Total Sector Nominations Bangalore Hyderabad New Delhi Mumbai 
Chennai/ 
Pune/other 
Biotechnology 7 6 (86%) 1 0 0 0 
IT/Software 195 48 (25%) 19 17 32 79 
Healthcare/Pharmaceutical 11 5 (45%) 1  2 3 
Cleantech 6 2 (33%) 0 0 2 2 
Agribusiness/Agriculture 8 3 (38%)  1 0 4 
Telecom/Mobile 33 9 (27%) 3 4 7  
Finance 19 3 (16%) 3 1 4 8 
Total Nominations 583 145 (25%) 46 71 107 214 
Note. Adapted from http://hotteststartups.in/ 
 
This knowledge-based growth has implications for understanding why regions 
evolve certain ways and directions to go for growth. Cortright and Mayer (2002) presents 
five broad points for economic development: (1) focus on creating new knowledge in 
businesses as well as universities and laboratories; (2) regions do have agency, but the 
chaotic nature of knowledge-based growth makes economic development impossible to 
plan precisely; (3) the path dependent aspect of growth requires building on the local base 
of expertise; (4) innovation at all levels needs to be encouraged; and (5) knowledge-based 
growth has a snow-ball effect so opportunity needs to be inclusive.  These points help 
explain a region’s development and prescriptive direction.  The model for biotechnology 
development that has been proven to be economically successful in several countries is to 
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have clusters of similar companies situated around publicly funded academic and 
research institutions with strong credentials.  A key feature of this model is to have the 
public sector fuel the private sector with the supply of appropriately trained staff with 
skills required for growing biotechnology companies (Hine and Kapeleris 2007). 
Bangalore is not to the point of developing extensive new scientific knowledge, 
but it is hollowing out so many aspects of the biopharmaceutical business, including the 
drug discovery process to a limited extent, that is well positioned to develop and 
commercialize new knowledge if the financial and innovative environment pieces 
develop.  Although majority the patents (three fourths) in India are currently assigned to 
non-Indian multinational corporations (Mueller 2008), new knowledge is being created 
within the financial constraints in domestically based businesses as well as universities 
and laboratories.  The region is grappling with how to apply its agency and planning 
appears to be flexible.  The growth promotion is generally focused on the local base of 
expertise contract services using its skilled workforce and established institutional 
procedures.  Innovation and entrepreneurship is not being stifled, but progress needs to be 
made in this area.  
Financing of Indian Startups 
 
 Allen et al. (2006) conducted a survey of 213 small and medium sized firms in 
Hyderabad and Delhi.  They found that “the three most important financing channels for 
these firms during their start-up and growth periods are founders’ family and friends, 
trade credits and loans from financial institutions, including state-owned banks and banks 
specialized in lending to small- and medium-sized firms (e.g. the Small Industry 
Development Bank of India, or SIDBI, and State Financial Corporations, or SFCs). 
However, “credit availability is not uniform across the surveyed firms, and the market for 
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bank credit is clearly relationship-driven” (Allen et al. 2006, 4-5).  This survey also found 
that by far, family was the most important source of start-up funds for Indian SMEs, cited 
by over 85 percent of respondents.  This was also found to be an important source of 
funds for growth.  About 86 percent of firms viewed family and friends as a “very easy 
and low cost” source of funds.  As in other nations, bank financing for start-up firms is 
rare in India.  Dutz (2007) identifies several barriers to Indian micro, small, and medium 
enterprises (MSMEs) receiving bank loans for technology absorption.  These include a 
weak legal system, weaknesses in banks’ ability to assess and monitor risk, lack of 
reliable credit information, and insufficient market credibility for MSMEs (Dutz 2007).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Funding Stage of Biotechnology Companies. 
From Innovation and Entrepreneurship in Biotechnology, an International Perspective, by D. Hine 
and J. Kapeleris (2007, 50) 
The 3Fs: family, friends and fools
Direct government sources 
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Non-financial corporations – Pension funds 
Private equity/institutional 
Venture capital funds and Big Pharma 
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Venture capital is not an important source of financing in India, especially in the 
biotechnology sector.  Chaturvedi (2005) observes, “While the biotechnology industry 
needs substantial venture funds, the venture companies feel they are not getting attractive 
projects with high growth potential in the Indian context” (40).  Similarly, Palnitkar 
(2005) found that venture capital was not reaching Indian biotech companies.  A very 
small percentage of respondents to the Allen et al.’s (2006) survey felt venture capital 
was an important source of funds.  Palnitkar (2005) points to an alternative financing 
method: “The absence of venture capital in the early days and the onset of risk-averse 
venture funding today has compelled most Indian biotech start-ups to pursue a revenue-
earning business model from inception” (148).  The Indian Venture Capital Association 
reports that in 2006, private equity and venture capital investment in India totaled about 
US$7.5 billion.  Less than seven percent of that investment went to the healthcare and life 
science industry.   
The literature review indicated that commonly held theory requires strong 
intellectual property protection laws to be in place in order for effective external 
financing of invention commercialization to occur.  In the absence of external financing, 
determined entrepreneurs utilize their personal savings and funds from family and 
friends.  This alternative mechanism was widely observed in the companies surveyed in 
this study, as was the lack of private venture capital fund financing.  Such speculative 
diversification strategies were used through the early 1900’s in the United States 
(Lamoreaux et al. 2007).  
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Initial Financing 
The majority of the 20 biotech companies interviewed were initially funded by the 
founders of the company which is common in this field (see Figure 4.9).  Company 
founders provided complete or partial financing for 17 of the companies interviewed.  
Five companies (O, R, S, T and V) received financing from friends or family members in 
addition to the funding provided by the startup management team.  Eight founder-
financed companies (B, C, G, H, M, N, O and R) also received bank loans during the 
startup phase.  Companies C, O, and Q were the only firms that received some form of 
government funding at startup.  In addition to owner financing, Company K and Q were 
the only firms that received venture capital funding at startup.  Company N was the only 
firm to be financed exclusively through bank loans.  One quarter of the companies (D, E, 
F, L and N) realized revenues from startup.  The business model of these firms was 
primarily to sell services while they developed new products. Majority of the companies 
relied on more than one type of startup funding (see Table 4.23). 
Table 4.23  
Initial Financing of Indian Biotechnology Companies 
Company Owner Friends/Family Bank VC Govt Projects Other 
A       1 
B 1  1     
C 1  1  1   
D      1  
E 1     1  
F 1     1  
G 1  1     
H 1  1     
I 1       
J 1       
K 1   1    
L 1     1  
M 1  1     
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Table 4.23 (continued). 
Company Owner Friends/Family Bank VC Govt. Projects Other 
N   1   1  
O 1 1 1  1   
P 1      1 
Q 1   1 1  1 
R  1 1    1 
S 1 1      
T  1      
U 1       
V 1 1      
Company 
Count  
17 5 8 2 3 5 4 
 
Product Development and Growth Financing 
 
Financing of R&D activities and company growth came primarily from internal 
sources.  Owners of five companies (C, E, F, L, and R) injected additional capital into 
their companies to fund growth.  Ninety five percent of companies interviewed funded 
their growth from retained earnings, either as the sole source of funding or in addition to 
owner equity.  The only company not doing so still had a product in the development 
stage and the company did not have any revenues (see Table 4.24).  The financial 
discipline placed on publicly traded companies by regulatory authorities in the United 
States limits their ability to pursue long range speculative research outside of their 
existing markets and product lines.  Chesbrough (2003) argues that large companies 
perform better by acquiring early stage innovation companies than by developing radical 
innovations internally.  Thus, the current structure of the United States financial markets 
has venture capital firms making the early stage investment in biotechnology companies 
with the intent of selling to the large publicly traded company as an exit strategy (see 
Table 4.25 and Figure 4.10).  External sources of private financing in India, however, 
were far less prevalent.  Companies H, O and Q received financing from private equity 
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sources.  Companies D and O received loans from the government and only two 
companies were able to capitalize on the SEZ policy. However, both of these companies 
(T and U) were large generic pharmaceutical companies and had the financial 
wherewithal to comply with the requirements of setting up a SEZ. 
Table 4.24  
Growth Funding of Indian Biotechnology Companies 
Company How has recent growth been financed? Owner Revenues VC Govt 
A Service revenue  1   
B Revenue  1   
C Product sales 1 1   
D Government loans and 
continued support form 
government 
 1  1 
E Services and personal 
savings 1 1   
F Services and personal 
savings 1 1   
G Revenue  1   
H Buy-out  1 1  
I Service projects  1   
J Service projects  1   
K Services and collaboration  1   
L Revenue from other 
departments 1 1   
M Revenue  1   
N Revenue  1   
O Bank venture fund wanted 
exit (actual exit in 2006)   1 1 
P Service projects  1   
Q Product and service 
diversification  1 1  
R Still in product 
development stage 1    
S Sales  1   
T Publicly traded  1  1 (SEZ) 
U Publicly traded  1  1 (SEZ) 
V Sales and commissions  1   
Company  
Count 
 5 21 3 4 
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Despite the financial reforms, India’s financial sector remains small and 
underdeveloped.  According to O’Neill and Poddar (2008) the state still dominates the 
sector, holding 70% of banking assets, a majority of insurance funds and the entire 
pension sector. Additionally, markets are lacking in corporate debt, currency and 
derivatives.  This leads to a lack of credit and low financial savings.  Although total credit 
has risen rapidly in recent years, it is still at 50 percent of GDP and especially low 
compared with China at 111 percent of GDP.  Within this, consumer credit remains 
abysmally low (at 11% of GDP) compared with an Asian average of over 40% of GDP.  
Household savings tend to be in physical assets and gold, and risk diversification 
channels are not available.  To meet its growth potential, India needs to pursue financial 
reforms to channel savings effectively into investment, meet funding requirements for 
infrastructure and enhance financial stability.  Savers need to have access to a broad 
range of financial instruments, while borrowers should be able to access local debt and 
equity (O’Neill and Poddar 2008).  This type of financial environment is especially 
limiting for science and technology based ventures like those in biotechnology, which 
require substantial risk capital outlays over a long period of time.  For comparison 
purposes, the funding of biotechnology companies in the United States between 1997 and 
2003 is shown in Table 4.25 and the corresponding Figure 4.10 (Burrill 2004).  
Investment in biotechnology companies peaked sharply in 2000 and dropped equally 
sharply after that as well.  Debt financing took on a larger portion of the total funding 
after 2000, whereas follow-on equity investments was the largest chunk of investment 
prior to the year 2000.  The use and availability of increasing debt financing would 
indicate that lenders saw this sector as a less risky investment starting in 2000 and 
indicative of some level of technology maturation. 
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Table 4.25  
Financing of Biotechnology Companies in the United States 1997-2003 
Public        
 1997 1998 1999 2000 2001 2002 2003 
IPO  $        688   $       369   $         670  $      6,490   $        440   $       445 $        453 
Follow-on  $     1,601   $       521   $      5,805  $    12,651   $     2,539   $       979 $     3,536 
PIPEs  $     1,283   $       977   $      1,433  $      4,061   $     1,741   $       907 $     2,051 
Debt  $     1,288   $    1,262   $      1,520  $      5,728   $     4,848   $    5,251 $     7,170 
        
Private        
VC  $       569   $       800   $      1,084  $      2,872   $     2,397   $    2,688  $     2,841 
Other  $       184   $         84   $         184  $         203   $            9   $       178 $        294 
        
Total  $    5,613   $    4,013   $   10,696   $    32,005   $  11,974   $  10,448 $   16,345 
Note. Adapted from Burrill (2004). Figures are in millions. 
[IPO: Initial Public Offering; PIPEs: Private Investment in Public Equity; VC: Venture Capital] 
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Figure 4.10. Financing of U.S. Biotechnology Companies (Figures in $ millions) 
  
143
External Environmental Factors 
According to Walker et al. (2003), the environmental characteristics, which favor 
a prospector strategy, include the industry itself being in an early stage of product and 
structure development with undeveloped or still unidentified market segments.  There are 
few established competitors and a single firm may hold most of the market share.  The 
technologies are still emerging.  These conditions hold true for the nascent biotechnology 
industry in India.  Industry data show that publicly traded pharmaceutical companies in 
India had revenues of approximately $15 billion on 2007 and the life science related 
biotechnology sector revenue was only $2 billion for that period.  Only one 
biotechnology pharmaceutical company appeared on the list of top 20 companies in the 
life science industry.  Biocon was at 16th position on that list, but its revenues grew 29% 
between 2006 and 2007.  Such market conditions are common in the biotechnology 
sector and companies operating in this environment are likely to pursue a prospector 
strategy as per the literature.  Technical skills are critical for entrepreneurs or companies 
in establishing a biotechnology venture, but not sufficient for successfully exploiting 
business opportunities in this industry.  Limited experiential learning experiences on the 
business side “do not support robust strategic judgment, particularly in an industry where 
change can be considered a constant rather than a variable”  (Hine and Kapeleris 2007, 
32).  Given the strong push from the government of India in the biotechnology sector, the 
relationship between public institutions and the research base is likely to be extensive 
with less involvement of the private sector in discovery and basic research.  
Consequently, commercial opportunities arising from fundamental research will be 
rooted in the culture of the academic institutions.  According to Hine and Kapeleris 
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(2007), “It is often difficult for the biotech venture that has been spun-off from university 
research to change its culture and strategy toward a fully commercial focus” (47). 
Table 4.26 shows the various external conditions conducive to type of strategy 
adopted by a company.  The research observed that market characteristics of this sector in 
India are such that it would encourage prospectors, along with the level of technology 
development.  The factors listed for competition and business strengths on the other hand 
tend to favor the adoption of analyzer or defender strategies.  The industry structure is 
still evolving and there are only a few large entities controlling the marketplace.  There 
are many smaller players and a future shakeout of the competition is likely.  Practically 
all of the companies interviewed indicated that there were competing technologies 
available for their product or service.  The defenders were taking the “low cost defender 
approach” with the better, faster and cheaper value proposition to compete in the market 
place. 
Table 4.26  
Environmental Factors Favorable to Adoption of Individual Business Strategies 
External 
Factors Prospector Analyzer Defender 
Market 
Characteristics 
Industry in 
introductory or early 
stage of life cycle; 
many potential 
customer segments as 
yet unidentified 
and/or undeveloped. 
Industry in late growth 
or early maturity stage 
of life cycle; one or 
more product offerings 
currently targeted at 
major customer 
segments, but some 
potential segments may 
still be undeveloped. 
Industry in maturity or 
decline stage of life 
cycle; current offerings 
targeted at all major 
segments; sales 
primarily due to repeat 
purchases/replacement 
demand. 
Technology New emerging 
technology; many 
applications as yet 
undeveloped 
Basic technology well 
developed but still 
evolving; product 
modifications and 
improvements-as well 
as emergence of new 
competing 
technologies-still likely. 
Basic technology fully 
developed and stable; 
few major 
modifications or 
improvements likely 
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Table 4.26 (continued). 
External 
Factors Prospector Analyzer Defender 
Competition Few established 
competitors; industry 
structure still 
emerging; single 
competitor holds 
commanding share of 
major market 
segments. 
Large number of 
competitors, but future 
shakeout likely; industry 
structure still evolving; 
one or more competitors 
hold large shares in 
major segments, but 
continuing growth may 
allow rapid changes in 
relative shares. 
Small to moderate 
number of well-
established 
competitors; industry 
structure stable, though 
acquisitions and 
consolidation possible; 
maturity of markets 
means relative shares 
of competitors tend to 
be reasonably stable 
over time. 
Business’s 
relative 
strengths 
Strategic business unit 
(SBU) or parent 
company has strong 
R&D, product 
engineering, and 
marketing research 
and marketing 
capabilities. 
SBU or parent has good 
R&D, product 
engineering, and 
marketing research 
capabilities, but not as 
strong as some 
competitors; has either 
low-cost position or 
strong sales, marketing, 
distribution, or service 
capabilities in one or 
more segments. 
Differentiated 
Defender: SBU has no 
outstanding strengths 
in R&D or product 
engineering; costs are 
higher than at least 
some competitors; 
SBU’s outstanding 
strengths are in process 
engineering and quality 
control and/or in 
marketing, sales, 
distribution, or 
customer service.  
Low-Cost Defender: 
SBU or parent has 
superior sources of 
supply and/or process 
engineering and 
production capabilities 
that enable it to be a 
low-cost producer; 
R&D, product 
engineering, 
marketing, sales or 
service capabilities 
may not be as strong as 
some competitors. 
Note. Adapted from Walker et al. (2003, 74) 
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There is a general consensus in the literature that certain conditions are necessary 
for a biotechnology cluster, particularly biopharmaceutical, to arise. Prevezer (1997, 
1998) found a strong science base with specialized labor, specialized inputs, and 
specialized knowledge that spills over as the greatest explanatory factor for biotech 
clustering in the US.  Chiesa and Chiaroni’s (2005) in-depth analysis of biotech clusters 
in Cambridge (UK), Heidelberg (Germany), Aarhus (Denmark), Marseille (France), 
Milano (Italy), Paris-Evry (France), Uppsala (Sweden), Biovalley (Switzerland) and Bay 
Area and San Diego in the US identified four main driving forces of biotechnology: (1) 
the availability of funds (e.g., venture capital, government funds), (2) the presence and 
exploitation mechanisms of scientific research, (3) industrial characteristics such as a 
critical mass, integration, and mechanisms to attract key managerial and commercial 
people, and (4) supporting factors such as a legal framework, public acceptance, and 
promotion.  These studies, mostly in developed countries, found common patterns for 
successful biotechnology centers.  It is noted that the various segments of the 
biotechnology industry develop clusters with different characteristics. 
Biopharmaceuticals, agro-food and environment/energy biotechnology create distinctive 
economic geographies.  Cooke (2002, 8) notes that biotechnology is a “knowledge-
driven” sector and firms cluster in proximity to knowledge sources and while universities 
are “key-magnets” for attracting industry, investors and attorneys play a critical role in 
transferring science from laboratory scientist to commercial entrepreneurs. 
During interviews with members of the investment and research community based 
in the United States, the researcher found that capital base is not easily available for 
entrepreneurs in India for capital-intensive industries such as biotechnology, where it 
takes millions of dollars to bring a drug to market.  It appears that investment in 
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biotechnology is at the big company level with more established revenue streams and 
product offerings rather than companies requiring venture capital.  In general investments 
by venture capital and private equity firms have been mostly in the service sector and 
other sectors showing local growth such as retail and construction.  Finance and the right 
type of finance at the right time is a challenge.  According to an interviewee at one of the 
compnaies, “if you have money, it is easy to get money and much of the biotech is 
controlled by a few players in India.” 
Investments driven solely on the basis of unique intellectual property have not 
come to the forefront even in the information technology sector, hence TRIPs compliance 
is not a significant driver for biotechnology investments; rather, the investments are in 
health care delivery.  The bottleneck for development of the biotechnology industry and 
other IP driven industries is not the lack of TRIPs or strong IP regime, but the lack of 
research institutions who are breeding scientists and technologists who do not have the 
requisite skills to go out and start businesses in their respective fields based on their 
research.  India needs to build the ecosystem where it nurtures entrepreneurship as well 
as a specialized workforce to work in the biotechnology sector.  A lack of understanding 
of technology licensing protocols according to established western norms was also 
pointed out during an unstructured interview.  The culture of just taking technology, 
copying it or slightly modifying it without permission is still a part of the business 
landscape although the government official interviewed point out that they are committed 
to enforcing intellectual property rights and encourage indigenous process and product 
technology development. 
India’s role in drug development will be limited in the near future especially at the 
small company level because they will not have the financial capability or access to 
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capital to undertake such efforts.  Less resource intensive businesses such as 
bioinformatics and contract research organizations may continue to grow.  Additional 
regulatory requirements such as U.S. Food and Drug Administration (FDA) or the 
European equivalent will impose additional burdens on small startups.   
A positive development over the last 10 years now is that capital is not 
constrained like it used to be and is available to younger entrepreneurs.  Entrepreneurs 
are driven by equity value creation and they are self-selecting in some sense to attract 
capital when they are willing to take growth of the company rather than maintain control 
of the company for a long time.  There is a slight shift in the attitude in moving away 
from the choice to run a company that may provide them with a life-time of employment.  
Private equity will find good deals and entrepreneurs are looking at exit 
strategies/liquidation options even when starting businesses.  One of the investment 
managers interviewed for this research saw the GDP growth as the main driver for capital 
flowing to India with plentiful opportunities in various aspects of healthcare 
commercialization except for novel biotechnology drug development.  Given the 
regulatory and clinical trial risks required to be undertaken in developing a drug, it is 
better to take that risk in US or Europe where technology base is stronger and the 
financial return profile is much better.  Foreign investments in India are seeking both 
local growth potential as well as export potential.  A recent study found that India’s vibrant 
private sector, which has the expected high level of entrepreneurial culture supported by a high 
level of innovativeness, seems to be well positioned for an entrepreneurial outburst in the new 
privatized environment (Deshpande et al. 2004).  Different groups like TiE and NEN are 
becoming influential in helping budding entrepreneurs. TiE in particular now has good 
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brand recognition and reputation internationally for connecting entrepreneurs with each 
other and investors.   
According to comments from an industry equipment supplier, while the whole 
biotech sector is growing, it is in its early stages of development.  There are three things 
that are holding back the explosion of biotech in India: (1) access to technology, (2) 
educational qualifications of the workforce and (3) lack of funding for basic 
biotechnology research.  In India, students are not taught biotech and its potential benefits, 
but focus is still on information technology.  This is particularly true in rural India.  Rural 
Indian students are poor en masse and they cannot afford education and what they need is 
for the government to support educational opportunities to earn while they learn.   
The organizational cultures were not specifically compared in this research, but a 
previous study was available which compared internal company cultures of an Indian 
agri-biotech with that of an American biotech company, which formed a joint venture in 
India (Miller et al. 2005).  The comparison of cultures of MAHYCO and Monsanto are 
compared and summarized in Table 4.27.  This study also looked at the decision makers 
at the two companies and found that decision making power was concentrated at the top 
in the Indian company whereas it was more distributed through the management 
hierarchy down to the lowest level possible in the organization.  Respect for senior 
managers and especially the founding family members was a strong at MAHYCO.  
Respect towards elders is an integral component of the Indian culture and is signified by 
two different words for “you.”  When addressing elders or individuals less familiar to a 
speaker, the Hindi word “aap” is used, but the word “tu” is the commonly used to address 
friends or peers.  The idea of long-term employment with a single employer is still 
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prevalent in India, but it does not necessarily lead to a diversity of job experiences over 
the course of employment.   
 
Table 4.27 
Comparison between Business Cultures of an Indian and a U.S. Biotechnology Company  
Business Culture Components  MAHYCO (Biotech seed company) Monsanto 
Employee involvement in decision making Low High 
Employee level of decision making Upper management Diverse 
Employee-management relations Formal Informal 
Loyalty and commitment High Moderate 
Tenure expectations High Low 
Variety of job experiences Low High 
Indian connections and networks High Low 
Margin potential Moderate High 
Comfort with change Low High 
Note. Adapted from Miller et al. (2005) 
 
Miller et al. (2005) also studied the Indian connections and network of both 
companies and found that even though Monsanto had been in India for 51 years, they did 
not have the relationships and trust with leaders in government and regulatory agencies to 
legally and fairly influence the registration processes.  However, the MAHYCO 
organization and the Barwale (founders) family did.  Therefore, early in the life of the 
alliance, Monsanto gave responsibility for working with external Indian stakeholders to 
MAHYCO and provided support and training.  The study, however, did not look at 
professional networking of MAHYCO but observed the personal contacts and influence 
of the company founders.  The study also found that MAHYCO management had a low 
level of comfort with change.  Information gleaned from Miller et al.’s (2005) research 
leads the research to speculate that MAHYCO may be categorized as an analyzer since 
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the company management was very traditional in many ways but was also seeking new 
opportunities by partnering with a multi-national company like Monsanto.  Any such 
categorization would have to be confirmed by evaluating this company using the 
structured methodology used for the current research. 
In summary, these results show the Indian biotechnology sector to be a vibrant 
and rapidly growing sector of India’s economy.  Biotechnology is getting significant 
attention from policy makers and the scientific academic institutions.  The Indian 
government has attempted to link the science sector with the business sector by providing 
incentives for innovation activities, however limited financial resources and insufficiently 
qualified human resources remain two major challenges for domestic companies (Fan 2008).  
The biotechnology industry now has a small number of homegrown companies, which 
are beginning to garner recognition beyond the borders of India.  By and large the sector 
is comprised of smaller firms, most of which are self-funded and are generating revenues 
from sales of their services to stay in business.  They are not necessarily involved in 
cutting edge research leading to new biotechnology based therapies, but performing 
standard research procedures for larger national and international firms on a contractual 
basis or seeking to produce generic products.  The change in the intellectual property 
regime has raised the bar to allow product patents and granted protections in accordance 
with western countries, but the companies interviewed for this research were not 
concerned with these changes. 
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CHAPTER V 
CONCLUSIONS, POLICY RECOMMENDATIONS, AND FUTURE RESEARCH  
Significant Findings 
This dissertation demonstrates that classification of companies according to Miles 
and Snow is a feasible framework for use in an emerging technology such as 
biotechnology and a developing country like India.  The results, however, were 
somewhat different from those discussed previously in research on western 
biotechnology companies.  Analyzers formed the largest group (45%) of companies 
interviewed in India, followed by prospectors (30%) and defenders (20%).  Only one 
company exhibited the pattern of behaving as a reactor.  However, it is noteworthy that 
the sole reactor has to be potential to be a prospector with the right strategy in place since 
this company operates in a newly emerging market and is capable of offering a broad 
range of services.  The researcher classified this company as a reactor due to their lack of 
a defined focus on clearly explaining the product offering.  It is an encouraging sign for 
the Indian biotechnology sector to have all but one of the companies fall in one of three 
categories: prospectors, analyzers or defenders.  According to the Miles and Snow theory 
adopting any one of the three strategies leads to a successful enterprise.  All companies 
appeared to have adopted a strategy to operate in the biotechnology sector based on their 
technical strengths.  This research has shown that Miles and Snow framework is indeed 
applicable to studying firms in a developing nation such as India as well as in an 
emerging technology sector like biotechnology.  
While nineteen of the twenty companies interviewed were following strategies 
that may lead to successful outcomes, the choice of the analyzer strategy was observed 
most commonly.  The research team attributed this in part to the lack of well-developed 
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capital systems in India that limited technology dependent companies to seek and secure 
capital for innovative, but financially and technologically risky ventures.  Even though 
motivations were different for different company founders, this research found a level of 
entrepreneurship and willingness to take a risk by self-funding the early stage of the 
venture was common among all of them.  Most of the companies (85%) in the interview 
sample were self-funded by the owners at the startup stage and continued or growth 
funding came primarily (95%) from revenues generated from sales and services provided 
by the respective companies.  Venture capital (VC) structures are still in the early stages 
of development in India and private equity investment activity was greatly reduced along 
with the downturn in the global economy in 2009.  The extremely small volume of angel 
and seed stage funding activity, as seen in Figure 5.1, is highly limiting for startup of 
entrepreneurial ventures.  Only three companies utilized government assistance for initial 
financing and most cited the bureaucracy or idiosyncrasies that had to be dealt with in 
order to secure public funding.  Data published by VCCEdge (2009), a web-based 
provider of information on private equity and mergers and acquisitions transactions in 
India, indicate that private equity capital is flowing into sectors of construction, retail, 
energy, information and communication technology or areas of local growth as shown in 
Table 5.1.  Venture capital investors interviewed for this research also echoed the same 
trend.  The recent growth of India’s economy presents many far less risky opportunities 
for investors in sectors other than biotechnology or novel drug development.  One of the 
hedge fund managers interviewed by the researcher stated without hesitation that India 
was not a “drug development destination” in the near future from the VC standpoint and 
they were willing to invest in all aspects of healthcare commercialization except for 
biotechnology drug development.   
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Figure 5.1. Private Equity Breakdown.  
From VCCEdge (http://www.scribd.com/doc/24765295/Annual-Deal-Roundup-2009) 
 
Table 5.1  
Private Equity Deal Volume and Value in India in 2009 
Sector Volume Deal Value ($ million) Average Deal Size 
Real Estate 20 657 43.8 
IT/IT Service 47 621 15.9 
Energy 16 538 41.4 
Logistics 15 354 23.6 
Telecom 5 336 84 
Banking, Finance & 
Insurance 32 244 8.4 
Manufacturing 34 242 9.3 
Note. Adapted from VCCEdge (http://www.scribd.com/doc/24765295/Annual-Deal-Roundup-2009) 
 
Most of the companies interviewed for this research were not attempting to be the 
first ones to market with new products and were not reliant on a high degree of research 
and development intensive activities.  Only six out of the twenty companies were trying 
to develop new-to-market products.  While several companies were conducting research, 
they are doing this research for other companies on a contractual basis or playing other 
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roles in the biotech value chain such as providing data analysis or manufacturing 
diagnostic kits for disease detection.  These companies may never move up the value 
chain to become drug development, or new biological molecule development companies.  
The focus for drug development in India may also not be centered on “feel good” life 
style enhancing drugs such as Viagra but more focused on drugs needed to tackle local or 
regional health conditions.  Given the significant social implications of providing low 
cost health care to the masses, the Indian government has played a significant role in 
controlling the price of medicines.  While many Indian pharmaceutical companies have 
thrived in a price control environment (Amsden 2001) by selling generic medicines, this 
scenario presents a different monetary value proposition for introducing new drugs in a 
market in hopes of maximizing profits.  This would be a deterrence to follow a prospector 
strategy.  While the external factors of market characteristics and technology 
development in biotechnology as indicated in the matrix from Walker et al. (2003) would 
favor the adoption of a prospector strategy, the regulatory environment in India appeared 
to deter the companies from doing so.  Some of these analyzers (three such companies 
were identified in this current sample) have the potential to become prospectors if the risk 
capital is available and policies, which help nurture the smaller enterprises by investing in 
novel research. 
India represents a large market with rapid growth in healthcare sector and foreign 
investment is very eager to purse these opportunities.  Development in the near term in 
the healthcare sector will be in the areas of healthcare insurance, pharmaceutical retail, 
contract research and generic drug manufacturing.  The list of top 20 biotechnology 
companies by revenue published by BioSpectrum includes established and familiar 
names of the Indian pharmaceutical industry like Wockhardt and Ranbaxy as well as well 
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as multinational companies like GlaxoSmithKlein, Monsanto (agricultural biotech), and 
Novo Nordisk (BioSpectrum).  It is evident some Indian pharmaceutical companies are 
beginning to make inroad into the biotechnology model seen in the West.  One of the 
generic drug companies interviewed for this research is making efforts to develop a new 
line of biotechnology therapeutics by licensing technology from an academic researcher 
in the United States.  None of the biotechnology companies, except for one, interviewed 
for this research saw themselves as an acquisition target by the large pharmaceuticals.  
Only one company among those interviewed by acquired by a foreign company.  VC and 
PE (private equity) have driven entrepreneurs to seek exit strategies for their ventures 
rather than building companies to provide them with a lifetime of income.  There is some 
evidence that this is happening in the biotech sector as well as evident from recent buyout 
of Shantha Biotechnics by the French company Sanofi Aventis for 550 million Euros.   
According to VCCEdge, this was the second largest merger and acquisition deal in 2009. 
 
Figure 5.2. A Typical Medicine Retail Shop in New Delhi.  
 
The Indian healthcare sector still faces many challenges as it evolves and 
consolidating and regulating a highly fragmented pharmaceutical retail system is among 
the major ones.  Many drugs are sold a few doses at a time by small “mom-and-pop” 
retail outlets referred to as chemist shops as shown in Figure 5.2.  The researcher took 
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these pictures in New Delhi during the visit in 2009.  A study by the consulting firm 
Deloitte estimated there were between 700,000 and 800,000 such retail outlets in India 
(Snyder et al. 2008).  The “chemist” pictured here is a first cousin to the researcher and 
the store was initially opened by the researcher’s paternal uncle about 25 years ago who 
was actually a trained pharmacist.  The store in these pictures had a footprint of no larger 
than 10 feet by 10 feet, but was a miniature version of a Walgreens or CVS Pharmacy 
complete with cosmetics, toiletries, baby needs, medical monitors, and prescription and 
non-prescription drugs.  It is unclear how such stores are regulated by any government 
authority or how drugs are sourced for retailing.  In the researcher’s past experience of 
living in India, even prescription drugs may be purchased from such outlets without a 
formal doctor’s prescription.  India is one of the largest manufacturers of generic drugs in 
the world and most drugs available at such outlets are the generic versions even though 
they may be labeled with the manufacturers’ private labels.  Given their higher cost than 
conventional generic medicines, it may be difficult to control the distribution and sale of 
biotechnology based drugs or biologics under such market conditions and the risk of 
imposter drugs being marketed could be very high.  The lack of understanding of the 
functionality of such drugs by the “chemists” and the consuming public may also lead to 
unintentional affects.  The Department of Biotechnology (DBT) issued a draft plan in 
May 2008 to form the National Biotechnology Regulatory Authority (NBRA) as “an 
independent, autonomous and professionally led body to provide a single window 
mechanism for biosafety clearance of genetically modified products and 
processes.”  However, the plan does not adequately address the retail sale and distribution 
of biologics and the plan was not formally adopted at the time of publishing this 
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dissertation.  The plan does recognize the need for developing a mechanism to train and re-
train regulatory officials on a continuous basis. 
A key weakness identified in several companies interviewed was a lack of a 
coherent marketing strategy.  Most did not have well defined marketing efforts and 
spreading information about their companies through “word of mouth” or personal 
connections seemed to be quite common.  All of the companies did have websites, but the 
amount of content and level of sophistication was varied across the board.  According to 
Miles and Snow (1978), aggressive marketing is one of the characteristics of prospectors.  
Growth of some companies was limited due to financing reasons, and most of the 
companies were self-funded in the early stages of the business.  Established 
pharmaceutical companies are seeking to take advantage of the SEZ regulations and one 
company was able to acquire land to construct bio-vaccine research and production 
facility.  However, SEZ policy is not conducive to smaller biotechnology companies and 
other “incubator” type facilities are needed to foster the growth of such companies 
especially which may require specialized equipment. Innovation in process is occurring, 
albeit it is pharmaceutical processing and production of generic chemical drugs and now 
likely to get into biosimilars rather than new drug discovery and development.   
The research found that TRIPS compliance did not seem to be a significant issue 
for the firms in the biotechnology industry as many of them were not seeking patent 
protections.  None of the companies interviewed even mentioned the change in patent 
regime, which took effect in 2005.  This perspective held true from the investment 
community interviews as well since they were not expecting these companies to develop 
new drugs and were not making investments based on the promise of new blockbuster 
drugs.  The government official interviewed for this research believed that TRIPS 
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compliance would be good for the industry in the long run and not create a short term 
barrier to entry.  There are still critical issues related to intellectual property (IP) 
management and protection in India.  According to one of the interviewees based in the 
United States, the culture to pay for IP (licensing technology) is not well developed 
among Indian pharmaceutical companies and negotiations with researchers who are 
developing technologies could be challenging and take a significantly long time to agree 
upon terms of licensing.  Inability to effectively protect their IP was mentioned by two 
companies as a barrier to growth.  Both of these companies were typed as prospectors and 
were developing products, which required new ways of doing things and would be good 
candidates for receiving patents.  Another interviewee expressed strong suspicion of the 
Indian Patent Office to maintain confidentiality on the patent disclosure during the 
patenting process.  It was believed that large corporations and drug companies have 
means to gain “back-door” access to information disclosed in competitors’ patents and 
felt their knowledge would be compromised if they chose to file a patent.  The concept of 
intellectual property was also not understood by some companies in the interview in the 
same context as used in the western countries.  A lot of the service companies (CRO’s or 
bioinformatics) considered the use of non-disclosure agreements with their customers as 
a means of protecting IP, and confused maintaining confidentiality of their client’s 
research or IP.  An issue which will pose a major challenge for India, not just with drug 
patents, but product patents in an technological field was pointed out by Mr. Shrikumar 
Suryanarayan, Director General of ABLE, during the interview which took place in 
Mumbai in October 2008.  According to Suryanarayan, India has a lost a generation of 
patent office personnel including patent examiners who understood how to evaluate 
product patents because they did not award any such patents in over 30 years.  An entire 
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re-learning process will have to take place to understand the mechanisms for awarding 
product patents. 
India’s clustering approach to biotechnology is evident with Bangalore, 
Hyderabad, Mumbai and Delhi-NCR as the leading hubs of biotechnology related 
activity.  Additional cities showing strong biotech activity are Chennai, Pune and 
Ahmedabad.  Bangalore’s IT sector has had a definite influence on the biotech sector as 
evident from the large concentration of bioinformatics firms in that area compared to 
other cities.  The state of Karnataka has also promoted this industry heavily and having 
Biocon, one of India’s prominent biotechnology companies and its entrepreneurial CEO 
Kiran Mazumdar-Shaw headquartered there, has helped grow this industry gain a 
foothold in Bangalore.  Bangalore has a very temperate climate and lower levels of 
pollution than other large metropolitan areas like Mumbai and New Delhi; hence it has 
attracted many multi-national companies in the information technology sector.  Getting 
around the city can still be challenging during rush hour (see Figures 5.3-5.5) and several 
company officials interviewed cited lost productivity due to long traffic delays.   
 
Figure 5.3. Mixed Traffic at a Traffic Signal in Bangalore. 
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Figure 5.4. A Traffic Policeman Directing Traffic in New Delhi. 
 
 
Figure 5.5. Rush-hour Backup at a 30-lane Wide Toll Plaza between New Delhi and 
Gurgaon, Haryana. 
 
 
Linkages of smaller biotech companies in India were not well developed and poor 
networking mechanisms were observed especially amongst companies.  Most linkages 
pointed out were with universities and few with the industry organization ABLE.  It may 
be a regional issue, but none of the companies in Bangalore or Mumbai mentioned 
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having ties with BCIL (BCIL is located in New Delhi).  The culture of entrepreneurship 
is evolving in India and organizations such as TiE are playing an important role in 
nurturing entrepreneurs, however this organization has not made strong inroads into the 
non-IT based enterprises and “bioentrepreneurs” feel out of place at networking events as 
pointed out by one of the company founders.  Universities are providing scientific 
training but are not producing bioentrepreneurs which presents a bottle neck for the 
growth of the Indian biotech industry as identified by a venture capitalist interviewed 
during the course of the research.  There is still a cultural stigma attached with failure of a 
business in the Indian society, and ironically this will be an impediment in the growth of 
a business sector like biotechnology where failure rates are high.  There is still a lack of 
basic infrastructure to support development of biologics.  An example cited by an 
interviewee was the relative unavailability of freezers capable of going down to –80ºC in 
India, which are common place in laboratories conducting biotechnology work in the 
United States.  Some of the instrument manufactures interviewed at the conference in 
Mumbai pointed out that bulk of the sales were still in basic analytical equipment and 
only a few companies could afford the more advanced equipment, although that was 
changing. 
Terrorism and communal tensions are still a reality that India contends with on a 
regular basis.  The research teams meetings with the Mumbai TiE group as well as a 
representative of Nexus India Capital, a venture capital firm, were cancelled due to local 
riots that erupted during the stay in Mumbai.  The unrest was caused by supporters of Raj 
Thackre when was jailed on charges of attacks on northern Indians living and working in 
Maharashtra. Mr. Thackre is the leader of the Maharashtra Navnirman Sena (MNS) and a 
divisive but influential political leader.  A bombing on train occurred on the same day in 
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the northeastern part of India giving the researchers a glimpse of the grim political 
realities in India.  Billboards by various political parties playing the blame game, such as 
the one shown in Figure 5.6, were often spotted along city streets mainly in Mumbai and 
New Delhi and strategically parked riot control police vehicles (see Figure 5.8) are not an 
uncommon sight.   
 
  
Figure 5.6. A Billboard in Mumbai by One Political Party (Bhartiya Janata Party – BJP) 
Blaming Their Opposition (Congress Party) for Increase in Fear, Hunger, Inflation and 
Terrorism. 
 
Many public places such as hotels and shopping malls have security checks at 
their entrances.  Figure 5.7 shows security guards at the Mumbai Grand Hyatt Hotel 
inspecting a vehicle including its underside with mirrors. This is the other side of India 
which can disrupt business as usual – communal riots on a given day are actually 
business as usual and are part of the external environment for all businesses to operate in.  
India has also faced many serious terrorist attacks and the most egregious attack came 
just a month after the research team was in India.  Security checkpoints at hotel entrances 
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and armed riot police posted in crucial areas of cities reiterated the underlying tension of 
the situation.  Just one month after the research team was in India, armed gunmen 
terrorized the city of Mumbai starting on November 26, 2008 and continued the siege in 
five locations around the city including the very famous landmark Taj Hotel.  More than 
170 people were killed in these attacks believed to be perpetrated by Pakistani nationals. 
 
  
 
Figure 5.7. Security Guards Check Each Vehicle Entering the Premises of the Mumbai 
Grand Hyatt Hotel.  
 
 
Figure 5.8. A Riot Control Police Van Parked in One of the Central Areas of New Delhi 
Frequented by Locals and National and International Tourists.  
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The researcher visited India after a long gap of fifteen years and was surprised 
and impressed to find the diffusion and prevalence of information and communication 
technologies at the very grass roots level.  The researcher observed very contrasting 
technologies and life styles were blended in today’s India.  Figure 5.9a shows a very 
traditional flower lady near the entrance of a temple in south India.  This picture could 
easily have been taken thirty of forty years ago, but behind her is a sign painted on the 
wall promoting the use of email, webcam and digital photography.  Similarly the use of 
manually-powered rickshaws (Figure 5.9b) are still a common means of transportation in 
New Delhi, but the passenger and even a rickshaw driver seen in the far left corner of the 
picture are now able to afford cellular telephones. 
 
 
Figure 5.9. Old and New India Coming Together (A. Flower seller near a temple in the 
small town of Thanjavur, Tamil Nadu state; B. Rickshaw driver and passenger on a New 
Delhi street) 
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Policy Recommendations 
This research has implications for company managers and policy makers.  The big 
question to answer is: Should India encourage biotechnology prospectors?  The response 
to this question may be examined by looking at the biotechnology value chain, how it is 
changing and the funding model for biotechnology companies.   
The model for the biotechnology industry value chain is evolving rapidly as 
industry realizes the need to outsource various aspects of the drug development process 
in order to mitigate risk as well as utilize companies which may be developing specific 
expertise.  The generally accepted model for biotechnology commercialization shown in 
Figure 5.10 is a linear progression of steps starting from the idea generation stage (basic 
research) to the manufacturing and marketing of biological compounds (Hine and 
Kapaleris 2006).  The new model emerging, dubbed as the “dis-integration” of the 
biotechnology value chain by noted industry analyst Stephen Burrill is shown in Figure 
5.11.  India needs to better identify where on the biotech value chain it needs to play 
given the current capital and infrastructure constraints.  The Indian government has to 
decided whether it wishes to promote more companies to follow prospector strategies or 
whether the analyzer strategy being currently pursued by a majority of the companies in 
the interview sample is appropriate and conducive to the external factors.  The 
researcher’s recommendation is that an analyzer strategy in the near term will be better 
suited for Indian companies as it will allow them to be cash flow positive while 
continuing to look for related opportunities. 
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Figure 5.10. Biotechnology Value Chain.  
From Innovation and entrepreneurship in biotechnology, an international perspective: Concepts, 
theories and cases, by D. Hine and J. Kapaleris, 2007. 
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Figure 5.11. The “Dis-integration” of the Biotechnology Industry.  
 
From Life sciences…circa 2004: Biotech’s back on track, S. Burrill, 2004. 
 
India may not be able to compete on price alone as Indian wages rise, rupee 
strengthens and other lower cost providers start catching up to India as they are doing in 
the IT sector.  From this standpoint, it is important for India to nurture and grow more 
prospector companies especially in fields like biotechnology where the scientific frontier 
is wide open.  As the some the Indian companies like WIPRO, Infosys and TCS have 
started moving up the IT value chain, biotechnology companies will have to start moving 
up the biotechnology value chain also.  The entry of established Indian pharmaceutical 
companies into the biotechnology space is a logical progression and is already taking 
place, albeit the focus is still on biosimilars (generic biotechnology drugs) rather than 
new drug development.  To fully exploit the potential of biotechnology for the masses in 
Indian and other developing countries, these companies will need to focus on developing 
new therapies often neglected by the western drug companies. 
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Based on this research, a critical need has been identified to train patent officers, 
examiners and support staff capable of evaluating and awarding product patents.  Strong 
patent protection in real terms as well as in perceived terms is necessary for individuals 
and companies to move forward with development of unique technologies.  Lack of 
intellectual property protection will deter entities from following a prospector strategy. 
Training patent examiners and officials could be an area of collaboration between the 
governments of India and the United States with U.S. based product patent attorneys and 
affiliated experts providing targeted training and help in establishing enforceable 
protocols for a secure but transparent patent regime.  The efforts may be led by an 
appropriate non-governmental organization or an academic institution.  A team from the 
US Food and Drug Authority (USFDA) recently funded and trained 24 drug inspectors 
through workshops for conducting clinical trial audits to keep a tab on human 
experiments going on across the country.  The second phase of training state drug 
inspectors was funded by the World Health Organization (Dey 2009) 
One of the biggest challenges in this research was to obtain data which were 
consistent from one source to another.  Multiple industry directories were used to extract 
information about the biotechnology companies and it was observed that there were 
differences in how the companies were classified.  A recommendation for the policy 
makers is to adopt a uniform coding system to standardize the definitions for categories 
of biotechnologies such as contract research organizations or bioinformatics.  The 
researcher only found one NAICS code in the United States pertaining directly to 
biotechnology: 541710 only broadly covers research and development in physical, 
engineering and life sciences.  India could lead the way in developing a coding scheme 
for the biotechnology industry, which will help in capturing and cataloging industry data 
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and provide policy makers and industry experts and future researchers with a clearer view 
of the industry. 
Inter-company networking is key, as is further promoting of networking with 
academia and industry.  The researcher used LinkedIn as a measure of connections for 
the company officials, but such professional and social networking sites may used to 
increase stakeholder connections and facilitate cross-border interactions with foreign 
firms and organizations.  The publish-versus-patent debate has to be adequately 
addressed in this sector in India.  The DBT report touts the number of research 
publications while not giving significance to the number of patents issued as it is a small 
number.  This indicates low rates of commercialization of technologies being developed 
through government funding. 
A further modification to the SEZ policy is suggested to include growth of startup 
enterprises – they may not necessarily have to be new brick and mortar facilities but 
could be enclaves within educational campuses, in close proximity to the research 
clusters. Encourage academic professionals to start entrepreneurial ventures is very 
important and such efforts are just emerging in Bangalore at the Institute for 
Bioinformatics and Applied Biotechnology (IBAB).  IBAB lists one spinout company on 
its website (IBAB), but the section of the website on entrepreneurship is lacking in real 
substance.  India needs to encourage scientists and researchers who can take the new 
developments to markets and viable commercial enterprises around these technologies 
and foster a generation of “bioentrepreneurs.”  Having gained independence in 1947 from 
the British Empire, India is still a young country trying to find its place in the world 
order.  It is country with hope and aspirations and a mural painted (see Figure 5.12) on 
the side of a building in Mumbai succinctly depicted the mindset of urban and 
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progressive India.  Ironically, this building was located directly across the street from the 
Mumbai Grand Hyatt Hotel where every vehicle entering the premises is checked for 
explosives. 
 
Figure 5.12. Mural on the side a of building in Mumbai beckons “dreamers” 
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Most importantly, a critical need has been identified in the literature for inter-
organizational collaboration in the biotechnology industry as the science is so broadly 
distributed that no single firm has all the necessary capabilities.  This view has been 
expressed for the United States where hundreds of small science-based entrepreneurial 
biotechnology companies have been formed.  There are severe limitations to market 
transactions and disincentives to vertical integration. Instead, through a combination of 
mutual need, repeated interaction, and membership in a common technological 
community, networks of collaborative ventures serve as the primary institutional 
arrangement governing exchange and production.  Shan and his fellow researchers have 
also written about inter-firm collaboration in the biotechnology industry (Shan et al. 
1994).  Another reason for encouraging collaborations between industry and academic 
institutions is to jointly pursue grant opportunities which not necessary be available to the 
private sector only. 
Role of non-governmental organizations (NGO’s) such as ABLE and BCIL and 
AIBA and CII could be enhanced with them working with each other to gain a critical 
mass and give the industry a stronger voice.  The need for developing collaborative 
networks may be presented somewhat differently for the developing counties and the 
researcher is proposing the following “butterfly model” of inter-organizational 
collaboration.  It is again a qualitative model at this point and would have to be validated 
by empirical research or case studies of networks, which may be structured in such a 
manner. 
The Butterfly Model for Inter-Organization Collaboration 
 
Based on issues highlighted in the literature, and the need for NGO’s to play an 
active but transparent role in furthering emerging technology sectors and projects, a 
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qualitative model of inter-organizational collaboration is proposed Figure 5.13).  This 
graphic model, which the researcher is calling the “Butterfly Model,” shows the 
interdependency of various entities and the need for a coordinating or key NGO to 
facilitate the collaboration between funding streams and research efforts into viable 
private sector enterprises.  Partnership with sister NGO’s is also important to build grass 
roots support for deploying new technologies and in identifying individuals or businesses 
that may be the early adopters.  
 
Other
NGO’s
BUTTERFLY MODEL
an inter-organizational framework of collaboration
for deploying emerging technologies
Research, Policy & 
Workforce Development
Commercialization & 
Demonstration
Private
Sector
Academia/
Research
State/Federal
Government
Coordinating
NGO
NGO
Board
Financial
Auditors
Project
Evaluators
(NGO: Non-Governmental Organization)  
Figure 5.13. Butterfly Model for Inter-Organization Collaboration. 
 
 
This model was developed after the researcher’s experience in managing a 
renewable energy program called the Strategic Biomass Solutions (SBS) since 2005 at 
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the Mississippi Technology Alliance (MTA).  Although qualitative in nature, the 
Butterfly Model is a practical model and reflects the operational approach for the SBS 
program.  MTA an independent, non-profit organization with a 501(c)3 legal status, 
organized SBS after receiving a grant from the United States Department of Energy 
(USDOE) for the specific task of helping commercialize near-term biomass-to-energy 
technologies.  SBS initially functioned in the capacity of project funding provider and is 
now focusing on helping startup companies and project developers seek early stage 
capital.  An ad-hoc proposal evaluation team was formed that consisted of individuals 
from out-of-state reviewers in order to limit any personal biases towards the projects or 
principal investigators.  SBS is primarily accountable to the USDOE for financial, 
technical and environmental impact reporting.  SBS financial outlays go through an 
internal review process and expenditures have to be justified to the USDOE.  Additional 
oversight is provided by the Board of Directors of the Mississippi Technology Alliance 
and an annual external audit by a professional audit form.  SBS has fostered formation of 
university-industry relations and also works closely with other non-profit organizations 
around the country.  These are like-minded organizations actively seeking to compile and 
disseminate objective information on renewable energy systems. MTA-SBS measures its 
success by the amount of federal funding leveraged with private and state dollars, total 
number of projects carried out, private sector revenue impact after project 
implementation, and the number of companies and entrepreneurs served by connecting 
them to private sector investment opportunities. The issue-specific knowledge base and 
multiple partnerships are sources of leverage for the MTA-SBS to achieve the stated 
goals of program.  It is the researcher’s belief that there are similarities between the 
structure of the emerging biotechnology and renewable energy sectors, hence the model 
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initially developed for deploying renewable energy technologies is applicable in 
biotechnology also.  Among the main similarities are the broad impact these two sectors 
have on humanity, the high cost of product development, high barriers to entry because 
the industry is controlled by a few very large players in the energy and pharmaceutical 
sectors.  While the regulations governing the energy and healthcare sector are different, 
the both are heavily regulated industries. 
Giving central authority to an NGO is not without risks.  The apparent, or in some 
cases real, lack of accountability has led to the credibility issue for many NGO’s.  Even 
though McGann and Johnstone (2005) recognize that the NGO’s have made many 
positive contributions in domestic and international affairs, they call this issue a “crisis of 
transparency and accountability” for the NGO’s.  They point out several reasons why 
NGO’s risk losing their credibility.  Although NGO’s may be required to provide expert, 
reliable and unbiased information to policy makers, McGann and Johnstone (2005) 
maintain that NGO’s seldom hold neutral positions on policy issues, and without proper 
disclosure and transparency, may lead to potential conflicts of interest.  Funding for most 
NGO’s comes from governments, multilateral agencies, or private funds from 
foundations or individuals, and they are accountable to their donors and seldom 
accountable to the funds recipients (Townsend and Townsend 2004).  An ever-expanding 
role in world events has also brought greater scrutiny of the activities of the NGO’s, 
which has led some groups to realize the need to maintain better information about their 
operations.  Ryu et al. (2004) suggest the formation of NGO networks early on in the 
process for optimal knowledge sharing and use of human and financial resources.  Lewis 
and Madon (2004) point out that NGO’s are seeking three types of information to catalog 
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their activities, which will help them attain greater accountability and enhance their 
effectiveness.  These needs are: 
• A higher-quality of information about their grass-roots efforts and 
development and dissemination of best management practices; 
• Broader knowledge of macro-economic and political policy at local and 
national levels, as well as other non-state entities; 
• Input and output allocation or scarce human, financial and material resources. 
Of particular interest to the biotechnology NGO’s will be the “insider strategy” 
that seeks to “attain influence by working closely with negotiators and governments by 
providing policy solutions and expert advice.”  (Gulbrandsen and Andersen 2004, 56).  
Knowledge accumulation and publishing research-based reports addressing specific 
topics is also a part of the insider strategy usually followed by “advisory NGO’s.”  The 
issue-specific intellectual base held by an advisory NGO becomes a source of leverage or 
capital when providing expert advice and analysis to policy and decision makers 
(Gulbrandsen and Andersen 2004) 
As with the implementation of any strategy that may require the deployment of 
new technologies, it is imperative to identify entities or individuals who are willing and 
capable of “test-driving” the new products or processes.  Rogers’s (1995) “diffusion of 
innovation” theory suggests that diffusion is a process by which an innovation is 
communicated through certain channels, over a period of time among the members of a 
social system.  Interpersonal and mass communication is needed to create and share 
information, which leads to an awareness of the innovation.  Communication and the 
channels used for information dissemination are both critical steps in the process to reach 
a mutual understanding of relative advantages of an innovation, which then leads to 
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subsequent adoption of an innovation.  The social system in the case of agri-biotech 
could comprise the farming community which needs to be informed about a new crop 
they can grow and harvest or a process to increase yields of existing crops they are 
already accustomed to growing. The adoption outcome is dependent on the individual 
types who make the “yes/no” decision at various stages of diffusion.  Innovation is also 
required in arriving at appropriate policies which will encourage the market development 
for not only biotechnology products but also other emerging technologies in fields such 
as alternate and renewable forms of energy and nanomaterials as well as in training a 
workforce to adapt to skills demanded by this industry. 
Finally, a contrarian view of the biotechnology industry was presented by 
Hopkins et al. (2007) where they attempt to shed the “myth of the biotech revolution” 
(566).  The researchers contend that policy makers may be misled by the promise of a 
revolutionary impact on healthcare and economic development as the speed and extent of 
technological prowess may be over-estimated.  Hopkins et al. (2007) point out that 
biotechnology is “following a well-established incremental pattern of technological 
change and ‘creative accumulation’ that builds upon, rather than disrupts, previous drug 
development heuristics” (566).  The Indian policy makers have to be able to listen to 
various business models and differing viewpoints being developed in this industry and 
understand where the largest impact can be made with the lowest barrier to entry in the 
near term and the long term.   Hopkins et al. (2007) point out for example that 
introducing gene or protein based drugs will require novel manufacturing techniques and 
this would be well suited to exploit India’s competencies given their track record for 
innovation in manufacturing processes.  Hopkins et al. (2007) write that medical 
innovation is not just the simple application of new scientific knowledge, as new drugs 
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have to show clinical utility in practical, real-world situations.  Shared expectations are 
needed to ensure the co-ordination of the large amounts of resources needed for major 
innovations.   
Social scientists studying technological change in biotechnology are not, 
therefore, passive investigators, but are active co-producers of the expectations that drive 
the industry and they have a have a responsibility to critically engage with the intellectual 
tools they bring to the exercise (Hedgecoe and Martin 2003).   
Future Research 
 This research has opened two main avenues for future research. First, given the 
limited number of companies in the interview sample in the current research, future 
efforts could involve a much larger sample to conduct quantitative analysis on the Indian 
biotechnology sector. This would require the use a self-typing technique for Miles and 
Snow (1978) categorization on the part of the company managers.  Creation of the larger 
sample size will be facilitated by the possession of two industry directories (BioSpectrum 
and BCIL) which were acquired during the course of the present research.  While a larger 
sample size will allow the results to be generalized for biotechnology companies in India, 
it may lead to severe response bias.  A second area of research is to find case studies in 
India or other developing countries to validate the butterfly model of inter-organizational 
collaboration.  The researchers could seek examples where a new technology may have 
been deployed in a developing country and seek to understand the dynamics of 
relationships between various actors involved in such cases.  Real life examples of 
collaboration between various organizations will help lend credibility to this model and 
aid in the adoption of such a scheme for future technology intensive deployments. 
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APPENDIX A 
SURVEY INSTRUMENT FOR USE WITH  
INDIAN BIOTECHNOLOGY COMPANIES 
India Firm Survey Instrument 
 
Firm: ______________________________  Firm representative: _________________________ 
 
BUSINESS BACKGROUND 
 
Years in Operation/year of start-up: ______________________________ 
 
Main product: _________________________________;  
 
How long in production?_______________, Are you looking to replace it?_______________ 
 
What/Who was the inspiration for this product?______________________________________ 
  
Other products:  _______________________________________________________________ 
 
How often are new products launched? __________________________________ 
 
Does using your products require a new way of doing things for your customers? __________ 
If YES, Explain how: __________________________________________________________ 
 
Is your product more, or less complex than previous ones? ________________________ 
 
Number of employees: _____________________ Average age of employees: ____________ 
 
Annual/previous year sales: ________________________ 
 
Sales growth in past….years:  One: ___________________  Five: ___________________ 
 
MANAGEMENT TEAM 
 
Company founded by: ___________________________________________ 
 
 Current position with firm: _________________________________ 
 
 Future plans with the firm: _________________________________ 
 
Who are the main decision makers for the firm? _____________________________ 
 
 Do the decision makers own part of the company? _________________ 
Are decisions collective or unanimous?_____________________ 
 
What are the backgrounds of those decision makers? (scientist/business/government official/other) 
__________________________________________________________ 
Are there expatriates (non-Indian) on the management team? ________________________ 
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Are there expatriates (non-Indian) on the scientific/engineering team? ____________________ 
 
Networking: how are members of the management team are tied into or exposed to outside entities (other 
companies/researchers/etc.)? __________________________________________ 
______________________________________________________________________________ 
 Professional organizations: _________________________________________________ 
Do you hold brainstorming or ideation sessions?   _____________If Yes, how often?_________ 
INTELLECTUAL PROPERTY 
 
Where did it come from (internally developed/external source)? _________________________ 
 
 If internal, how was it developed? ___________________________________________ 
 
Does the company have external partners? ___________________________________________ 
 
Is there a specific target customer/market? ___________________________________________ 
 
How is the company’s intellectual property protected? _________________________________ 
 
Are there competitive technologies? _______________________________________________ 
 
Value proposition (what differentiates the company’s products?) _________________________ 
MARKETING 
 
Is the company searching for new customers? _________________________________ 
 
What is the marketing process? ___________________________________________ 
(in other words…how do you inform and persuade your customers to use your products?) 
 
Are there future (not yet implemented) marketing plans? _______________________________ 
 
Do your customers easily understand benefits of your products?  _________________________ 
 
GOVERNMENT INVOLVEMENT 
 
What types of assistance do you receive from the government? __________________________ 
____________________________________________________________________________ 
Examples? ____________________________________________________________________ 
Type of assistance from international organizations ____________________________________ 
FINANCE 
 
How was the initial product development funded? (individual investors/other firms/off-shore 
investors/government) ___________________________________________________________ 
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How has more recent growth been financed? _________________________________________ 
Is debt financing used? ___________________________________________________ 
 
What is the role of government investment? __________________________________________ 
 
 Cash subsidies from the government? ______________________ 
 
 Loans from the government? _________________________ 
 
What was the process for obtaining financing? ________________________________________ 
______________________________________________________________________________ 
 
Did financiers require third party technology validation? ________________________________ 
Did any attempts at obtaining financing fail? _________________________________________ 
 
Are there expectations attached to certain funding sources?  
 Expected return on investment? _________________________________ 
 
 Limitations on operations? __________________________________________________ 
 
  Minimum asset/cash balance? ________________________________ 
 
 Liquidity event (when do investors expect their money back)? _____________________ 
 
Is the management team receiving equity in the company as compensation? _______________ 
 
Is the company’s growth limited by financing difficulties? ______________________________ 
 
Future financing needs? 
 Short term (less than one year)? ____________________________ 
 
 Long term? ____________________________________ 
 
What metrics does the company use to monitor/track success? ___________________________ 
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APPENDIX B 
SAMPLE EMAIL TO SOLICIT MEETINGS WITH 
BIOTECHNOLOGY COMPANIES IN MUMBAI 
 
Subject: Possible Meeting October 20 to 22 in Mumbai 
 
Dear Mr/Dr/Sir/Madam, 
 
I am part of a team of scientists/entrepreneurs wishing to establish connections with 
biotechnology and renewable energy (RE) companies during a visit to India in October 
2008. The objective of the visit is to develop collaborative networks to improve the 
research, development, and commercialization of innovative biotechnology and RE 
research in the U.S. and India.  I read with great interest about Nexus India Capital on the 
internet as well as your personal views on clean tech in India.  We hope to better 
understand the challenges and opportunities faced by innovative companies, the likes of 
which you work with on a regular basis. My sincere hope is that you may be able to assist 
us in getting connected to some of these companies. 
 
The University of Southern Mississippi has one of the world’s top polymers and high 
performance materials programs and is working closely with the GE India Technology 
Centre to develop stronger connections with India’s booming biotechnology sector. This 
research is being funded by a National Science Foundation grant (IGERT) to examine 
innovation in biotechnology.  Some of the graduate students on the team are from Ph.D. 
programs in polymer science and medicinal chemistry and each has launched their own 
start-up company.  I am Ph.D. candidate in International Development and work full-time 
for a non-profit organization which helps startup companies and entrepreneurs to obtain 
seed and angel stage funding; my research interest is in renewable energy technology 
adoption. 
 
Some of our team members including myself will be visiting Mumbai during the week of 
October 20th to 23rd.  During that week they will be attending the BioProcess 
International conference.  We would greatly appreciate an opportunity to make a short 
visit with you that week at a mutually convenient location.  A member of our team will 
be telephoning you this week to discuss an appropriate time.  I look forward to speaking 
with you and I hope you are interested in building a relationship with the University of 
Southern Mississippi.  I believe that given your experiences of living in the US will 
provide us a unique insight on the commercialization process in India and thank you in 
advance for your kind consideration. 
 
Sincerely, 
 
Sumesh 
 
Sumesh Arora 
Director of Strategic Biomass Initiative 
Mississippi Technology Alliance 
134 Market Ridge Drive 
Ridgeland, MS 39157 
601-960-3659 (voice) 
601-960-3605 (fax) 
sarora@mta.ms  
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APPENDIX C 
SAMPLE EMAIL TO SOLICIT MEETINGS WITH 
BIOTECHNOLOGY COMPANIES IN BANGALORE 
 
Re: Possible Meeting October 20 to 25 in Bangalore 
 
Dear Dr.xxxx, 
 
I am part of a team of scientists/entrepreneurs wishing to establish connections with 
biotechnology companies during a visit to India in October 2008. The objective of the 
visit is to develop collaborative networks to improve the research, development, and 
commercialization of innovative biotechnology research in the U.S. and India.  We hope 
to better understand the challenges and opportunities faced by innovative biotechnology 
companies such as yours.  
 
The University of Southern Mississippi has one of the world’s top polymers and high 
performance materials programs and is working closely with the GE India Technology 
Centre to develop stronger connections with India’s booming biotechnology sector. This 
research is being funded by a National Science Foundation grant to examine innovation 
in biotechnology.  Each of the graduate students on the team was carefully selected from 
the Ph.D. program in polymer science and medicinal chemistry and each has launched 
their own start-up company.  
 
We will be visiting Bangalore during the week of October 20th to 25th.  We would greatly 
appreciate an opportunity to make a short visit to your company at that time.  A member 
of our team will be telephoning you next week to discuss an appropriate time.  I look 
forward to speaking with you and I hope you are interested in building a relationship with 
the University of Southern Mississippi.  
 
Sincerely, 
 
(Signed by various research team members) 
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APPENDIX D 
IRB APPROVAL 
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APPENDIX E 
PRIVATE EQUITY INVESTMENT ACTIVITY IN INDIA  
ON A REGIONAL BASIS 
 
 
 
From 2009 Annual Deal Roundup, VCCEdge 
(State names are in blue)
Maharashtra 
Gujarat 
Karnataka 
Andhra 
Pradesh 
Tamil Nadu 
Uttar Pradesh Rajasthan 
Madhya Pradesh 
Punjab 
Jammu & Kashmir 
Haryana 
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